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“The most beautiful thing we can experience is the mysterious. It is the source of all true art and all 
science. He to whom this emotion is a stranger, who can no longer pause to wonder and stand rapt in 
awe, is as good as dead: his eyes are closed.” – Albert Einstein 
“I haven’t failed…I’ve found ten thousand ways that don’t work.” – Thomas Edison 
“You find a gem in this #*&^@!” – David Maass  
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Abstract            
The discovery and characterisation of novel small molecule drug candidates is a medical priority. 
Recent advances in synthetic organic chemistry allow the de novo production of diversity oriented 
synthetic compound libraries and synthetic modification of natural products to provide candidate 
compounds for screening as potential therapeutics, bioactive agents or genetic probes. Small drugs 
function through interaction with complex genetic networks and pathways. However, it is difficult to 
characterise these interactions on a genome wide level to achieve understanding of drug 
mechanism. Here, discovery based approaches are utilised to achieve system wide parsing of 
biological mechanism, in an attempt to characterise the action of novel synthetic compounds and 
natural product derivatives.  
Chemical genomic analysis allows for such understanding by examining growth profiles of a genomic 
deletion library of Saccharomyces cerevisiae mutants in the presence of sub-inhibitory 
concentrations of drug. The gene targets of small molecule compounds can be identified by noting 
deletion strains which display increased sensitivity, indicating chemical interaction with the 
associated gene network. In addition, the development and characterisation of resistant mutants 
can be used to identify putative drug targets. In this strategy, characterisation of the mechanism of 
resistance gives insight into drug mode-of-action. This study develops a high throughput yeast 
inhibition assay to identify bioactive compounds from a synthetic organic compound library, and 
attempts to characterise mechanism of action by establishing a profile of each compound’s 
interaction with these gene networks; and mapping a resistance mutation to provide evidence of 
inhibitory mechanism. Two candidate compounds are identified, FC-592 and FC-888.  
FC-592 displayed cytostatic inhibition. Further, yeast tag microarray homozygous profiling (HOP), 
chemical structure analysis, and cell-cycle analysis via flow cytometry for this compound provided 
evidence for a mechanism of poor specificity that targets glycoprotein biosynthesis and the 
secretory (Sec) pathway, as well as the cell-division cycle (CDC) pathway. Attempts to characterise a 
mutant resistant to this compound via synthetic genetic array mapping were unsuccessful when the 
resistance mutation proved to mediate a slow growth phenotype, abrogating the Synthetic Genetic 
Array Mapping approach utilised. Pending further analysis, it is suggested that this compound could 
have a role as a genetic probe in future exploration of the Sec and CDC pathways. 
Chemical structure analysis and a non-specific HOP screen chemigenomic profile suggested that FC-
888 is an alkylating agent with a broad affinity for cellular nucleophiles. The compound 
demonstrates cytotoxic activity, and its efflux is not mediated by the pleiotropic drug resistance 
(PDR) network. It is suggested that the compound could find utility as a probe dissecting processes 
related to cellular defence against non-DNA specific alkylation. 
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1. Introduction           
1.1 Drug discovery 
Drug discovery is the process by which compounds are discovered or designed, identified and 
characterised in order to perform as therapeutic agents or for some other biologically useful task. A 
multidiscipline science, drug discovery combines expertise in the diverse fields of medicine, 
molecular biology, pharmacology and chemistry. In the past many drugs have been discovered either 
by identifying the active ingredient from traditional remedies (Fabricant and Farnsworth, 2001) or by 
serendipitous discovery (Drews, 2000). However, more modern understanding in chemistry, 
genetics, physiology and biotechnology allow a much more purposeful approach, accelerating the 
drug discovery pipeline (Warrington, 2003). 
This is necessary because there are many thousands of diseases that affect the human body, 
reducing life spans and causing suffering all over the world. Causes include viruses, pathogenic 
micro-organisms such as bacteria and fungi, cancers and the breakdown of normal biological 
function. The search is on going to identify novel molecular entities (NMEs) that could be of 
potential benefit in combating these illnesses and reducing patient mortality and morbidity. 
In the modern world, this is most often achieved through high throughput screening techniques 
which allow a large array of potential drugs to be assayed in a time and cost effective manner. 
Advances in genetics, computer modelling and pharmacology have meant that target based assays 
that begin with picking out a medically relevant drug target (Gibbs, 2000), and rational drug design 
(Thiell et al. 2003) are possible. Improvements on legacy techniques are required because drug 
discovery is still a lengthy, "expensive, difficult, and inefficient process" with low rate of new 
therapeutic discovery (Anson et al. 2009). The funding limitations faced by research facilities mean 
that cost is a critical factor, with the average research and development cost associated with each 
NME approaching US$1.8b over a time period of 13.5 years (Paul et al. 2010). 
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Finding new drugs through traditional means is becoming increasingly difficult as obvious drug 
targets have been thoroughly exploited. This means there few if any single major gene targets left in 
the art and design of new drugs. In many cases, the drugs that we rely on today (so called trade 
drugs) are suboptimal in their function. Current classes of antibiotic drugs are being rendered 
useless by newly evolving resistant microbes (Arrias and Murray, 2009). The problem is made worse 
because no new antibiotic compound structures have discovered since the mid 1960’s (Payne, 
2008). Microtubule stabilising anti-cancer drugs such as Paclitaxel, the mainstay of many current 
anti-cancer regimes, cause significant side effects such as bleeding, and have poor specificity for 
target (cancerous) cells (Goodman and Walsh, 2001). Of course, for many diseases, such as HIV, 
there is no current effective drug cure. These data indicate the continuing need for new and 
improved NMEs to treat the pathology of the 21st century. 
Areas in which NMEs could improve on the current pharmacopoeia include the efficacy against many 
diseases; safety and side effects; and factors such as absorption, distribution, metabolism, and 
excretion or ADME (Balani et al. 2005). In order to achieve advances in these areas it is vital to 
determine the mechanism of action of a biologically active compound. 
1.2 Mechanism of action 
The mechanism of action (MOA) refers to the specific biochemical interaction through which a drug 
substance produces its pharmacological effect. This is very important for selecting compounds with 
good target selectivity, a critical component of most therapeutic strategies. Understanding at the 
biochemical level how a given NME is achieving its effect also allows for the potential to optimise 
delivery, adjust dosage, combine with other chemical agents or even make synthetic modifications 
to the molecule itself to improve therapeutic outcomes (Sliwkowski et al. 1999). From a pecuniary 
perspective, MOA understanding is vital to patent applications and the intellectual property 
protection that allows a NME to progress to market (United States Court of Appeals for the Federal 
Circuit, 2008-1248). 
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A critical part of early phase drug development is the identification of off-target drug effects, known 
colloquially as side effects. NMEs could potentially affect multiple targets, or a single target could 
itself affect multiple pathways and processes. Statin drugs, used to lower cholesterol levels by 
competitive inhibition of the enzyme HMG-CoA reductase (Lewington et al. 2007) also cause a 
reduction in systemic levels of ubiquinone (Co-enzyme Q10) due to its shared biosynthetic pathway 
with cholesterol (Kishi et al. 1977). This is associated with muscular myopathy (Marcoff and 
Thompson, 2007). Early identification of such off target effects allows for potential amelioration: 
reworking of the compound in chemical synthesis or some other strategy, or else discarding the 
compound before resources are spent developing it further. 
In the worst case a widely used drug could cause severe pathological effects across a population 
before such side effects were identified, such as in the case of the anti-nausea and 
chemotherapeutic drug thalidomide. Widely prescribed for pregnancy associated morning-sickness, 
thalidomide was withdrawn in 1961 after being found to cause severe birth defects (Silverman, 
2002). Interest in thalidomide relates to its multiple targets, including inhibition of the production of 
interleukin-6 (IL-6), activation of apoptotic pathways through caspase 8-mediated cell death 
(Anderson, 2005) and inhibition of tumour necrosis factor-alpha (TNFα)(Burkholz, 1997) providing a 
range beneficial effects including suppression of multiple myeloma and reduction in leprosy 
associated necrosis as well as its analgesic and antiemetic properties. 
However, thalidomide’s glutarimide moiety intercalates in guanine-cytosine rich regions of DNA 
(Koch and Czejka, 1986; Huang and McBride, 1997). In utero, such effects inhibit expression of IGF-I 
and FGF-2, genes which stimulate angiogenesis of developing limbs, ears and eyes (Stephens et al. 
2000). If such off target effects could have been identified at the laboratory stage, much damage in 
the original use of this drug would have been avoided.  
It is also important to note that not all such off target effects are harmful. Drugs with promiscuous 
activities have proven their worth in combating multiple diseases. The γ-aminobutyric acid analogue 
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Gabapentin, approved for treatment of seizures and postherpetic neuralgia in adults, has side-
effects which are useful in treating neurological conditions such as bipolar disorder, essential 
tremor, hot flashes, migraine prophylaxis, neuropathic pain syndromes, phantom limb syndrome, 
and restless leg syndrome (Vedula et al. 2009). In these cases a validated characterisation of an 
NME’s genome wide mechanism of action could lead to further applications than a limited target 
based screen would be able to. 
1.3 Screening 
NME screening strategies are increasingly target based (Schreiber, 2000; Winzeler et al. 1999). 
Target-based drug discovery begins with the identification of the function of a potential therapeutic 
drug target and understanding its role in the disease process. In this manner, it can be thought of as 
a ‘reverse’ type screen, where the answer is known (the drug target) and the question must be 
found (the drug). However, the adoption of target based strategies has not resulted in increased 
drug discovery, and is in fact correlated with a decline in NMEs adopted for clinical trial (Sams-Dodd, 
2005).  
There are several issues associated with this approach. Target based discovery requires a validated 
drug target to pursue, and the process of target validation is complex and associated with a high 
degree of uncertainty. In addition, many pathologies are too complex to be targeted by a single gene 
or pathway based assay (Sams-Dodd, 2005, Sams-Dodd, 2006). Further, a drug discovery assay 
limited to screening for a specific target effect risks overlooking other potential functionalities of 
candidate compounds – a serious problem if such compounds are unique or rare. 
An alternative approach to assaying NMEs with biological activity is a mechanism based, ‘forward’ 
screen. This strategy seeks to characterise the mechanism of action of a known bioactive compound 
and takes advantage of the ease of screening for broad based biological activity via inhibition assays. 
This allows a far greater reach in the mechanism space explored: it is possible to find drugs affecting 
a greater range of targets than those for which there are adequate models. 
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A ‘forward’ screening approach takes advantage of in vivo assay design. By definition, the entire 
biological system must be present to determine the drug target. This prevents the use of 
biochemical based in vitro designs, but allows for characterisation against a more realistic model, an 
important consideration during drug development (Sams-Dodd, 2006). 
Comparatively recent advances in molecular biology have allowed screening in this manner. The 
characterisation of the genome and gene manipulation techniques have given rise to a set of tools 
and a level of understanding which allow for sophisticated probes into a molecule’s function within 
the cell. Conclusions can be drawn from an array of data according to our understanding of the rules 
of genetics and biological function. In this way, like piecing together a puzzle, powerful 
determinations can be made that would not be possible via simple biochemical routes. Assays 
incorporating genomics and the construction of gene deletion libraries are among those techniques 
that can be used to assess drug mechanism. 
At this point it should be noted that simply finding new therapeutics is not the only possible goal of 
this type of research. Many small molecule inhibitors (SMIs) such as cycloheximide, which inhibits 
protein synthesis (Schneider-Poetch, 2010) can be used as functional probes to dissect gene 
mechanism, protein function, genetic pathways and other cellular processes. Research 
encompassing the ‘forward’ approach could also reveal compounds that act on certain pathways, 
allowing them to be used as probes in this manner. 
Many such probes are useful for activating or inactivating certain protein functions, providing tools 
to differentiate gene function in healthy and diseased cells (Strausberg and Schreiber, 2003). The US 
National Cancer institute has taken this approach with their “Cancer Drug Discovery: Diversity 
Generation and Smart Assays” program (Strausberg and Schreiber, 2003), of which a critical 
component is the construction of a diverse array of SMI probes. 
In designing small molecule bioactivity screens, it is crucial to maximise the utility of the generally 
small amounts of compound available. In a research setting, obtaining additional quantities of novel 
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compounds is often difficult, so minimising usage in assay design is essential. Several strategies for 
reducing compound usage are discussed in further chapters. 
1.4 Genetic Networks 
The central dogma of molecular biology holds that a gene produces an RNA transcript which 
produces a protein which produces biological work. As Francis Crick (1970), the original framer of 
this concept himself states, the overall genetic control of a cell is far more complicated. Drugs 
typically work through interacting with genes and gene products to have an effect on biological 
processes. However, genes typically do not work in isolation, but work with each other in complex 
pathways and networks.  
A gene network or genetic regulatory network (GRN) is a collection of genes, which may be located 
throughout the genome, which interact with each other through their RNA and protein products, 
along with other cellular components to control cellular processes by governing the rates at which 
genes in the network are transcribed into mRNA (Davidson and Levin, 2005). Protein products can 
include structural elements and enzymes, amongst others which do work within the cell, as well as 
transcription factors which increase or decrease the expression of other genes. In this way it can be 
seen that a gene network is a complex web of genes which can perform multifaceted tasks via its 
regulatory mechanisms. 
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Figure 1.1 An example of a genetic regulatory network. Receptor proteins respond to stimulus in the form of input signals, 
for example a certain cellular toxin, and activate a promoter for another gene which produces a protein to respond to the 
stimulus. This protein might activate further genes and so on, until a complex response is produced to a specific set of 
conditions. Source: United States Department of Energy. Public Domain. 
A further characteristic of genetic networks is their ‘buffered’ nature. A series of redundant genes 
and pathways means that many regulatory and developmental systems produce phenotypes that 
are robust to environmental and genetic variation (Levy and Siegel, 2008). Genes and gene network 
nodes which contribute to this robustness are known as phenotypic capacitors and help an organism 
respond to varied stresses by covering up altered gene expression caused by genetic mutation or 
environmental stress. From an evolutionary standpoint, this provides a mechanism for genetic 
polymorphisms to accumulate without significantly ablating cell function. The prime example of this 
phenomenon is Hsp90, a molecular chaperone that targets an important set of signal transduction 
proteins and has been extensively studied in Drosophila and Arabidopsis (Bergman and Siegel, 2003). 
These experiments reveal that Hsp90 suppresses phenotypic variation under normal conditions and 
releases this variation when functionally compromised by environmental stress, suggesting a 
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constitutive role in adaptation. It has also been shown to exert pleiotropic effects on key 
developmental processes, meaning the function of Hsp90 is linked to many measurable phenotypes. 
From a drug discovery perspective, the interconnectedness of genes within these pathways and the 
robust nature of genetic networks make them useful for assessing interactions between drug targets 
and genes (Tong et al. 2001), as well as dissecting the mechanism of bioactive compounds in search 
of therapeutic applications (Carragher et al. 2012). 
NMEs that inhibit, stimulate or otherwise interact with genes or pathways within these genetic 
networks can be designed or screened for. This allows for a changing paradigm of drug discovery. 
Instead of focusing on a single drug and its drug target, an integrated approach that encompasses 
entire gene networks can be used to develop a multi-drug strategy (Carragher et al. 2012). In this 
way, combinations of targeted agents could be effective in treating complex disease mechanisms 
such as tumours, where monotherapies are quickly subverted by clonal overgrowth of resistant cells. 
1.5 Synthetic compound libraries 
As mentioned previously, modern drug discovery often involves screening small molecules for their 
ability to bind to a protein target. An important parameter of drug discovery programmes then is the 
design and assembly of such libraries. Common sources for these small molecules include natural 
products harvested from biological sources and groups of synthetic compounds derived from 
diversity based synthesis. Each has its benefits and drawbacks as a source of such compounds. 
Advanced methods for stereoselective and combinatorial organic synthesis have increased the 
efficiency with which small natural product-like molecules can be prepared (March and Smith, 2001; 
Brown and Poon, 2005). Using stereoselective techniques such as the Sharpless epoxidation (Takano 
et al. 1991), chemists are able to take simple precursors through to complex products without 
unwanted racemisation, allowing greater control of synthetic products.  
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Combinatorial chemistry, wherein precursors are treated with a series of different reagents and 
conditions to produce libraries of varied compounds in a time and cost effective manner have 
become a primary source of NMEs for biological screening over the last 20 years (Koehn and Carter, 
2005; Schreiber, 2000; Newman and Cragg, 2007). Using these techniques along with computer 
modelling, it is possible to rapidly and inexpensively build large libraries of compounds, whilst still 
maintaining control of the types of chemical structures produced (Gordeeva et al. 1992) in order to 
target a desired chemical structural space. 
This is important for drug discovery because the random generation of large libraries, whilst 
impressive from an empirical point of view, has not resulted in increased drug discovery productivity 
(Newman and Cragg, 2007). Feher and Schmidt (2003) report that compared with natural products, 
synthetically derived compounds have a high attrition rate in the drug discovery process. They note 
that this is likely because reduced chirality (median chiral centres = 0) and reduced structural rigidity 
(median rotatable bonds = 3) are characteristic of combinatorial derived products in comparison to 
natural products (median chiral centers = 5; median rotatable bonds = 1)(Blunt et al. 2008).  
This has seen the rise of diversity oriented combinatorial synthesis – compound collections that aim 
at coverage of a chemical space, instead of vast numbers of compounds (Ramasamay and Visuki, 
2012; Burke and Schreiber, 2004). Such a paradigm allows structural diversity of NMEs, potentiating 
the screening of a range of biological activities within a library, instead of a series of closely related 
molecules which are likely to have similar activity profiles. 
Candidate compounds for a synthetic library can be limited to ‘drug like’ compounds as a means to 
improve efficiency. This stems from the observation that many drugs share a series of properties, 
some of which are enumerated in Lipinski’s rule of 5 (Lipinski et al. 2001) and the work of Arup 
Ghose et al. (1999) as including simple parameters such as molecular mass (<500 da.) and number of 
hydrogen bond donors (<5) to more complex parameters such as molar refractivity (40-130). Use of 
these criteria limits the number of compounds that must be assayed to manageable levels. 
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The primary strength of synthetic libraries as a drug discovery tool is the ease with which they can 
be developed and screened. Diversity oriented synthesis (DOS) as exemplified in Stuart Schreiber’s 
laboratory (Schreiber, 2000), can easily produce an array of greater than 92% purity in sufficient 
quantity for NMR spectroscopy identification in only 3-4 steps of synthesis. It is easier to develop a 
large range of natural product-like synthetic compounds than it is to squeeze them from limited 
quantities of, for example, obscure sea sponges. The down side of course is a lower ‘hit ratio’ 
compared to natural products (Gullo et al. 2003). Natural products have typically evolved alongside 
their targets, and are therefore highly likely to have bioactivity. By their existence these compounds 
must be the results of biological pathways: an organism wouldn’t expend energy manufacturing 
metabolites if those metabolites didn’t have a biological function. Marine natural products, because 
of the potential to be rapidly diluted in ocean waters, have typically evolved to be especially potent 
(De Vries and Beart, 1995).  
However, the discovery and harvesting of such compounds is often fraught with difficulties and 
expense (Capson, 2009). Many promising natural product leads are taken from compounds 
associated with traditional or indigenous knowledge (Fabricant and Farnsworth, 2001). However, the 
pool of such knowledge is finite, and there are often thorny intellectual property issues involved 
with such discoveries (Capson, 2009; International Council for Science, 2002; Convention on 
Biological Diversity, 2010). In addition, most patent laws don’t recognise ‘natural discoveries’ as 
patentable, and thus patent protection on natural products is only possible after some novel utility is 
shown (Barton and Emanuel, 2005; Rockman, 2004); the libraries themselves would be non-
patentable. 
A further complication with the use of natural product libraries is the need to elucidate structures of 
each compound, impractical for a small laboratory, whereas the structure of synthetic compounds is 
easily derived from steps in their synthesis inherent in the DOS process. Construction of new natural 
product libraries is therefore difficult and their use usually limited to characterised, commercially 
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available examples such as ENZO Life Science’s Natural Product Library (Davenport et al. 2005). For 
this reason, most new libraries constructed for screening are synthetic in nature (Dolle and Nelson, 
1999). 
Producing viable quantities of a compound for testing and further development is also a critical 
consideration. In a research setting, it is often impractical or impossible to harvest quantities of a 
natural product, sufficient for research purposes, from its original source – often a rare organism 
itself. Therefore, in most cases a viable synthesis has to be developed if a lead compound is to move 
forward in development. In some cases, such as that of the microtubule stabilising anti-tumour 
agent peloruside A, such a synthesis can prove difficult (Evans et al. 2009). For synthetic compounds, 
the synthesis is known by definition. 
1.6 Saccharomyces cerevisiae 
A model organism is a species that is studied to understand biological phenomena, with the prospect 
that discoveries made in the model organism will provide insight into the analogous workings of 
other organisms, notably humans (Fields and Johnston, 2005). Appropriate model organisms allow 
investigation of the mechanisms of these phenomena with minimal difficulty and expense. 
Organisms which have a fully sequenced genome allow relative ease in identification of gene 
function and gene interactions and are part of the compendium of appropriate genetic models. 
A particularly effective model organism for this purpose is the budding yeast Saccharomyces 
cerevisiae. There are several factors that contribute to S. cerevisiae’s utility in this area (Forsburg, 
2001). Firstly, there is the ease of genetic manipulation. Unlike ‘higher’ organisms, yeast strains such 
as S. cerevisiae and Schizosaccharomyces pombe can grow and divide both as haploid and diploid 
systems. As a result of this, recessive mutations can be easily recovered in haploid cells, but 
mutations in essential genes need not result in inviability in diploid cells.  
Yeast is very amenable to many modern genetic manipulation techniques. They can be readily 
transformed via plasmid uptake and PCR based techniques (Forsburg, 2001). Due to homologous 
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recombination during the sexual reproduction cycle, creating genomic-scale libraries of yeast strains, 
such as gene knockout and over-expression libraries, is possible (Winzeler, 1999; Rine, 1991; Tong et 
al, 2001). These allow systematic analyses – such as the development of comprehensive synthetic 
lethal redundant pathway networks – which are invaluable in discovery based strategies, wherein a 
specific target might not be known. 
A variety of selective techniques are available when working with S. cerevisiae clones. For example, 
the carboxylase gene ADE2, which catalyses a step in the 'de novo' adenine biosynthetic pathway, 
can be used to select for plasmid uptake: the build-up of the nucleotide precursor 5'-phosphoribosyl-
5-aminoimidazole and subsequent accumulation in the vacuole causes a red colour in the yeast 
colony, which can be alleviated by the addition of a functional copy of the gene on a plasmid (Jones 
and Fink, 1982; Heiter et al. 1985). 
 
Figure 1.2 The ADE2 assay identifies cells with successful plasmid expression. Δade2 mutants display a red phenotype, 
which is rescued to a pink phenotype upon successful plasmid uptake and expression whilst WT cells remain white. The 
utility of this assay is that it allows recovery of all genotypes. This is useful when it is necessary to select for plasmid loss as 
well as plasmid uptake, for example when an auxotrophy selection must be reused at a later stage. Reprinted by 
permission from Macmillan Publishers Ltd: Nature Reviews Genetics, Forsburg, 2001. 
Other important molecular techniques and concepts used with yeast include induced mutagenesis, 
temperature sensitive strains (Forsburg, 2001), genetic footprinting (Smith et al. 1995) and the 
generation of ‘gene knockout’ null mutants (Winzeler et al. 1999).  
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Resistant mutant generation is a common strategy for identifying the target of compounds (Heidler 
and Radding, 1995). In this strategy, random mutagenesis is used to generate a mutant population 
which is selectively screened for resistance to a compound of interest. The mutation is then 
characterised to give insight into the mechanism of resistance, and therefore potentially the 
mechanism of action.  A resistance mutant approach is discussed further in Chapter 4. 
Temperature sensitive (TS) mutations are typically conditional loss of function alleles whose 
phenotypic effect is exacerbated when grown at a non-permissive temperature (Forsburg, 2001; 
Hartwell et al. 1970). This allows for the creation of mutations in essential genes that would 
otherwise be non-viable. 
DNA footprinting is an older technique used to validate the functions of many hitherto putative 
genes at the dawn of the genomic age (Smith et al. 1995). Random insertional mutagenesis using 
transposition of a marked Ty1 transposable element is induced in a large population of cells, 
generating Ty1 insertional mutations at diverse sites. Such a population is then tested for phenotypic 
effects (such as red colouration of colonies – this technique was used to identify the function of the 
ADE2 gene mentioned above (Smith et al. 1995)). Relevant colonies are then selected, and the 
disrupted gene identified using Ty1 based PCR primers. 
One of the most powerful strategies for determining genetic function both as regards to gene-gene 
and gene-drug interactions involves the use of ‘knockout’ mutants or single gene null mutants 
(Winzeler, 1999; Forsburg; 2001; Tong, 2001; Gaiever et al. 2003; Tong 2007; Nislow & Gaiever, 
2007; Ho et al. 2009; Roemer et al 2012). In this strategy a particular compound or gene mutation is 
assayed against a library of null mutants, attempting to identify interactions via an enhanced or 
mitigated phenotype. This approach is explored in Chapter 3. 
The cell cycle in S. cerevisiae is very similar to the cell cycle in humans and is regulated by 
homologous proteins. The diploid sexual cycle means tests can be conducted for complementation, 
homologous recombination, or epistasis; impossible to do in haploid organisms because they require 
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two copies of the gene.  In addition, the ~6300 genes that comprise S. cerevisiae’s genome have 
been sequenced (Boone et al. 2007), even if the function of each is not fully understood. This 
understanding of the genome helps in investigating the potential of drug candidates because genetic 
interactions can be examined in a comprehensive, systematic way.  
As a eukaryote, S. cerevisiae shares much of the complex internal cell structure of higher plants and 
animals, such as the Golgi apparatus, endoplasmic reticulum and mitochondria. There is 
considerable conservation of both cellular components as well as individual genes between yeast 
and human cells (Forsburg, 2001). The conservation of many mechanisms between S. cerevisiae and 
the cellular processes of humans mean that it is a good model for the exploration of genetic disease: 
Foury (1997) estimates that 30% of genes that are implicated in human disease have direct yeast 
orthologues. S. cerevisiae however does not have the high percentage of non-coding DNA (‘junk’ 
DNA) found in higher eukaryotes, which often make research difficult (Goffeau et al. 1996). 
S. cerevisiae is a small single celled organism with a short generation time, allowing for the swift 
production and maintenance of multiple specimen lines at low cost. In addition, it is much easier to 
produce transgenic yeast cells through transformation than it is with higher order model organisms 
(Nickoloff and Hoekstra, 1998). This is in contrast with animal models such as Mus musculus which 
displays greater correspondence to human biology but is more difficult to manipulate, handle and 
maintain (Kyle and Hilton, 2005). S. cerevisiae therefore occupies an important niche in medical 
genetic research: enough homology to higher organisms for results to be meaningful, whilst being 
cost and effort effective enough to enable high throughput strategies.  
This thesis utilises many of the tools herein described to characterise the target and mode-of-action 
of bioactive compounds derived from chemical synthesis and synthetic modification of natural 
products. Routine and leading-edge toxicity assays were used to screen the 254 compound library 
followed by a mutagenesis approach to create mutants resistant to FC-592, one of the most potent 
of these compounds. An advanced mapping strategy was used in an attempt to identify the 
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resistance mediating genes. It is hoped that the activities of the studied compounds will produce 
lead compounds for further development as novel therapeutics or genetic probes. 
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2. Bioactivity Assays          
2.1. Introduction 
2.1.1. Background 
Interest in Saccharomyces cerevisiae remains high, both as a model organism to study basic 
eukaryotic cell biology and as a system for lead discovery of therapeutics, a process helped by the 
high conservation of cellular processes between yeast and mammalian cells (Hartwell, 2002). Use of 
S. cerevisiae in screens can potentiate the development of natural products (Barrett, 2002) and 
synthetic compounds (Parsons et al. 2006) to the clinic. This type of biological analysis is held to be 
vital in exploiting the potential of new lead compounds (Jefford & Hartwell, 1998). 
There are several approaches that can be taken when screening for bioactive compounds with S. 
cerevisiae based assays. The development of arrayed, genome-wide deletion libraries (Mager & 
Winderickx, 2005) and the availability of arrayed chip based expression- (Zhou et al. 2005) and 
barcode- assays (Ho et al. 2009) have allowed genomic methods for dissecting bioactivity, with 
hierarchical clustering based on compound sensitivity profiles (Parsons et al. 2004). 
Haploinsufficiency profiling (Gaiever et al. 2003) can be used to identify target pathways. These are 
all automatable systems that are amenable to high throughput strategies. However, they are 
resource intensive; thus novel compound libraries should be pre-screened for bioactivity by simpler 
methodologies so resources are not wasted investigating inert compounds.  
The simplest way to determine whether a candidate compound displays bioactivity is through an 
inhibition assay. This gives a first indication that the compound is in some way interacting with 
biological processes within the cell, preventing normal phenotypic expression. The chief advantages 
of this preliminary assay are that it is easy to perform in high throughput, and it is time and cost 
effective. An effective high throughput assay at this point allows us to narrow down the possible 
candidates to those with interesting biochemical effects. It is possible however, that more subtle 
variant phenotypes are missed through this type of assay. Because inviability or reduced growth is 
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the phenotype being screened for in this case, less obvious effects such as altered expression of 
certain proteins might be missed. Screening is typically done at a high concentration for this reason: 
It stands to reason that any compound which affects a cell’s normal phenotype will be deleterious to 
that cell’s growth at a high enough concentration. 
2.1.2. The halo assay 
Ideally, the initial inhibition assay would be quantitative, easily automated, and compatible with 
high-throughput screening robotics. Typically a dose response against a range of concentrations in 
liquid media might be employed (Collinson & Dawes, 1992; Broekaert et al. 1990). However, a 
particularly efficient assay for identifying inhibition without the need for complex dilution arrays is 
the halo assay (Gassner et al. 2007), a solid phase assay wherein yeast cells are seeded throughout a 
liquid agar nutrient medium. When the agar sets, compounds are robotically spotted atop the solid 
agar surface and allowed to diffuse. This creates a natural concentration gradient. After incubation, 
inhibitory compounds produce a distinctive ‘halo’ pattern in the yeast bloom, with more potent 
compounds producing larger halos. 
 
Figure 2.3 Distinctive 'halo' patterns show up around the locations of spotted inhibitory analogues of crambescidin. The 
pinned compounds show up as white spots on the surface of this plate. In this case fractions from HPLC-fractionation of the 
marine sponge Monanchora unguifera were spotted. Note the high potency of the crambescidin rich fractions in 
comparison to a rapamycin control spot. Reprinted with permission from American Chemical Society: Journal of Natural 
Products, Gassner et al. 2007. 
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2.1.3. The PDR Network 
S. cerevisiae is well known for its broad spectrum multidrug resistance (Balzi & Goffeau, 1995). This 
has been linked to a series of genes within the pleiotropic drug resistance (PDR) network (Balzi & 
Goffeau, 1991), and take the form of a complex genetic network of at least twenty genes underlying 
resistance to cytotoxic compounds and more generally implicated in membrane transport functions 
(Akache et al. 2004). 
These genes can be grouped into three broad classes (Balzi & Goffeau, 1995): ATP-binding cassette 
(ABC) membrane transport proteins such as SNQ2, PDR5, and YCFI; major facilitators superfamily 
membrane transport proteins such as ATRI and SGE1; and finally transcription factors including PDRI, 
PDR3, PDR7, PDR9, YAP1, and YAP 2, which regulate and control cellular responses to drug insult. 
The PDR network causes obvious problems with drug discovery strategies utilising yeast: it can 
drastically reduce cytosolic concentrations of the candidate compounds making identification of 
potential bioactives more difficult. This is especially the case in inhibition type assays such as the 
halo assay where cellular concentration of the compound must remain high enough to prevent 
growth.  
 
Figure 2.4 Regulatory transcription factors of the PDR network. Arrows represent regulatory interactions, wherein 
multiple S. cerevisiae regulators, including PDRI, PDR3, PDR7, and PDR9, control the expression of various membrane 
transport associated genes. Note the feedback mechanism associated with PDR3, whose promoter has been shown to have 
different binding sites activated by both PDR1p and PDR3p (Delahodde et al. 1995). Reprinted with permission from 
Springer Science: Journal of Bioenergetics and Biomembranes, Balzi & Goffeau, 1995. 
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The effect of the PDR network on an assay such as described could be quite deleterious. In a similar 
zone of inhibition assay (Meyers et al. 1992), PDR attenuated mutants displayed zones of inhibition 
that were over twice as big in inhibition tests for antimycin (15 ng applied compound), 
chloramphenicol (30 μg), erythromycin (5 μg) and lincomycin (60 ng). Other compounds (oligomycin 
(375 ng), ethidium bromide (150 ng)) displayed no increased potency in the PDR attenuated strains. 
This strongly implies that some compounds are able to be bound by PDR associated membrane 
transporters and are thus not substrates for the PDR efflux pumps. It is clear however that an 
inhibition assay utilising a PDR competent strain risks significantly reduced sensitivity. This is a 
problem when available quantities of candidate compounds are limited, or concentration ranges are 
limited by solubility factors etc. There is little or no structural correlation between compounds which 
are substrates and those which aren’t (Balzi & Goffeau, 1995), meaning there is no way to predict 
what type of compounds might be missed as potential bioactives. 
The sensitivity can be improved by the use of an attenuated PDR strain. In the above example 
(Meyers et al. 1992) the PDR5 membrane transporter gene is disrupted with the Tn5 transposon 
(Leppert et al. 1990), rendering a hypersensitive cell.  
In the current study, attenuation is achieved through disruption of the PDR1 and PDR3 transcription 
factors. Since these transcription factors regulate multiple efflux pumps, affecting a broad array of 
genes (including the auto-regulating PDR3 feedback mechanism), the hypersensitivity effect should 
be correspondingly greater. 
The yeast PDR network is analogous to the human multidrug resistance (MDR) system (Ueda et al. 
1987). If the goal of the drug discovery program undertaken is human therapeutics, then an 
attenuated PDR based model is of less use. After all, a drug that only works in a non-drug resistant 
strain isn’t going to be very good at treating diseases in multidrug resistant cells, and such 
compounds might have a high attrition rate during lead development. However, Miyamoto et al. 
(2002) report similar resistance to some drugs (such as reveromycin A) in MDR mammalian cells as 
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PDR attenuated yeast cells. Whilst this study is not a comprehensive review of compounds, it 
suggests that PDR attenuated strains may make a better model for MDR mammalian cells than a 
wild type strain.  
In addition, as mentioned in a previous chapter there are other goals to drug discovery projects such 
as the identification of genetic probes. Since the function of these tools is not predicated on their 
effect against wild type targets (further work can be done in PDR attenuated model strains), their 
utility is not compromised by being substrates for the PDR efflux pumps. It is therefore worthwhile 
trying to identify these compounds by using the PDR attenuated model. 
The pdr1Δ/pdr3Δ strain used in this project was constructed by PCR mediated disruption of the 
PDR1 and PDR3 loci from the y7092 background strain with the NatR resistance cassette and URA3 
deletion cassette from the plasmid vector E. coli strains p4339 and pAG60 respectively, by Namal 
Coorey and Dr. David Bellows of the Chemical Genetics Laboratory, Victoria University of Wellington. 
2.1.4 The IRL Set of Synthetic Organic Compounds 
A screening library of novel organic compounds was obtained from Dr. Richard Furneaux of 
Industrial Research Limited, Gracefield, Lower Hutt. The library consists of 254 compounds 
consisting of (a) residual samples from a diverse array of research projects related to the 
development of novel pharmaceuticals and agrochemicals, including intermediates, by-products and 
final products, and (b) compounds derived by synthetic modification of New Zealand sourced 
diterpenoid natural products that had been donated to IRL by Professor PK Grant, University of 
Otago, on his retirement (Richard Furneaux, personal communication). 
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2.2 Aims and objectives 
The aim of this chapter is to develop a high throughput screening method for novel drug candidates, 
and characterise the inhibition profiles in PDR pump deficient strains, of at least one small molecule 
drug candidate. The key objectives are: 
1. Develop and run a high throughput inhibition assay 
2. Screen a library of compounds to identify bioactives 
3. Characterise MIC and PDR profiles of these compounds 
2.3 Methods and materials 
2.3.1 Yeast strains 
Strain Genotype 
Y7092 MATα; can1Δ::STEpr-Sp_his5; lyp1Δ; his3Δ1; 
leu2Δ0; ura3Δ0; met15Δ0; LYS2+ 
YCG326 MATα; pdr1Δ::NAT; pdr3Δ::URA3; can1Δ::STEpr-
Sp_his5; lyp1Δ; his3Δ1; leu2Δ0; ura3Δ0; 
met15Δ0; LYS2+ 
pdr5Δ MATa; pdr5Δ::KanR; pdr1Δ::NAT; pdr3Δ::URA3; 
can1Δ::STEpr-Sp_his5; lyp1Δ; his3Δ1; leu2Δ0; 
ura3Δ0; met15Δ0; LYS2+ 
yor1Δ MATa; yor1Δ::KanR; pdr1Δ::NAT; pdr3Δ::URA3; 
can1Δ::STEpr-Sp_his5; lyp1Δ; his3Δ1; leu2Δ0; 
ura3Δ0; met15Δ0; LYS2+ 
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snq2Δ MATa; snq2Δ::KanR; pdr1Δ::NAT; pdr3Δ::URA3; 
can1Δ::STEpr-Sp_his5; lyp1Δ; his3Δ1; leu2Δ0; 
ura3Δ0; met15Δ0; LYS2+ 
 
2.3.2 Growth media 
Yeast growth assays were performed in the following media formulations. All media was made up 
with distilled deionised H2O (ddH2O) and autoclaved at 120˚C for 20 min. Sterile glucose was added 
to media post autoclave: 
Yeast peptone dextrose (YPD): 1% (w/v) yeast extract (Bacto), 2% (w/v) peptone (Bacto), 2% (w/v) 
D-glucose (SigmaAldrich). 
Synthetic complete (SC): 0.17% bacto-yeast nitrogen base (Becton, Dickinson & Company), 0.1% 
(w/v) monosodium glutamate 0.2% (w/v) amino acid mix (stock (55.2 g total): 3 g adenine, 2 g 
arginine, 2 g uracil, 2 g inositol, 0.2 g para-aminobenzoic acid, 2 g alanine, 2 g asparagine, 2 g 
aspartic acid, 2 g cysteine, 2 g glutamic acid (MSG), 2 g glutamine, 2 g glycine, 2 g histidine, 2 g 
isoleucine, 10 g leucine, 2 g lysine, 2 g methionine, 2 g phenylalanine, 2 g proline, 2 g serine, 2 g 
threonine, 2 g tryptophan, 2 g tyrosine, 2 g valine), 2% glucose. 
Synthetic deficient (SD) – Ura: As above except without uracil in the amino acid mix. 
NAT: Where noted, 100 μg/mL (final concentration) nourseothricin (ClonNat, Werner Bioagents) was 
added to media after sterilization. 
G418: Where noted, 200 μg/mL (final concentration) geneticin (G418, Invitrogen) was added to 
media after sterilization. 
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Agar: Where noted, 2% (w/v) select agar (Invitrogen) was added before sterilization (YPD) or 
autoclaved separately and added afterwards (all other media). 
MOPS: Where noted, media is buffered to physiological pH with 25 mM MOPS (Invitrogen) buffer 
(final concentration, ~pH 7.0). 
2.3.3 Compounds and chemicals 
As stated in the introduction section, the library of compounds used in this assay was provided by 
Dr. Richard Furneaux of Industrial Research Ltd, in 1.5 mL eppendorf tubes. These compounds were 
dissolved in pure dimethyl sulfoxide (DMSO, SigmaAldrich), to a concentration of 10 or 20 mg mL-1, 
depending on the mass of compound available (appendix 1). The molar concentrations ranged from 
14.3 mM – 165 mM with a median of 35.5 mM. Cycloheximide (SigmaAldrich) and Rapamycin (LC 
Laboratories) were also dissolved in DMSO at a range of concentrations for comparative analysis. All 
compounds were stored at -20˚C.  
2.3.4. Halo assay 
A 20 mL overnight culture of YCG 326 (~16 h, 30˚C in shaking incubator) in SD-Ura broth media was 
initiated and cell titre determined via haemocytometer. The culture was then diluted to 1.0 × 108 
cells mL-1 with fresh SC. SC agar media was produced as above and buffered to ~pH 7.0 with MOPS 
buffer with a final concentration of 25 mM. The low pH of SC media attenuates the bioactivity of 
many pharmacologically active compounds. Buffering of the media to near neutrality reverses this 
effect. MOPS buffer works best for solid phase assays, as the commonly used HEPES buffer produces 
gas bubbles in the plates after incubation. Media was cooled to ~50˚C, ensuring it was not so hot as 
to kill cells (<55˚C), before cells are inoculated into media for a final concentration of ~2×105 cells 
mL-1. 40 mL liquid media was poured into rectangular polystyrene omnitrays (Singer) and allowed to 
set. 50 μL of each IRL compound was plated into 96 well 1 mL round bottom plates (SigmaAldrich). 
The first and last columns (1 & 12) and rows (A &H) were filled with DMSO to avoid evaporation 
effects in the experimental samples either in the plates themselves or after transfer to liquid phase 
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assays.  2 μL of each compound was pin transferred via pinning robot (CyBio, CyBi-Well Channel 
Pipettor fitted with P996 2 μL pins) in 96 well format onto an identifiable location on the plate and 
allowed to diffuse into agar for 5 min. Plates were then incubated at 30˚C for 24 h. Photographs of 
plates (Canon Powershot S3-IS) were then taken using ZoomBrowser EX remote shooting software 
(Canon Inc, NY, USA) and contrast enhanced using ImageJ software (National Institutes of Health). 
Halos were measured in mm and subjectively graded as there was variation in quality of inhibition 
zones as well as size. 
2.3.5. Dose response assays 
Liquid media dose response assays were conducted to determine minimum inhibitory 
concentrations of each identified inhibitory compound. Serial dilutions of each compound were 
performed in DMSO at a half log10 scale in 96-well reagent plates, along with DMSO (negative 
control) and cycloheximide (positive control). The plate format and molar concentrations used in 
each well are given in Appendix 1. A single YCG326 colony was inoculated into 3 mL of SC broth and 
incubated at 30˚C on a 40 rpm rotary drum overnight. Cell titre was determined via 
haemocytometer, diluted with fresh SC MOPS to a final concentration of 5×105 cells mL-1 and 
vortexed to create a homogeneous suspension. 100 μL of media containing cells was dispensed 
(Eppendorf Xplorer Plus 8 Channel Electronic Pipette) into each well of a clear 96 well flat-bottom 
polystyrene cell culture plate (Interlab) and 1 μL aliquots of each dilution were dispensed in triplicate 
using a multi-channel pipettor (Eppendorf Research Plus 8 Channel) into these wells, along with 1% 
DMSO controls. Plates were vortexed at 1000 rpm for 30 s to mix completely and incubated at 30˚C 
for ~18 h. Following incubation, cultures were resuspended by vortexing at 1000 rpm for 30 s and 
the absorbance measured at 590 nm in a spectrophotometer (EnVision 2102 Multilabel Plate 
Reader, Perkin Elmer, Waltham, Ma, USA). Residual growth (%) was determined by comparing the 
turbidity in each condition against the mean absorbance for DMSO control (Abs590 (experimental)/ 
Abs590 DMSO (control)) × 100 for each unique condition.  
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2.3.6. pH sensitivity assays 
Dose response assays were carried out to determine selected bioactive compounds’ relative potency 
in differing pH conditions. A culture of YCG326 was grown overnight in 3 mL SC broth (30˚C, 40 RPM 
on rotary drum). Cell titres were determined via haemocytometer, diluted to 5×105 cells mL-1 with 
fresh SC (~pH 4.0) and SC MOPS (25 mM final concentration, ~pH 7.0) in two different media 
solutions and vortexed to create a homogeneous suspension. 100μL aliquots of each media type 
were dispensed into cell culture plates as for dose response assays protocol. Dilutions (all final 
concentrations) of 1.13 mM, 357 μM, 113 μM, 35.7 μM, 11.3 μM, 3.57 μM and 1.13 μM for FC-888, 
and 354.61 μM, 112.13 μM, 35.46 μM, 11.21 μM, 3.54 μM, 1.12 μM and 354.6 nM for FC-592 were 
prepared. 1 μL aliquots of each dilution were dispensed in triplicate into wells containing each media 
type, along with triplicate 1 μL DMSO controls. Plates were incubated and measured as for the dose 
response assays protocol. 
2.3.7. PDR mutant sensitivity assays 
Dose response assays were carried out to determine the inhibition profiles of the identified 
inhibitory compounds FC-592 and FC-888 in PDR mutants. Yeast cultures of Y7092 (Wild Type), 
YCG326 (Δpdr1::NAT; Δpdr3::URA3), yor1Δ, pdr5Δ and snq2Δ were grown overnight in 3 mL SC broth 
(30˚C, 40 RPM on rotary drum). Cell titres were determined via haemocytometer and diluted to 
5×105 cells mL-1 with fresh SC. 100μL aliquots of media with cells were dispensed into cell culture 
plates as for dose response assays protocol. Dilutions of FC-888 and FC-592 were prepared as for pH 
sensitivity assay and dilutions of cycloheximide (CHX) prepared (final concentrations) at decrements 
of 10 μM, 3.16 μM, 1 μM, 316 nM, 100 nM, 31.6 nM and 10 nM. 1 μL aliquots of each dilution were 
dispensed in triplicate into wells, along with triplicate 1 μL DMSO controls. Plates were incubated 
and measured as for the dose response assays protocol. 
2.3.8 Solid state dose response assays 
A half-log dilution series was created in DMSO for FC-888 and FC-592 with final concentrations of 
112.9 μM, 35.7 μM, 11.3 μM, 3.57 μM, 1.13 μM, 357 nM, 113 nM & 35.7 nM along with 354.6 μM, 
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112.1 μM, 35.5 μM, 11.2μM, 3.55 μM, 1.12 μM, 355 nM & 112 nM respectively. 3 μL of each 
dilution, along with 1% DMSO and 100 nM rapamycin controls, was aliquoted into 1.5 mL micro-
centrifuge tubes and 297 μL molten SC Agar pipetted into the tubes, one at a time. The mixture was 
gently pipette mixed, avoiding bubble formation. The mixture was then transferred into a clear flat-
bottom 48-well plate (Interlab), again avoiding bubbles, and allowed to set. A culture of YCG326 was 
grown overnight in YPD, cell titre determined via haemocytometer and diluted to 5×105 with fresh 
YPD and cell suspension vortexed to ensure homogenization. 2×2 μL of this suspension was spotted 
into each well, allowed to diffuse for 5 min then incubated for ~40 h at 30˚C. Photographs (Canon 
Powershot S3-IS) were then taken using ZoomBrowser EX remote shooting software (Canon Inc, NY, 
USA) and visually inspected to determine cell growth. 
2.3.9 Colony forming unit assays  
A YCG326 culture was grown overnight in 5 mL SC (30˚C, 40 RPM on rotating drum), cell titre 
determined via haemocytometer and diluted to 5×105 cells mL-1 with fresh SC. 1 mL aliquots of this 
cell suspension were dispensed into sterile 15 mL falcon tubes. 10 μL dilutions (all final 
concentrations) of FC-592 (500 μM), FC-888 (1.12 mM), cycloheximide (100 μM), and rapamycin (10 
μM) as well as a 1% DMSO control, were pipetted into individual tubes and vortexed to mix. The 
tubes were incubated at 30˚C for ~16 h on a rotating drum. The treated cells were transferred to 
sterile 1.5 mL microcentrifuge tubes (Eppendorf) and centrifuged at 13000 rpm for 30 s (Eppindorf 
5415r microcentrifuge). Supernatant was discarded and cells washed by vortexing in 1 mL sterile 
ddH2O. This wash step was repeated twice, centrifuged a final time, 100 μL ddH2O added to the 
pellet and vortexed to mix. Cell titre of washed cells was determined via haemocytometer and 
diluted to 5×104 cells mL-1 with sterile ddH2O. 200 μL pools of ddH20 were pipetted onto separate 
SC agar petri plates, and 20 μL of each sample dispensed carefully into these pools, to give ~1000 
cells per plate. The pooled cells were evenly spread over the surface of the plates with the aid of a 
sterile glass rod and allowed to dry for ~20 min. The plates were then inverted and grown at 30˚C for 
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~48 h, after which they were photographed (Canon Powershot S3-IS) using ZoomBrowser EX remote 
shooting software (Canon Inc, NY, USA) and visually inspected to determine cell growth. 
2.3.10 Liquid phase comparison assay 
In order to determine the efficacy of the halo assay method, a comparison assay was conducted in 
liquid media. A 20 mL overnight culture of YCG 326 (~16h, 30˚C in shaking incubator) in SD-Ura broth 
media was initiated. Cell titre was determined via haemocytometer, and culture diluted to 5.0 × 105 
cells mL-1 with fresh SC and buffered to ~pH 6.5 with MOPS buffer with a final concentration of 25 
mM. 100 μL aliquots of this cell suspension were dispensed in clear flat bottomed 96-well cell 
culture plates (Interlab). 2 μL aliquots of each compound in the IRL compound library were pin 
transferred via pinning robot (CyBio, CyBi-Well Channel Pipettor fitted with P996 2μL pins) into these 
wells, which were then incubated at 30˚C for ~18 h. To determine cell density, absorbance was 
measured at 590 nm in a spectrophotometer (EnVision 2102 Multilabel Plate Reader, Perkin Elmer, 
Waltham, Ma, USA). Residual growth (%) was determined by comparing the turbidity in each 
condition against the mean absorbance for DMSO control as described in the dose response assay 
protocol. 
2.4 Results 
2.4.1 Halo assay 
Potential bioactives in the IRL synthetic organic compound set were screened by halo assay. 22 
compounds were identified as inhibitory, showing bioactivity in PDR compromised yeast cells. 
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Figure 2.5 Halo assay shows inhibitory activity in novel compounds. 254 IRL compounds (10 or 20 mg mL-1) were pinned 
onto 5 halo assay plates seeded with ~2×10
5
 cells mL
-1
 YCG326. 22 compounds produced visible halos indicating inhibitory 
bioactivity. Halos were ranked quantitatively (mm) and qualitatively (1-5). Some halos had indistinct edges and were hard 
to see on photographs. These were ranked qualitatively only. 
Halo assay hits 
IRL 
Set 
Hits             
Catalogue 
# 
Mass 
(g) 
Molecular 
mass 
Conc. 
(mg/mL) 
Conc. 
(mM) 
Halo 
Size 
(mm) 
Halo 
Assay 
Score 
(1-5) 
FC-018 0.0124 262 10 38.1679  5.0 4 
FC-526 0.0069 ?? 10 ??  4.5 4 
FC-561 0.0124 268 10 37.3134  4.0 2 
FC-566 0.0138 268 10 37.3134  - 1 
FC-567 0.0108 ?? 10 ??  - 1 
FC-570 0.0054 326 10 30.6748  - 1 
FC-571 0.0114 382 10 26.178  4.5 3 
FC-574 0.0171 308 20 64.9351  - 2 
FC-575 0.0159 282 10 35.461  - 2 
FC-578 0.0049 ?? 10 ??  4.5 3 
FC-580 0.0174 264 20 75.7576  3.0 2 
FC-582 0.0062 330 10 30.303  - 1 
FC-588 0.0081 248 10 40.3226  4.0 3 
FC-589 0.0174 322 20 62.1118  - 1 
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FC-592 0.0079 282 10 35.461  5.0 4 
FC-596 0.0135 308 10 32.4675  - 2 
FC-599 0.0102 280 10 35.7143  - 2 
FC-697 0.0134 363 10 27.5482  3.5 2 
FC-732 0.0091 142 10 70.4225  - 1 
FC-734 0.0028 415 10 24.0964  - 1 
FC-856 0.0010 174.5 10 57.3066  4.0 3 
FC-888 0.0223 177 20 112.994  5.5 5 
Table 2.1. Data on IRL compounds recording hits in halo assay. Halo size, which scales with compound potency (Gassner 
et al. 2007), shows a range among hit compounds of the IRL synthetic library set. Of particular note are FC-018, FC-526, FC-
592 and FC-888, which display large, defined halos. Many hits, such as FC-567, produced only minimal halos, with indistinct 
edges. For this reason they were assessed qualitatively. 
Of 254 compounds in the IRL synthetic compound library, 22 displayed inhibitory activity in the halo 
assay. This translates to a hit rate of 8.66%. Typical drug discovery programmes utilising synthetic 
combinatorial libraries have produced a hit rate of less than 1% (Verheij & Robeson, 2002), 
indicating the abnormally high bioactivity ratio of compounds within this library. 
2.4.2 Dose response assays 
Half log dose response assays were carried out using YCG326 in SC MOPS to determine potency of 
inhibitory compounds identified in the halo assay. Molecular data for three compounds, FC-526, FC-
567 and FC-578, was unavailable. For this reason, molar concentrations could not be calculated for 
these compounds. Since these would require time and effort to determine, these compounds were 
discarded at this point. A further two compounds, FC-018 and FC-734 did not show complete 
inhibition even at the highest concentrations. In the case of FC-018, this was despite a strong 
indication of inhibitory activity in the halo assay. 
Minimum inhibitory concentrations ranged from ~11.21 μM for FC-592 to ~650 μM for FC-574. This 
compares to MICs of typical antifungals such as amphoteracin B (1-4 μM) and fluconazole (64 
μM)(Markovich et al. 2004), although these were not established in ΔPDR cell lines. The two most 
potent compounds, FC-592 and FC-888 were selected for further study. 
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FC-592 
 
Figure 2.6 FC-592: (2R,3R,4aR)-4-butyl-3-
(hydroxymethyl)-4a,8,8-trimethyl-decalin-2-ol is a 
synthetically modified diterpine natural compound 
from New Zealand. 
 
FC-888 
 
Figure 2.7 FC-888: ethyl 3-bromoprop-2-ynoate is a 
synthetic compound developed by IRL in Gracefield, 
New Zealand 
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Figure 2.8 19 compounds from the IRL library were assayed via dose response for inhibitory activity in the YCG326 strain of yeast. Of these, 17 displayed complete 
inhibition within the concentration ranges tested. FC-018 did not display any inhibitory activity in the tested range (<381.68 μM), despite showing as a strong hit in the halo 
assay. FC-592 and FC-888 were the most potent compounds tested, displaying MICs of ~10 μM.
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IRL Set 
Compound 
Potency   
Catalogue # 
Minimum Inhibitory Concentration 
(μM) 
FC-018 >380 
FC-526 ?? 
FC-561 37.31 
FC-566 37.31 
FC-567 ?? 
FC-570 97.00 
FC-571 82.78 
FC-574 649.35 
FC-575 35.46 
FC-578 ?? 
FC-580 239.57 
FC-582 30.30 
FC-588 40.32 
FC-589 196.41 
FC-592 11.21 
FC-596 324.68 
FC-599 112.94 
FC-697 87.12 
FC-732 222.70 
FC-734 >240 
FC-856 57.31 
FC-888 11.29 
Table 2.2 17 MICs of the IRL compound library. Compounds from the IRL library showed complete inhibition against 
YCG326 at the concentration ranges tested. 
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2.4.3 pH dependant inhibitory activity assay for FC-592 and FC-888 in YCG326.  
The effects of varying pH conditions on the biological activities of FC-592 and FC-888 were assayed 
via liquid dose response with a PDR attenuated yeast strain. Both compounds were tested against 
YCG 326 in SC media (~pH 4.0) and SC MOPS media (~pH 7.0). No significant difference in inhibition 
profiles or MICs was observed between low pH and neutral pH conditions in either FC-592 or FC-888 
indicating that the biological activities of neither compound are pH dependant. 
 
Figure 2.9 FC-592 does not show pH dependent biological activity in a YCG326 based dose response assay. Similar 
inhibition profiles are seen in SC (~ph 4.0) and SC MOPS (~pH 7.0) media, as well as displaying similar MICs of ~10 μM. 
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Figure 2.10 FC-888 showed no significant difference in inhibition profile in differing pH conditions in a YCG326 based 
liquid dose response assay.  Similarly to FC-592, this suggests that FC-888 does not have pH dependant biological activity, 
displaying an MIC of ~10 μM in both SC (~ pH4.0) and SC MOPS (~pH 7.0) media. 
 
2.4.4 PDR dependant inhibition assay 
Liquid dose response assays were performed using 5 yeast strains. Yor1Δ, pdr5Δ and snq2Δ, 
obtained from the Boone Array, as well as YCG326 (Δpdr1; Δpdr3) and a wild type control, Y7092, 
were assayed against FC-592, FC-888 and cycloheximide (CHX, as a known substrate for the PDR 
pumps) as a control to determine the PDR network’s effect on each drug. 
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Figure 2.11 FC-592 shows differential sensitivity to PDR competent and PDR attenuated cells. FC-592 was ~3-fold more 
potent in Δyor1 cells and YCG326 cells, with MICs of ~10μM. It showed no significant difference in comparison to WT cells 
for Δsnq2 and Δpdr5 cells (MIC ~35 μM). This strongly suggests that FC-592 is a substrate for the membrane ATP-binding 
cassette (ABC) transporter YOR1p, which is regulated by the PDR1 and PDR3 transcription factors. 
 
 
Figure 2.12 In contrast to FC-592, FC-888 did not show differential sensitivity in the PDR dose response assay. No 
significant difference was seen in sensitivity to FC-888 between PDR competent WT cells and PDR attenuated cells, 
including Δpdr5, Δsnq2, Δyor1 and YCG326. This suggests that FC-888 is not a substrate for the PDR mediated efflux 
pumps. 
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Figure 2.13 Cycloheximide (CHX), a known substrate for PDR mediated efflux pumps (Balzi et al. 1987), serves as a 
positive control for the PDR sensitivity assay. Δpdr5 and Δyor1 strains, along with the PDR attenuated YCG326 strain, 
displayed increased sensitivity to CHX compared to a WT strain. The Δsnq2 strain did not show increased sensitivity over 
the wild type, suggesting the Snq2p membrane ATP-binding cassette (ABC) transporter is not involved in CHX efflux. These 
results, which follow expectations from the literature (Alamgir et al. 2010), show that this assay is effective in identifying 
PDR substrates.  
Results from this assay indicated that FC-592 is a substrate for the PDR mediated efflux network. 
Specifically, evidence suggests that the Yor1p ATP-binding cassette (ABC) transporter, mediated by 
PDR1 and PDR3 transcriptions factors, is responsible for FC-592 efflux. This is suggested by three-fold 
increased sensitivity to FC-592 seen in yor1Δ and YCG326 (Δpdr1; Δpdr3) strains compared to a wild 
type. Inability to efflux the compound means higher cytoplasmic concentrations of FC-592 are 
therefore likely to build up in these strains. This sensitivity was not seen in snq2Δ and pdr5Δ strains, 
indicating FC-592 has no affinity for either of these efflux pumps. 
No significant difference in sensitivity to FC-888 was seen in the PDR competent and PDR attenuated 
strains. This suggests that FC-888 is either not a substrate, or a very poor substrate for the PDR 
mediated efflux pumps. 
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2.4.5 Solid phase dose response 
In order to detect any differences in potency for FC-592 and FC-888 based on assay type, a solid 
phase dose response assay was conducted to compare with liquid phase dose response results. Half-
log decrements of each compound were incorporated into SC Agar media in 48-well plate format 
along with 1% DMSO and 100 nM rapamycin controls. Dilute cell suspensions of YCG326 were 
spotted onto each well to test sensitivity. 
 
Figure 2.14 Solid state dose responses reveal the sensitivity of YCG326 yeast cells to FC-592 and FC-888 on agar media. 
Rows A and B consist of FC-888: these cells showed no inhibition at any concentration level. Rows E and F consist of FC-
592: cells were entirely inhibited at concentrations of 112.1 μM and above, whilst growth is mostly inhibited at 35.5 μM. 
Row C consists of 100 nM rapamycin as a positive control, and row D consists of 1% DMSO as a negative control. Complete 
inhibition was seen in positive controls, whilst full growth was seen in the negative controls, showing the assay worked as 
expected. 
The solid phase dose response assay revealed the severely attenuated potency of FC-888 in solid 
phase. Whilst FC-888 inhibited growth at ~ 11 μM in liquid phase assays, no inhibition was seen even 
at the highest concentration (112 μM) in the solid phase assay. This raises interesting questions 
112.9 μM 35.7 μM 11.29 μM 3.57 μM 1.13 μM 357 nM 112.9 nM 1% DMSO 
354.6 μM 112.1 μM 35.5 μM 11.2 μM 3.55 μM 1.12 μM 354.6 nM 1% DMSO 
FC-888 
100 nM 
rapamycin 
1% DMSO 
FC-592 
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about cellular uptake of this compound, especially considering strong inhibition was observed for 
this compound in the solid phase halo assay.  
FC-592 also showed some attenuated activity compared to the liquid phase assay, although not 
nearly to the same degree. The compound still inhibited growth at 35.5 μM, although growth still 
occurred at 11.2 μM. This indicates an MIC somewhere between 1-3 fold lower than the same 
compound in liquid media.  For drug saving considerations, this means that further work with this 
compound will be more efficient in liquid than on agar based media. 
2.4.6 Liquid phase comparison assay 
To determine the efficacy of the halo assay, a comparison was made to a more traditional technique, 
using a liquid media inhibition assay. The IRL compound library was pinned into SC MOPS media 
containing YCG326 cells and grown for ~18 h. Optical absorbance was used to determine growth 
rate, with residual inhibition percentage (100-(Abs(Exp)/Abs(Cont)×100) of at least 20% being 
considered inhibitory. Figure 2.15 displays the compounds identified as inhibitory in this assay. There 
were a far greater number of bioactive compounds identified here than there were from the halo 
assay. However FC-592 and FC-888 had already been selected based on previous results for further 
investigation, and so the newly identified bioactive compounds such as FC-017 and FC-517 were not 
explored further at this time. However, these remain a possibility for future investigation. 
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Figure 2.15. 53 compounds from the IRL library showed inhibitory activity of at least 20% in YCG326 in a liquid based inhibition assay. Compounds displaying inhibition >90% are essentially 
completely inhibitory in this assay, with the remainder accounted for in background variation. This included all the compounds that were identified in the halo assay except for FC-571 and FC-
734. A significant number of compounds were identified as having complete or near complete inhibition despite not showing up at all on the halo assay. This intriguing result suggests a 
possible difference in drug uptake between liquid phase cultures and agar based media, which has clinical ADME implications. In addition these data demonstrate the increased sensitivity of a 
liquid based assay compared to a halo type solid phase assay. 
0
20
40
60
80
100
120
FC
-0
17
FC
-0
18
FC
-5
00
FC
-5
17
FC
-5
24
FC
-5
26
FC
-5
31
FC
-5
39
FC
-5
46
FC
-5
48
FC
-5
49
FC
-5
51
FC
-5
53
FC
-5
58
FC
-5
61
FC
-5
64
FC
-5
66
FC
-5
67
FC
-5
69
FC
-5
70
FC
-5
73
FC
-5
74
FC
-5
75
FC
-5
76
FC
-5
78
FC
-5
80
FC
-5
81
FC
-5
82
FC
-5
84
FC
-5
85
FC
-5
88
FC
-5
89
FC
-5
90
FC
-5
91
FC
-5
92
FC
-5
94
FC
-5
96
FC
-5
97
FC
-5
99
FC
-6
97
FC
-7
32
FC
-7
42
FC
-7
44
FC
-8
08
FC
-8
30
FC
-8
56
FC
-8
66
FC
-8
68
FC
-8
78
FC
-8
79
FC
-8
87
FC
-8
88
FC
-9
10
In
h
ib
it
io
n
 (
%
) 
Compound catalougue # 
Inhibitory compounds from the IRL compound library 
42 
 
2.4.7 Colony forming unit assay 
A colony forming unit assay was performed by treating YCG326 cells with high doses of FC-592 and 
FC-888 to determine if those compounds displayed cytotoxic or cytostatic activity. These were run 
alongside controls consisting of DMSO, cycloheximide treated cell (a known cytostatic compound) 
and rapamycin (a known cytotoxic compound) treated cells. Data from this assay would prove 
whether FC-592 and FC-888 killed cells outright (or caused irreversible growth arrest, which amounts 
to the same thing), or merely halted growth whilst in the presence of the compound. 
 
 
  
Figure 2.16 DMSO treated control shows good growth 
for colony forming unit assay. This result acts as a 
baseline for drug treatments. 
Figure 2.17 Cycloheximede treated control. Cells 
recovered from high dose CHX treatment, but 
showed a higher attrition rate than the DMSO treated 
control. Note the prevalence of petite colonies, a 
phenotype associated with the loss of mitochondria 
in the parent cells.   
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Figure 2.18 Rapamycin treated control. Cells 
treated with high dose RAP do not recover. 
Rapamycin irrevesably inhibits the TORC1 
complex and serves as a model of a cytotoxic 
compound. 
Figure 2.19 FC-592 treated cells recover after 
washing and growth on nutrient media. A lower 
proportion of cells survive compared to a DMSO 
treated control however, suggesting that cells 
are undergoing attrition, whilst not replenishing 
the population during FC-592 treatment. Few 
petite colonies are seen, in contrast with CHX 
treated cells. These data suggest that FC-592 has 
cytostatic activity. 
Figure 2.20 FC-888 treated cells do not recover 
after washing and growth on nutrient media. It 
is apparent that FC-888 displays cytotoxic activity, 
either irreversibly inhibiting or directly killing 
YCG326 cells. 
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Results of the colony forming unit assay show that FC-592 displays cytostatic activity, whilst FC-888 
is cytotoxic. This result has implications for both compounds. Chemotherapy of cancer, treatment of 
skin diseases and treatment of certain infections are conditions which are often treated with 
cytostatic drugs (Pervin et al. 2001). Cytostatic drugs can have a more specific mechanism that 
allows for increased target selectivity, for example of tumours (Chapes et al. 1988). 
Cytotoxic agents such as FC-888 have several mechanisms, but tend to be broader in action 
(Valeriote & Vanputten, 1975). Compounds may cause necrosis, in which cells lose membrane 
integrity and die rapidly as a result of cell lysis, or apoptotic pathways can be activated. Alternatively, 
the compound can cause irreversible inhibition of enzymatic activity, preventing cell proliferation 
and leading to eventual cell death (Poulin et al. 1992). 
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2.5 Discussion 
2.5.1 Biologically active organic compound screening 
This project identified a range of biologically active small molecule organic compounds. The library 
of compounds obtained from Industrial Research Ltd. consisted of purely synthetic intermediates, 
by-products and enantiomers of organic synthesis work, and synthetic derivatives of natural 
products. This library was screened for inhibitory biological activity for mode of action studies in a 
yeast model system. 254 novel compounds were screened for inhibitory activity producing 22 ‘hits’ 
for inhibitory activity on a ‘halo’ assay.  
Several other compounds identified as inhibitory either possessed incomplete molecular mass data 
(meaning determining molar concentration was impossible), or proved too weak in a liquid phase 
dose response assay. These compounds were discarded from further study, although remain as a 
possible future project. 
Traditionally, most drugs have either been natural products or synthetic derivatives of natural 
products. By 1990, over 80% of drugs fell into one of these two categories (Li & Vederas, 2009). Only 
in recent times have advances in chemistry lead to a focus on other sources such as synthetic 
diversity oriented libraries (Koehn & Carter, 2005). In addition, this focus on synthetic sources has 
not lead to an increase in drug discovery (Gullo et al. 2006). This may be in part because of the 
complex structures of natural products with numerous oxygen-containing substituents and an 
abundance of centres of stereochemistry found in natural product derivatives (Butler, 2004). 
This tendency is borne out by this project. Most of the hits found were synthetically modified 
diterpene natural products from New Zealand plant sources. These compounds include FC-561, FC-
566, FC-567, FC-570, FC-571, FC-574, FC-575, FC-578, FC-580, FC-582, FC-588, FC-589, FC-592, FC-
596 and FC-599. From a biology perspective, this makes sense as natural product compounds are 
presumed to have evolved for specific targets.  
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Although it was decided not to expend resources characterising the mode of action of all the 
compounds identified as bioactive, information provided by Dr. Richard Furneaux suggested that 
compounds in the 500 series are likely to have similar structures, being derived from similar natural 
product compounds. This in turn means that compounds within this series are likely to have a similar 
mode-of-action. For this reason it was decided to only attempt to characterise one of the 
compounds in this series, FC-592. This compound was the most potent relative to the yeast strains 
tested of all the diterpene natural product derivatives, and was thus regarded as having the best 
chance for mode-of-action identification. 
Of the purely synthetic compounds identified, the most potent was FC-888. This compound was also 
selected for further study due to its novelty and potency. Novel synthetics are not common amongst 
emerging anti-fungal agents (Di Santo, 2008), and it was felt that characterisation of the mode-of-
action of this compound would prove interesting. 
2.5.2 The halo assay as an inhibition screen in yeast 
The halo assay uses yeast cells seeded within nutrient agar to test for inhibitory activity in 
compounds applied to the surface of plates. Since small molecule compounds disperse evenly from 
their point of application, regions closer to this point will carry a higher dose of the compounds 
(Gassner et al. 2007). Yeast cells in these regions are inhibited in a dose dependant manner, meaning 
that comparatively more potent compounds will produce larger halos. 
The halo assay in this project was effective in identifying inhibitory compounds, and did so in a way 
that is amenable to high throughput screening strategies. However, there were several issues with 
this method. Firstly, growing yeast within the agar produced gas bubbles which resulted in a series 
of split-like ‘bubbles’ within the medium. This problem was largely mitigated by switching from a 
HEPES based buffer to a MOPS based buffer, but remained an issue throughout the experiment. It is 
not known whether HEPES produces excess gas evolution, resulting in more ‘bubbles’, or produces a 
more brittle agar medium, causing more of the ‘bubbles’ to form given similar gas evolution. 
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Halo assay media takes a higher level of expertise to produce than an equivalent liquid based media. 
This is because a live cell culture must be added at the correct concentration to molten agar media 
that is cool enough to not heat kill the cells. In addition, this cool media becomes more difficult to 
pour into plates. These factors should be kept in mind when instructing inexperienced researchers in 
this technique. 
Whilst the halo assay performed well in identifying 
several inhibitory compounds, it proved to not be 
as sensitive as a liquid phase inhibition assay that 
was performed with the same compounds for 
comparison purposes.  Where the halo assay 
identified 22 such compounds, the liquid phase 
comparison revealed 53 compounds which caused 
at least 20% inhibition in ΔPDR cells. In addition, 
quantitative aspects of inhibition (data about each compound’s potency), had to be subjectively 
analysed in the halo assay (where the borders of the halos were often indistinct). Alternatively, a 
plate reading robot could be used to objectively measure inhibition levels in the liquid phase assay. 
Figure 2.21 Halo assay test plates using 25 mM HEPES (l) and 25 mM MOPS (r) to buffer media to physiological pH. A gas 
evolution in the HEPES plate caused a series of bubbles, which would have the potential to obscure any halos produced by 
the experiment. 
Figure 2.22 Comparison of inhibition assay results. Plate 
2 from the halo assay (top), and a visual representation of 
output from the equivalent liquid phase inhibition assay 
plate (bottom). More blue circles represent a higher level 
of inhibition. Many more hits are seen in the liquid assay 
than in the solid phase halo assay. 
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This introduces less error into the measurement of results and would produce less variation 
between researchers or labs working in parallel of the same or similar compounds. 
It should be noted that there were several compounds which were seen to potently inhibit yeast in 
the solid phase assay, but did not inhibit growth at all in liquid. The vice versa was also true. These 
results could be explained by differences in compound solubility or cellular uptake, and illustrate the 
differences in drug behaviour often seen between liquid phase and solid phase assays (Curran & 
Bugeja, 2005). 
2.5.3 Dose response assays 
A series of dose response assays were carried out in differing conditions to determine the 
characteristics of the studied compounds with regards to general potency, pH conditions, the 
pleiotropic drug resistance (PDR) network, and solid phase vs. liquid phase assay type. 
A liquid phase dose response assay showed that both FC-592 and FC-888 inhibited yeast growth in 
the low μM range. FC-592 inhibited all growth with a minimum inhibitory concentration of 11.21 μM 
in the PDR attenuated (ΔPDR) strain YCG326, and at ~35 μM in a wild type (WT) strain. FC-888 
inhibited growth at 11.29 μM in both ΔPDR and WT strains.  
The strong potency of both of these compounds has implications for further research. Although 
neither are being considered as lead compounds for medicinal research, they do display the potency 
required were such a direction to be undertaken. Because they are diluted in the bloodstream, and 
high molar concentrations of many compounds are associated with deleterious side effects (Bodor & 
Buchwald, 2000), bioactivity must be achieved at a relatively low concentration. In addition, high 
drug potency is associated with lower risk of idiosyncratic drug reactions (Uetrecht, 2001; Uetrecht 
2008). 
Typical therapeutic drugs such as the commonly used antiepileptic phenytoin, which is given at a 
plasma concentration of 20 – 40 μM, operate in the low μM range (Thompson, 2000). If used in a 
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hypothetical therapeutic setting, FC-592 and FC-888 would operate at a sub-inhibitory dose – i.e. 
likely in the high nM range. This means they are sufficiently potent to be considered for such an 
application if future research results justified it.  
Strong potency is also a requirement for anti-microbials, another potential application for inhibitory 
compounds. As well as the need to completely inhibit microbial growth to avoid the rise of antibiotic 
resistance (Drusano, 2001), high molar concentrations of these agents can have pharmacokinetic 
issues such as renal complications (Pea et al. 2007). Therefore a low MIC is required in the 
consideration of such agents. The common antifungal ketoconazole has an MIC range of 1-2 μM in 
WT S. cerevisiae (Zhanel et al. 1998), on the same order of magnitude as FC-888. This makes 
antimicrobial applications a viable direction for research with this compound. 
This project made use of a ΔPDR strain of yeast to increase sensitivity to the inhibitory compounds. 
This strategy proved effective in reducing the amount of compound required to conduct further 
assays. Conservation of compound became a key consideration in experimental design, as the 
available amount of each chemical was severely limited. ΔPDR cells were ~3 fold more sensitive to 
FC-592 relative to a WT equivalent allowing a greater amount of work to be done than would be 
possible with a WT strain.  
A PDR dose response assay comparing the sensitivity of FC-592 in ΔPDR cells, WT cells, and a range 
of efflux pump single deletion mutants (Δyor1, Δsnq2 and Δpdr5), suggested that the compound was 
a substrate of the YOR1 plasma membrane ATP-binding cassette (ABC) transporter. This efflux pump 
is known to mediate export of many compounds including oligomycin, amitrole and cycloheximide 
(Katzmann et al. 1995; Alamgir et al. 2010), many of which are organic anions (Cui et al. 1996). This 
suggests the possibility that FC-592 may be deprotonated; although this doesn’t reveal much about 
the target or mode-of-action of the compound as these PDR efflux pumps are known to mediate the 
transport of a wide range of unrelated substrates (Balzi & Goffeau, 1995). 
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On the other hand, FC-888 proved not to be a substrate for the drug efflux pumps mediated by the 
PDR network, with no differences in sensitivity observed between PDR attenuated strains and PDR 
competent strains. The high potency of FC-888 even in WT cells however, meant that sufficient 
quantities of the compound were available to complete all necessary work. 
The evidence that FC-592 is a substrate of the membrane ABC transporter Yor1p is an indication that 
it might reach the cytosol in an anionic or deprotonated state. This is because other compounds 
whose efflux has been shown to be mediated by this protein exist in anionic form (Cui et al. 1996). 
Supposing anionic dependant activity, one might therefore expect that at lower pH conditions, 
where protonation is driven, FC-592 would show ablated activity. However, this is not seen in a dose 
response assay conducted in varying pH conditions. Assays at ~pH 4.0 and ~pH 7.0 show identical 
inhibition profiles. Therefore, either the compound is not protonated even at low pH conditions, or 
its activity is not ablated by protonation. Because the mechanism by which PDR substrates are 
bound and effluxed from the cell is largely unknown (Balzi & Goffeau, 1995), there exists the strong 
possibility that Yor1p does not require an anionic substrate, and that FC-592 does not exist in a 
deprotonated form. However, there is no evidence in the literature to support this determination 
about Yor1p. 
Additionally, the pH dependant dose response assay showed that FC-888 was not affected by pH 
conditions either. This is expected for this compound however: a halogenated aliphatic ester, this 
compound has no hydrogens which are easily dissociated from it. Therefore it is unlikely to be 
affected by changing pH conditions. 
A solid phase dose response was conducted with FC-592 and FC-888 for comparison to liquid phase 
results. FC-592 was determined to have a ~3 fold higher MIC in a solid phase agar based assay. As 
previously mentioned, these differences could be due to differences in solubility of the compound in 
different media types or mechanism of cellular uptake. A more remote possibility is differences in 
metabolism between the solid phase interface and liquid culture. Microorganisms are known to 
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behave differently on a solid surface and in a liquid culture environment (ZoBell, 1943; Stotzky & 
Rem, 1967). Therefore differing metabolic activity could affect the concentration at which FC-592 
inhibits yeast growth. 
FC-888 was completely inactive at the concentration ranges tested in solid phase dose response 
assays. This is despite the fact that the compound displayed a potent inhibitory effect on the halo 
assay. Because the compound inhibited yeast growth on the agar based halo assay, it is unlikely that 
this reduction in inhibitory activity is the result of differences in solubility or cellular uptake. Instead 
it is proposed that the compound was degraded by the ~50˚C temperature to which it was subjected 
during plate production. The compound was applied to liquid SC agar during the making of plates for 
this assay, and could have been affected by this temperature. 
2.5.4 Colony forming unit assay 
An assay was conducted to determine whether FC-592 and FC-888 permanently killed cells (cytotoxic 
activity), or temporarily inhibited their growth (cytostatic activity). FC-592 treated cells managed to 
recover and grow on nutrient media after washing, although there were less colony forming units 
than in a DMSO treated control. This is likely because the cell population undergoes natural attrition 
whilst under compound treatment. Even though the compound does not directly kill the cells, 
because it stops the population replenishing itself, there are a lower proportion of viable cells after 
treatment relative to the control.  
Medicinally, cytostatic agents have proven very beneficial in fighting tumours with their ability to 
induce cell growth arrest (Chapes et al. 1988). Due largely to the multiple mutations they possess, 
cancer cells have very high death rates (New Zealand Institute of Chemistry, 2012). Thus, preventing 
reproduction leads to a reduction in tumour size. These drugs gain their anti-tumour specificity from 
the higher attrition rate found in these cell types 
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FC-888 treated cells did not recover in this assay, indicating that they were either directly killed or 
irreversibly inhibited by the treatment, and thus this compound exhibited cytotoxic activity. 
Cytotoxic agents function in a myriad of ways, including alkylation of DNA (New Zealand Institute of 
Chemistry, 2012) and induction of apoptosis (Wang et al. 2000). Whilst many cytotoxic agents have 
utility as chemotherapeutics treating non-infectious diseases (Fred Hutchinson Cancer Research 
Center, 2012), a primary use for them is as anti-microbial agents (Talbot et al. 2006). This is 
additional evidence that anti-microbial activity could be a potential application for a compound like 
FC-888. 
2.5.5 The chemistry of FC-592 and FC-888 
It is possible to glean some insight into the characteristics of novel compounds based on their 
chemical structure and predictions about their chemistry. There are several determinations that can 
be made about FC-592 and FC-888 in this manner. 
FC-592 ((2R,3R,4aR)-4-butyl-3-(hydroxymethyl)-4a,8,8-trimethyl-decalin-2-ol) is a non-polar 
saturated bicyclic alcohol. Therefore it is a fairly stable compound for which little obvious chemistry 
suggests itself. As previously mentioned, the compound’s apparent affinity for the plasma 
membrane ABC transporter Yor1p suggests that it might exist in an anionic state within the cytosol. 
A possible mechanism for such a reaction is: 
 
 
 
 
 
Figure 2.23 Lewis diagram anion formation. Although unlikely, it is possible that deprotonation could proceed on the basis 
of hydrogen bonding in the oxyanion product lowering the alcohol pKa. However, this is unlikely to have a realistic pKa 
value (Paul Teesdale-Spittle, personal communication), unlikely to occur below ~pH 12. 
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The anion product seems very unlikely in a cytosolic context because the pKa for proton dissociation 
likely requires highly basic conditions. Since the compound has proven to be similarly active in ~pH 
4.0 and ~ pH 7.0, this possibility can effectively be discounted. Therefore it is more likely that Yor1p 
in this case is mediating the efflux of a non-ionic molecule. Although Yor1p (Cui et al. 1996) has been 
associated with anion efflux, some substrates for the transporter, including cycloheximide (Dudley et 
al. 2005) and amitrole (Alamgir et al. 2010), are unlikely to be anionic in cytosolic conditions. 
Because of this the most likely explanation is that Yor1p more commonly mediates the efflux of non-
anionic species than is suggested in the literature.  
The compound is a highly lipophilic molecule with a polar diol region, that is likely to be a non-
specific binder to a range of hydrophobic pockets and environments, which might include the cell 
membrane or hydrophobic pockets within enzymes. Drugs with lipophilic properties are more easily 
incorporated into the phospholipid bilayer membrane (Schwendener & Schott, 2010), meaning they 
can diffuse across membranes without the need for pharmacokinetic strategies such as liposome 
incorporation. In addition, hydrophobic drugs are likely to have a high lipophilic efficiency (LiPE) 
score, which is associated with ‘druglikeness’ (Leeson & Springthorpe, 2007). LiPE is a statistical 
measure which combines metrics of the drug’s potency and lipophilicity (Edwards & Price, 2010). 
Quality drug candidates have a high LiPE, combining permeability through biological membranes and 
a reduced chance of idiosyncratic drug reactions and off-target toxicity (Uetrecht, 2001; Uetrecht, 
2008; Hughes et al. 2008). 
Some lipophilic antimicrobials such as the polyene macrolides are known to disrupt cell membranes 
(Bolard, 1986), leading to cell death by a number of mechanisms such as pore formation resulting in 
K+ leakage and the peroxidation of membrane lipids. However it is clear that FC-592 does not result 
in cell death, as it is a cytostatic compound rather than a cytotoxic one.  
In contrast, n-3 and n-6 polyunsaturated fatty acids have been shown (Diggle et al. 2000) to cause 
reversible antiproliferative and irreversible cytostatic effects, possibly due to lipophilic albumin-
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complexed fatty acid metabolites rapidly incorporated into normal cell membranes which are 
predicted to alter the functioning of proteins within cell membranes – causing cytostasis (Shires et 
al. 1989). Whilst there is no evidence that FC-592 has anything in common with these mechanisms, 
the several properties that they have in common (lipophilicity, cytostatic activity) makes it an 
intriguing direction for future research, which could include assays into cell membrane disrupting 
agents such as a β-galactosidase leakage assay (O’Niel et al. 2004). 
FC-592 bears some structural similarity to drimane 
sesquiterpenes. These compounds are members of the 
deterrent natural product terpene family which are 
characterised by reactive unsaturated dialdehyde moieties 
(Gershenzon & Dudareva, 2008), and are found in various 
plants, fungi, animals and marine invertebrates (Iken et al. 
1998). FC-592 lacks the aldehyde groups which are 
implicated in the mode-of-action for these compounds through activation of TPRA1, an ion channel 
involved in inflammatory pain signalling initiated through influx of extracellular Ca2+  into the cells 
(Escalera et al. 2008), and is therefore unlikely to act in the same manner. However, drimane 
sesquiterpene compounds are inactive absent the dialdehyde moiety (Szallasi et al. 1998), including 
lacking inhibitory activity at relatively high cytosolic concentration (~200 μM, Escalera et al. 2008). 
Therefore it is possible to conclude that the basic structure does not initiate a particular inhibitory 
cellular response. The activity of FC-592 is more likely to be mediated by its putative hydrophobic 
pocket binding properties. 
FC-888 (ethyl 3-bromoprop-2-ynoate) is a halogenated aliphatic alkyne ester. The bromine atom 
attached to the triple bonded carbon is a strong leaving group, meaning that the compound is highly 
susceptible to nucleophilic attack: 
Figure 2.24 Polygodial, a drimane 
sequiterpene found in a range of peppery 
shrubs. Source: Escalera et al 2008. 
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The substitution reaction proposed in figure 2.25 would see cellular nucleophiles such as DNA or 
certain amino acids bound to FC-888. The nucleophile attacks the electrophilic triple-bond (1), which 
is stabilized as an intermediate by HOMO-LUMO interaction with the carbonyl oxygen (2). Bromine 
leaves this unstable intermediate as a bromide ion, creating an overall stabilized organic cation (3).  
This reaction could have a range of deleterious effects including altering the structure of proteins, 
distorting the shape of nucleic acid chains, and interfering with the replication of DNA. However, 
further reactions are likely that could have bearing on the mechanism of the compound in a cellular 
context. Further reaction of product (3), still containing a highly reactive triple bond, is expected to 
be thermodynamically favourable, and could see the reaction proceed along several pathways: 
 
 
 
 
 
 
 
Figure 2.25 Nucleophilic substitution of bromine with a cellular nucleophile. The highly reactive triple bond and the 
strong Br leaving group make this an energetically favoured reaction. In this scenario, FC-888 would bind to multiple 
targets and affect many processes throughout the cell, including DNA transcription and replication.  . 
Figure 2.26 Nucleophilic substitution of FC-888 is completed. Unstable intermediates 4 & 5 undergo protonation to 
achieve the proposed stable final products (6 & 7). 7 is the energetically favoured product, whilst 6 is the sterically 
favoured product. Still prone to conjugate addition/elimination, 6 is an unlikely end product.  
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In these reactions, more stable products are created than (3). The unstable intermediates (4) & (5) 
are protonated resulting in an alkene ester. In (6), the bromine remains as a substituent. The 
likelihood of conjugate addition/elimination makes this an unstable intermediate as well, making (7) 
the energetically favoured product. The Nu groups are likely to be large macromolecules such as 
proteins or nucleic acids. The formation of (7) could possibly be sterically hindered, driving the 
equilibrium reaction back towards (6). However, alkylating agents such as cis-platin (Rosenber et al. 
1965) have proven to have potent DNA cross-linking properties (Thompson, 2007), showing the 
suggested mechanism for the formation of (7) is possible and has an empirical basis.  
This proposed mechanism suggests a great deal about the likely mode-of-action of the compound in 
inhibiting yeast growth. The primary mechanism of toxicity that suggests itself is DNA alkylation, 
which is compatible with the recorded activity of the related compound propyl hept-2-ynoate 
(PubChem, 2012). Soluble, electrophilic alkylating agents are highly toxic because of their ability to 
alkylate DNA, disrupting normal genetic function (Stefanidakis & Gwyn, 1993). Alkylated DNA either 
does not coil/uncoil properly, or cannot be processed by information-decoding enzymes.  
Bifunctional alkylation agents can form cross-links between the complementary strands (Tomasz et 
al. 1988), causing selective inhibition of DNA replication. For this reason, alkylating agents such as 
mitomycin C have been used to target rapidly dividing cells such as tumours (Tomasz, 1995), as they 
are more heavily affected than more slowly dividing, healthly, somatic cells. However, alkylating 
agents often have mutagenic effects (Schloacher et al. 2006), including carcinogenic mutations, 
resulting in higher incidence of cancer after exposure (Lawley, 1980). Assuming formation of product 
(7) above is favourable, FC-888 would be an example of a bifunctional alkylation agent, and could be 
explored for similar utility. 
Alkylating agents can target a broad array of cellular processes, and so may lack specificity desired in 
a therapeutic. In S. cerevisiae low levels of the alkylating agent methyl methanesulfonate have been 
shown to cause significant gene transcript increases in no less than 325 genes (Jelinsky & Samson, 
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1999), with decreases in a further 75. This illustrates the extensive range of effects that cellular 
alkylation can have, with affected genes ranging from DNA repair to heat shock to protein kinases. It 
should therefore be acknowledged that not all alkylating agents have the required specificity for 
pursuit as therapeutics. Most known therapeutic cross linking agents are large and complex enough 
to recognise 2-3 nucleotides as binding sites (Bose et al. 1992) or are active only in hypoxic 
conditions (Patterson et al. 2007). It is unlikely that FC-888 has sufficient structural complexity to 
mediate specific inhibition in this manner. However there are a few examples such as cis-platin that 
are structurally simple but useful therapeutically (Thompson, 2007). 
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3. Chemigenomic Analysis         
3.1 Introduction 
3.1.1 Gene networks 
Genes typically do not work in isolation, but work with each other in complex pathways and 
networks (Awad et al. 2012). Understanding how drugs operate as part of these networks, for 
example binding certain gene products to express a desired phenotype, is important to our ability to 
optimise and develop drugs into therapeutically useful treatments. Inherent in this understanding is 
dissecting complex sets of interactions between small molecule probes and a diverse set of genes 
and gene products, which in turn interact with other genes and gene products to create further 
downstream effects. 
The use of S. cerevisiae as a model allows an ingenious method of characterising the mechanism of 
drug candidate interaction with genetic networks, known as chemical genomic analysis (Zhao et al. 
2005; Singh-Babak et al. 2012).  
3.1.2 The deletion mutant array 
Per Boone et al. (2007), mutations in most eukaryotic genes have little distinguishable effect. Only 
~20% of genes appear to be essential for viability when individually deleted in haploid S. cerevisiae 
cells grown under normal conditions. This is evidence that the vast majority of genes do not work on 
their own to achieve their intended function, but as part of a robust and redundant genetic circuit 
which resists a loss of function at any one 
node. Indeed, this result illustrates the 
tendency of organisms to build buffering 
schemes that allow phenotypic stability 
despite genetic variation, environmental 
Figure 3.1 Gene deletion strains are created by PCR mediated 
mediated gene disruption strategy that exploits the high rate of 
homologous recombination in yeast. A kanR marker disrupts the 
gene of interest, and is flanked by unique 20 bp oligomer barcode. 
Reprinted by permission from Macmillan Publishers Ltd: Nature 
Reviews Genetics, Boone et al. 2007. 
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changes and random events such as mutations (Hartman et al. 2001).  
These two phenomena, interconnected gene networks and robust genotypes that can resist loss of 
function mutations in most genes, allow for an elegant tool to parse genetic interactions.  Given that 
null mutants are usually viable, researchers have built a library of such knockout mutants which 
encompasses the majority of the genome (Winzeler et al. 1999). Strains are constructed via PCR 
mediated disruption of individual ORFs with a kanamycin resistance marker flanked by a unique 20 
bp oligomer identifying barcode region. These libraries, which exist in haploid as well as homozygous 
and heterozygous diploid forms (Giaver et al. 2003), have become valuable tools for research into 
the function of gene pathways and regulatory networks (Zhao et al. 2005), disease systems 
(Munkacsi et al. 2012) and drug mechanism (Parsons et al. 2006). 
These feats are possible because whilst a knockout mutant for a non-essential gene may be viable, it 
is weakened in the specific pathway or network within which that gene is associated. A second 
deletion in the same pathway or a related process could cause an enhanced phenotype, which is 
readily detectable as a synthetic sick or synthetic lethal growth type (Tong et al. 2001). By mass 
mating a comprehensive gene deletion library such as the Boone Array (Tong & Boone, 2007, known 
as the Deletion Mutant Array or DMA) in ordered arrays with a second null mutant, double mutants 
displaying an enhanced growth defect can be identified. In this way, interactions between genes can 
be identified and a picture of pathways and networks can be built.  
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In an analogous manner, 
gene deletion libraries can be 
used (Nislow & Giaever, 
2007) to probe the 
mechanism of small molecule 
drugs. Gene knockout strains 
from an ordered library such 
as the Boone Array are 
assayed for sensitivity to the compound of interest.  Whilst each genetic network is typically able to 
compensate for a single gene deletion, if the network comes under insult from a chemical 
compound as well, it can often not recover. In this way, cells which are deficient in genes in a certain 
network are more vulnerable to chemical attack on that network. By analysing patterns of synthetic 
sick or synthetic lethal cell growth, the target pathways of the compound can be identified. Assays 
conducted using a heterozygous deletion library (where each strain has one functional copy of a 
gene) are known as Haploinsufficiency Profiling 
(HIP) assays, whilst homozygous based assays 
are known as Homozygous Profiling (HOP) 
assays. 
3.1.3 Barcode microarrays 
A key limitation of this approach is the quantity 
of compound used in such a chemigenomic 
array experiment. Typically the DMA is pinned 
onto agar plates containing a minimally 
inhibitory level of the drug. In the case of 
Figure 3.2 The DMA can be used to identify drug targets. Whilst the cell is viable 
when either the drug target or related gene is disrupted, it is incapable of surviving 
the double insult. By noting the pattern of phenotype enhancement in a chemical 
genomic array experiment, target pathways of individual drugs can be identified. 
Reprinted by permission from Macmillan Publishers Ltd: Nature Biotechnology,  
Parsons et al. 2004. 
Figure 3.3 Parallel analysis of large pools of deletion 
mutants allow populations of pooled mutant cells to be 
screened for sensitivity in a drug efficient manner. Pooled 
cells are grown in the presence or absence of a growth-
inhibitory drug. Genomic DNA is extracted from the pool, 
barcodes representing each individual strain are PCR 
amplified and stained with a fluorescent dye, and hybridized 
to a microarray chip. Drug-sensitive mutants are identified 
by a low signal for that barcode compared to an untreated 
control. Reprinted by permission from Macmillan Publishers 
Ltd: Nature Reviews Genetics, Boone et al. 2007. 
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scarce novel compounds however, this can be prohibitive. 
The development of yeast deletion libraries with identifying DNA barcodes allows a simple and 
elegant method conducting these experiments (Ho et al. 2009). Rather than conducting separate 
assays for each of ~6000 deletion mutants, it is possible to pool the mutants and treat them 
together with minimally inhibitory concentrations of the selected drugs. The inhibition profile of 
each mutant within the pool is determined by extracting the genomic DNA and hybridizing to a bar-
coded microarray chip. This is typically done alongside an untreated control, using competitive 
hybridization (Giaever et al. 2002). Genes of greater relative importance for a drug condition 
diminish faster relative to those with no import in the presence of that drug, and the hybridized tag 
signal for that strain is lower on the micro array chip. Therefore, those genes required for growth 
under a certain condition can be identified and ranked in order of their relative contribution to 
fitness in a single experiment. 
3.1.4 Glycosylation biosynthetic processes and the unfolded protein response 
Glycosylation is the reaction in which a glycosyl donor (carbohydrate), is enzymatically joined to a 
hydroxyl or other functional group of a glycosyl acceptor, typically proteins, lipids, or other organic 
molecules (Drickamer and Taylor, 2006). Glycosylation biosynthetic processes are important for co-
translational and post-translational modification of cellular products, serving a variety of structural 
and functional roles in membrane and secreted proteins.  
During this project evidence suggested that one of the studied compounds, FC-592, may disrupt 
glycosylation biosynthetic processes and processes linked to the secretory pathway. A possible 
consequence of this disruption could be the mis-folding of proteins in the endoplacmic reticulum 
(ER), a process that could lead to activation of the unfolded protein response. 
The unfolded protein response (UPR) is a cellular stress response that is conserved between many 
eukaryotic organisms, including yeast and mammals (Bernales et al. 2006). The UPR is activated in 
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response to an accumulation of unfolded or misfolded proteins in the lumen of the ER, where a 
series of reactions restores normal cell function by halting protein translation and upregulating 
signalling pathways controlling chaperones involved in protein folding (Okamuraa et al. 2000) and 
the induction of ER-associated protein degradation, or ERAD (Meusser et al. 2005). The transcription 
factor Hac1p is activated by the threonine-kinase transmembrane mis-folded protein sensor Ire1p, 
which splices a translation inhibiting intron from HAC1 (Jonikas et al. 2009; Bernales et al. 2006). 
Hac1p transcriptionally upregulates a series of chaperones such as Kar2p, PDI1 and FKB2p 
(Casagrande et al. 2000), which restore proper ER function. A Hac1p-responsive promoter driving 
green fluorescent protein (GFP) expression can be used as a reporter to indicate activation of the 
UPR. Visualisation of Hac1p driven GFP expression is achieved via confocal microscopy (Peter 
Bircham, personal communication; Bircham et al. 2011).  
Glycosylation stabilises folding of proteins during and soon after synthesis and its disruption often 
results in activation of the UPR. Thus activation of the UPR is a possible method to confirm 
disruption of glycosylation biosynthetic processes. A negative result does not rule out an effect on 
glycosylation however, as levels of protein misfolding may be too low to activate the UPR. Other 
glycosylation targets are also possible, as the process is also present in the cytoplasm and nucleus as 
the O-GlcNAc modification (Zachara et al. 2004), among others.  
 
3.2 Aims and objectives 
The aim of this chapter is to determine chemigenomic inhibition profiles for the selected novel 
compounds FC-592 and FC-888, and to characterise a target gene or pathway. The key objectives 
are: 
1. Perform a chemigenomic analysis experiment using barcode microarray techniques with FC-
592 and FC-888 
63 
 
2. Confirm sensitive mutant profiles through dose response 
3. Use analytic techniques to establish a likely target for each compound 
3.3 Methods and materials 
3.3.1 Yeast strains 
Strain Genotype 
Y7092 MATα; can1Δ::STEpr-Sp_his5; lyp1Δ; his3Δ1; 
leu2Δ0; ura3Δ0; met15Δ0; LYS2+ 
YCG326 MATα; pdr1Δ::NAT; pdr3Δ::URA3; can1Δ::STEpr-
Sp_his5; lyp1Δ; his3Δ1; leu2Δ0; ura3Δ0; 
met15Δ0; LYS2+ 
Boone Array Pooled Homozygous array (HOP 
pool; Winzeler et al. 1999) 
MATa; xxxΔ::KanR; pdr1Δ::NAT; pdr3Δ::URA3; 
can1Δ::STEpr-Sp_his5; lyp1Δ; his3Δ1; leu2Δ0; 
ura3Δ0; met15Δ0; LYS2+ 
Individual Boone array single deletion mutants 
designated as xxxΔ 
MATa; xxxΔ::KanR; pdr1Δ::NAT; pdr3Δ::URA3; 
can1Δ::STEpr-Sp_his5; lyp1Δ; his3Δ1; leu2Δ0; 
ura3Δ0; met15Δ0; LYS2+ 
YCG266 - 4xUPRE-GFP TEF2pr_mCherry, Mat Alpha, can1Δ::STE2pr-
Sp_his5; his3Δ1; leu2Δ0; ura3Δ0; 
met15Δ::4xUPRE-GFP-URA3; 
lyp1Δ::TEF2pr_mCherry-NAT LYS2+;  
 
3.3.2 Growth media 
Yeast growth assays were performed in the following media formulations. All media was made up 
with distilled deionised H2O (ddH2O) and autoclaved at 120˚C for 20 min. Sterile glucose was added 
to media post autoclave: 
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Yeast peptone dextrose (YPD): As in Chapter 2. 
Synthetic complete (SC): As in Chapter 2. 
Synthetic deficient (SD) – Ura: As in Chapter 2. 
NAT: As in Chapter 2. 
G418: As in Chapter 2. 
3.3.3 Compounds and chemicals 
General chemicals and materials used include: 100% methanol, ethanol (absolute), ethanol (96%), 
Dimethyl Sulfoxide (DMSO), MasterPure Yeast DNA purification kit (Epicenter Biotechnologies), and 
TE buffer (Tris 89 mM, boric acid 89 mM, EDTA 2 mM, pH 8.3). PCR reagents used include: 10x 
Platinum Taq buffer (Invitrogen), MgCl (50 mM), dNTPs (5 mM each) and Platinum Taq (5 units/µL, 
Invitrogen). Primers used consisted of the following: 
PCR Primers:  
1. D1     5'-CGGTGTCGGTCTCGTAG 
2. U1     5'-GATGTCCACGAGGTCTCT 
3. D2comp-Cy3 or –Cy5   5’-Cy [3/5]-CGAGCTCGAATTCATCGAT 
4. U2comp-Cy3 or –Cy5   5’-Cy [3/5]-GTCGACCTGCAGCGTACG 
Blocking primers: 
5. D2block    5'-ATCGATGAATTCGAGCTCG 
6. U2block    5'-CGTACGCTGCAGGTCGAC 
FC-592 and FC-888 were obtained from Dr. Richard Furneaux of Industrial Research Ltd. (Gracefield, 
New Zealand). These compounds were dissolved to working concentrations in DMSO. Dithiothreitol 
(DTT), a UPR inducer, was obtained from SigmaAldrich, and dissolved in ddH2O. 
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3.3.4 Determination of IC30 concentrations 
Dose response assays were conducted for FC-592 and FC-888 to determine 30% Inhibitory 
Concentration (IC30) concentrations. This is the concentration at which 30% of growth is inhibited 
compared to an untreated control. A 500 μL aliquot of the Homozygous Profiling (HOP) pool was 
seeded into ~50 mL SC G418 media and grown at 30˚C overnight in a shaking incubator. Cell titre 
was determined via haemocytometer and diluted to 105 cell mL-1 with fresh SC media. 10 mL aliquots 
of this cell suspension were dispensed into 50 mL Falcon tubes. Serial dilutions of each compound 
were performed in DMSO in 96-well reagent plates, along with DMSO (negative control) and 
cycloheximide (positive control). Dilutions (all final concentrations) of 35 μM, 31 μM, 27 μM, 23 μM, 
19 μM, 15 μM, 11 μM and 7 μM for FC-888, and 61 μM, 56 μM, 49 μM, 42 μM, 35 μM, 28 μM, 14 
μM and 7 μM for FC-592 were prepared, along with a DMSO control. 100 μL aliquots of each of 
these dilutions (plus control) were dispensed into separate tubes containing the cell suspension, and 
grown for ~15 h at 30˚C. Cell titre of each of these cultures was then determined via 
haemocytometer and cell counts recorded. 
3.3.5 Microarray HOP assay 
The microarray HOP assay was performed based on a protocol by Rosemary Heathcott of the 
Victoria University of Wellington Chemical Genetics Laboratory, adapted from Parsons et al. 2006. 10 
mL SC G418 was inoculated with an 0.5 mL aliquot of the HOP Yeast Knockout Pool. This was 
incubated overnight at 30˚C on a rotating drum. Cell titre was determined via haemocytometer and 
diluted to 5 × 105 cells mL-1 with fresh SC G418. This concentration insures at least 1 × 103 examples 
of each strain from within the pool are present in the starting culture. 10 mL parallel cultures were 
treated with IC30 concentrations of FC-592 (28 μM) and FC-888 (11 μM), alongside 1% DMSO 
controls. Cultures were incubated at 30˚C for ~15 h (10 cell divisions) and cell titre determined via 
haemocytometer to ensure ~30% growth inhibition. These cultures were then re-diluted to 5 x 105 
cells mL-1 with fresh SC G418 and treated with IC30 concentrations of the target compounds and the 
DMSO control for ~15 h (10 cell cycles). 
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DNA purification 
1.5 mL of each culture was harvested and genomic DNA purified using the MasterPure Yeast DNA 
Purification Kit, according to the manufacturer’s instructions. The genomic DNA was dissolved in 35 
μL TE buffer. DNA was then incubated with 1 μL 5μg/μL RNase A at 37°C for 30 min to remove RNA 
contamination.  
RNase was removed by extracting DNA with Phenol:Chloroform and the combined duplicates made 
up to 500 μL with ddH2O. 500μL of phenol/chloroform/isoamylalcohol (25:24:1) was added, the tube 
vortexed and spun for 10 min at 16000 g. The aqueous layer (containing the DNA) was removed and 
1 volume of chloroform added to it. This mixture was then further vortexed and spun at 16000 g for 
10m. 
The aqueous layer was removed and the DNA precipitated by adding 2.5 volumes (1 mL) 96% 
ethanol and 1/10 volume (40 μL) 3M sodium acetate (pH 5.3), and gently mixed by inversion. 
This mixture was then cooled at -20°C for 25 min and spun at 16000 g for 10 min, before the ethanol 
layer was poured off and the DNA pellet washed with 0.5 mL 70% ethanol. This was then spun at 
16000 g for 5 min and the ethanol poured off. The purified DNA pellet was redissolved in 35 μL TE 
buffer. 
Quantification of DNA with Hoechst 33258 dye 
200 μL of 2 μg/mL H33258 was pipetted into wells on a 96-well microtitre plate. Calf thymus DNA 
(Invitrogen) standards were made up at 20 ng mL-1, 50 ng mL-1, 100 ng mL-1, 200 ng mL-1, 500 ng mL-1, 
1 μg mL-1 and 2 μg mL-1 concentrations in microtitre wells, and 5 μL of each DNA sample was added 
to separate wells. Fluorescence was measured at 460 nm on a SpectraMax Plus384 Absorbance 
Microplate Reader (Molecular Devices) and DNA volumes calculated. DNA aliquots of each sample 
were diluted to 25 ng μL-1 for PCR. 
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PCR of UP and DN tags with Cy3 and Cy5 dye labelled primers 
Four PCR reactions were carried out to amplify the DNA products. Up (UP) and Down (DN) tags were 
amplified in separate reactions for both the control and experimental DNA samples. For each 
treatment (FC-592 & FC-888) eight PCR reactions were carried out at a final volume of 60 μL with 
final concentrations of 1.5 mM MgCl2, 0.2 mM dNTPs, 1 μM primers (D1(control), D1(treated), 
U1(c), U1(t), D2comp-Cy3(c), U2comp-Cy3(c), D2comp-Cy5(t), U2comp-Cy5(t)), and 4μL 25 ng μL-1 
DNA. Eight corresponding negative controls with ddH2O instead of DNA were also run to ensure 
absence of confounding contamination. Following the PCR reactions 5 μL of each PCR product was 
run on a high resolution 4% MetaPhor agarose gel (Lonza) with 10 bp marker to confirm presence of 
56 bp PCR product UP and DN tags. 
Precipitation of Cy labelled PCR products 
PCR products were then treated with blocking primers. These complimentary oligonucleotide 
sequences bind with the priming regions of the PCR products preventing them from binding with 
each other and allowing them to hybridize to the microarray. 55 μL aliquots of the four PCR products 
were combined with 20 μL of blocking mix (12.5 µL 100 µM U1 primer; 12.5 µL 100 µM D1 primer; 
12.5 µL 100 µM U2 block; 12.5 µL 100 µM D2 block; 50 µL dH20), and vortexed before 24 μL of 3 M 
sodium acetate pH 5.2, 600 μL of absolute ethanol, and 1 μL of 5 ng mL-1 linear acrylamide (acts as 
carrier for precipitation), whereupon the mixture was again vortexed and cooled at -20˚C for 1.5 h to 
precipitate the Cy labelled PCR products. The mixture was then centrifuged at 4˚C and 16000 g for 30 
min, the supernatant discarded and the pellet washed with 1 mL of 70% ethanol, before again being 
centrifuged at 4˚C and 16000 g for 5 min. At this point the ethanol was removed and the products 
dried briefly in the absence of light. Finally, the Cy labelled PCR products were redissolved in 50 μL 
dH2O. 
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Microarray hybridisation 
50 μL aliquots of labelled PCR product and blocking mix were added to 50 μL 2X Hybridisation Buffer 
(2 M NaCl, 20 mM Tris-HCl pH 7.5, 1% Triton X-100, 1 mM DTT) and gently pipette mixed. This 
hybridisation mix was denatutred at 95˚C for 2 min and applied to the active side of the gasket slide 
(Agilent Technologies Custom Microarray), sitting in the hybridisation chamber base, according to 
the instructions given in the Agilent Microarray hybridisation chamber user guide. The microarray 
slide was placed active side down on the gasket slide, the chamber assembled and placed in the 
hybridisation oven pre-heated to 42˚C and set to rotate speed 4. The completed microarray slide 
was scanned on a GenePix 4000B microarray scanner at the Otago Genomics Facility, University of 
Otago, Dunedin, NZ. 
Analysing Yeast Tag Microarray Image Data 
Data was extracted and fitted using Genepix 6.0 software, exported in spreadsheet format and 
normalised using SNOMAD (Standardization and Normalization of Microarray Data, from 
http://pevsnerlab.kennedykrieger.org/snomaninput.html) software so that the mean ratio across 
the range of signal intensities is 1 (0 on a log scale). The data was then log transformed in base 2 to 
approximate a normal distribution and mean log(intensities) and log(ratios) were graphed to give an 
M-A plot. Low intensity spots in cy3 (<500) were discarded to reduce data ‘noise’. Z-scores were 
calculated by dividing x-mean scores by standard deviation and ranked to reveal gene hits, which 
were recorded as being those data points 3 standard deviations or more above the mean. 
3.3.6 Confirmation dose responses 
Selected hits from the FC-592 microarray were assayed to confirm sensitivity. To conserve supplies 
FC-592, which were extremely limited, only hits related to the pathways being investigated were 
assayed in this fashion. Single colonies of sla1Δ, mon2Δ, vps74Δ, spf1Δ, gup1Δ, vps35Δ, csg1Δ, 
gda1Δ, ost6Δ, alg8Δ, hoc1Δ and alg8Δ along with a Y7092 control were separately inoculated into 3 
mL SC G418 and incubated overnight at 30˚C on a rotating drum (~40 rpm). Cell titres were 
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determined via haemocytometer and diluted to 5 × 105 cells mL-1 with fresh SC and vortexed to 
create a homogeneous suspension. 100 μL of media containing cells was dispensed (Eppendorf 
Xplorer Plus 8 Channel Electronic Pipette) into each well of a clear 96 well flat-bottom polystyrene 
cell culture plate (Interlab). 1 μL aliquots of 28 μM (final concentration) FC-596, were dispensed into 
each well and pipette mixed. Plates were vortexed at 1000 rpm for 30 s to mix completely and 
incubated at 30˚C for 12 h. Following incubation, cultures were resuspended by vortexing at 1000 
rpm for 30 s and the absorbance measured at 590 nm in a spectrophotometer (EnVision 2102 
Multilabel Plate Reader, Perkin Elmer, Waltham, Ma, USA). Residual growth (%) was determined by 
comparing the turbidity in each condition against the mean absorbance for DMSO control (Abs590 
(experimental)/ Abs590 DMSO (control)) × 100 for each unique condition. 
3.3.7 Gene Ontology (GO) Term analysis 
The Biological Networks Gene Ontology tool (BiNGO) is an open-source Java tool (Maere et al. 2005) 
to determine which Gene Ontology (GO) terms are significantly overrepresented in a set of genes. 
This allows statistical analysis of enrichment in a data set for genes within a certain GO term. GO 
terms exist within three hierarchically structured vocabularies that describe genes and gene 
products in terms of their associated biological processes, molecular functions and cellular 
components. ‘Hit’ genes for FC-592 and FC-888 were assessed according to the publisher’s 
instructions using BiNGO Java plug-in for Cytoscape (http://www.psb.ugent.be/cbd/papers/BiNGO/). 
3.3.8 Unfolded Protein Response expression assay 
A single colony of YCG266 was inoculated into 3 mL SC and grown overnight at 30˚C on a rotating 
drum. Cell titre was determined via haemocytometer, diluted to 5 × 106 cells mL-1 with fresh SC and 
vortexed to ensure homogenous suspension. 50 μL aliquots of this cell suspension were dispensed 
into wells in a PerkinElmer 384-well confocal microscopy plate. 8 mM, 4 mM, 2 mM, 1 mM, 0.500 
mM, 0.250 mM, and 0.125 mM dilutions (all final concentrations) of DTT along with an untreated 
control and 112 μM, 56 μM, 28 μM, 14 μM, 7 μM, 3.5 μM and 1.75 μM dilutions (all final 
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concentrations) of FC-592 along with 1% DMSO and ddH2O controls were aliquoted into separate 
wells. These treated cultures were incubated at 30˚C for 4 h, before being read with an Opera High 
Content Screening System confocal microscope (PerkinElmer). Excitation and emission wavelengths 
were 488 nm & 520 nm (GFP), and 561 nm & 600 nm (RFP) respectively. Data from this assay was 
analysed using Acapella software (PerkinElmer), with Ln(GFP/mCherry) being calculated to 
determine activation of the UPR. 
3.4 Results 
3.4.1 Determination of IC30 concentrations 
Dose response experiments were carried out for FC-592 and FC-888 over a narrow concentration 
range to determine IC30 concentrations. Cell titres were determined in triplicate via haemocytometer 
to ensure precision. The following concentrations were selected to proceed on to the microarray 
phase of the experiment: 
Compound Conc. (μM) 
Residual growth (% of 
DMSO treated control) Standard Deviation 
FC-592 28 74.81 6.75 
FC-888 11 83.00 4.26 
 
Figure 3.4 Dose responses were conducted over a single order of magnitude to precisely determine ~IC30 concentrations. 
28 μM FC-592 was found to inhibit 25% growth and 11 μM FC-888 was found to inhibit 17% growth. Note that these values 
do not correspond exactly with results obtained in earlier dose responses, as diploid cells are being used in this 
experiment. 
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3.4.2 Microarray Chemigenomic Profiling 
Chemigenomic profiles of FC-592 and FC-888 were generated using a yeast tag microarray based on 
the pooled homozygous diploid deletion mutant array (HOM DMA). These deletion mutant pools 
were competitively grown in the presence of 28 μM FC-592 and 11 μM FC-888, respectively. 
Genomic DNA for the pooled strains was extracted and amplified via PCR using barcode tag specific 
primers to generate a pool of oligomers representing strains grown in competitive conditions within 
the pool. Successful PCR was confirmed via agarose gel electrophoresis, before hybridization to the 
microarray chip. 
4713 DN tags and 3468 UP tags were successfully recorded for FC-592 after processing and 
normalisation of data. For FC-888, 3625 Dn tags and 3383 Up tags were successfully recorded. Genes 
represented by these tags were ranked according to their underrepresentation within the non-
essential yeast genome set, with those recording Z-scores (standard deviations from the mean) 
recorded as ‘hits’. Genes implicated in multidrug resistance (Hillenmeyer et al. 2008) were removed 
from this analysis as they are unlikely to contribute to a specific sensitivity mechanism with regards 
to an individual compound. 
FC-592 Chemigenomic profile ‘Hits’ 
ORF Gene Tag type Z-score Component Biological function 
YOR002W ALG6 Up -6.07403 1 Alpha 1,3 glucosyltransferase, involved in transfer of 
oligosaccharides from dolichyl pyrophosphate to asparagine 
residues of proteins during N-linked protein glycosylation; 
mutations in human ortholog are associated with disease 
YOR002W ALG6 Dn -3.73824 "  
YOR067C ALG8 Up -3.75501 1 Glucosyl transferase, involved in N-linked glycosylation; adds 
glucose to the dolichol-linked oligosaccharide precursor prior to 
transfer to protein during lipid-linked oligosaccharide biosynthesis; 
similar to Alg6p 
YOR067C ALG8 Dn -3.12691 "  
YGL148W ARO2 Dn -4.20699 2 Bifunctional chorismate synthase and flavin reductase, catalyzes 
the conversion of 5-enolpyruvylshikimate 3-phosphate (EPSP) to 
form chorismate, which is a precursor to aromatic amino acids 
YPR060C ARO7 Dn -4.85873 2 Chorismate mutase, catalyzes the conversion of chorismate to 
prephenate to initiate the tyrosine/phenylalanine-specific branch 
of aromatic amino acid biosynthesis 
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YBR036C CSG2 Dn -8.78656 1 Endoplasmic reticulum membrane protein, required for 
mannosylation of inositolphosphorylceramide and for growth at 
high calcium concentrations 
YMR202W ERG2 Dn -3.94833 3 C-8 sterol isomerase, catalyzes the isomerization of the delta-8 
double bond to the delta-7 position at an intermediate step in 
ergosterol biosynthesis 
YCR034W FEN1 Dn -4.87421 3 Fatty acid elongase, involved in sphingolipid biosynthesis; acts on 
fatty acids of up to 24 carbons in length; mutations have 
regulatory effects on 1,3-beta-glucan synthase, vacuolar ATPase, 
and the secretory pathway 
YCR034W FEN1 Up -4.16013 "  
YOL051W GAL11 Up -3.03883 4 Subunit of the RNA polymerase II mediator complex; associates 
with core polymerase subunits to form the RNA polymerase II 
holoenzyme; affects transcription by acting as target of activators 
and repressors 
YEL042W GDA1 Up -6.95308 1 Guanosine diphosphatase located in the Golgi, involved in the 
transport of GDP-mannose into the Golgi lumen by converting GDP 
to GMP after mannose is transferred its substrate 
YEL042W GDA1 Dn -5.85025 "  
YGL084C GUP1 Dn -6.43054 1 Plasma membrane protein involved in remodeling GPI anchors; 
member of the MBOAT family of putative membrane-bound O-
acyltransferases; proposed to be involved in glycerol transport 
YJR075W HOC1 Dn -4.59351 1 Alpha-1,6-mannosyltransferase involved in cell wall mannan 
biosynthesis; subunit of a Golgi-localized complex that also 
contains Anp1p, Mnn9p, Mnn11p, and Mnn10p; identified as a 
suppressor of a cell lysis sensitive pkc1-371 allele 
YOL081W IRA2 Up -3.01241 2 GTPase-activating protein that negatively regulates RAS by 
converting it from the GTP- to the GDP-bound inactive form, 
required for reducing cAMP levels under nutrient limiting 
conditions, has similarity to Ira1p and human neurofibromin 
YPR067W ISA2 Dn -3.56875 5 Protein required for maturation of mitochondrial and cytosolic 
Fe/S proteins, localizes to the mitochondrial intermembrane space, 
overexpression of ISA2 suppresses grx5 mutations 
YJL124C LSM1 Up -3.8604 4 Lsm (Like Sm) protein; forms heteroheptameric complex (with 
Lsm2p, Lsm3p, Lsm4p, Lsm5p, Lsm6p, and Lsm7p) involved in 
degradation of cytoplasmic mRNAs 
YNL147W LSM7 Up -3.03715 4 Lsm (Like Sm) protein; part of heteroheptameric complexes 
(Lsm2p-7p and either Lsm1p or 8p): cytoplasmic Lsm1p complex 
involved in mRNA decay; nuclear Lsm8p complex part of U6 snRNP 
and possibly involved in processing tRNA, snoRNA, and rRNA 
YPL187W MF(α)1 Dn -4.50944 6 Mating pheromone alpha-factor, made by alpha cells; interacts 
with mating type a cells to induce cell cycle arrest and other 
responses leading to mating; also encoded by MF(ALPHA)2, 
although MF(ALPHA)1 produces most alpha-factor 
YER028C MIG3 Dn -4.00841 4 Probable transcriptional repressor involved in response to toxic 
agents such as hydroxyurea that inhibit ribonucleotide reductase; 
phosphorylation by Snf1p or the Mec1p pathway inactivates 
Mig3p, allowing induction of damage response genes 
YNL297C MON2 Up -5.3557 1 Peripheral membrane protein with a role in endocytosis and 
vacuole integrity, interacts with Arl1p and localizes to the 
endosome; member of the Sec7p family of proteins 
YNL297C MON2 Dn -4.8626 "  
YGR165W MRPS35 Up -3.05333 5 Mitochondrial ribosomal protein of the small subunit 
YHL023C NPR3 Up -3.15708 2 Subunit of SEA (Seh1-associated), Npr2/3, and Iml1p complexes; 
Npr2/3 complex mediates downregulation of TORC1 activity upon 
amino acid limitation; SEA complex is a coatomer-related complex 
that associates dynamically with the vacuole; Iml1p complex 
(Iml1p-Npr2p-Npr3p) is required for non-nitrogen-starvation 
(NNS)-induced autophagy; required for Npr2p phosphorylation and 
Iml1p-Npr2p interaction; null mutant shows delayed meiotic DNA 
replication and double-strand break repair 
YLR338W OPI9 Dn -3.18778 6 Dubious open reading frame unlikely to encode a protein, based 
on available experimental and comparative sequence data; 
partially overlaps the verified ORF VRP1/YLR337C 
YML019W OST6 Up -3.01031 1 Subunit of the oligosaccharyltransferase complex of the ER lumen, 
which catalyzes asparagine-linked glycosylation of newly 
synthesized proteins; similar to and partially functionally 
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redundant with Ost3p 
YCR077C PAT1 Dn -3.32008 4 Topoisomerase II-associated deadenylation-dependent mRNA-
decapping factor; also required for faithful chromosome 
transmission, maintenance of rDNA locus stability, and protection 
of mRNA 3'-UTRs from trimming; functionally linked to Pab1p 
YBL051C PIN4 Dn -3.98754 6 Protein involved in G2/M phase progression and response to DNA 
damage, interacts with Rad53p; contains an RNA recognition motif, 
a nuclear localization signal, and several SQ/TQ cluster domains; 
hyperphosphorylated in response to DNA damage 
YBL051C PIN4 Up -3.9741 "  
YDR289C RTT103 Dn -3.28213 4 Protein that interacts with exonuclease Rat1p and Rai1p and plays 
a role in transcription termination by RNA polymerase II, has an 
RPR domain (carboxy-terminal domain interacting domain); also 
involved in regulation of Ty1 transposition 
YBL007C SLA1 Dn -3.30793 1 Cytoskeletal protein binding protein required for assembly of the 
cortical actin cytoskeleton; interacts with proteins regulating actin 
dynamics and proteins required for endocytosis; found in the 
nucleus and cell cortex; has 3 SH3 domains 
YOR290C SNF2 Up -8.30774 4 Catalytic subunit of the SWI/SNF chromatin remodelling complex 
involved in transcriptional regulation; contains DNA-stimulated 
ATPase activity; functions interdependently in transcriptional 
activation with Snf5p and Snf6p 
YOR290C SNF2 Dn -5.43934 "  
YBR289W SNF5 Dn -3.17721 4 Subunit of the SWI/SNF chromatin remodelling complex involved 
in transcriptional regulation; functions interdependently in 
transcriptional activation with Snf2p and Snf6p 
YEL031W SPF1 Dn -3.02362 1 P-type ATPase, ion transporter of the ER membrane involved in ER 
function and Ca2+ homeostasis; required for regulating Hmg2p 
degradation; confers sensitivity to a killer toxin (SMKT) produced 
by Pichia farinosa KK1 
YHR041C SRB2 Dn -4.35678 4 Subunit of the RNA polymerase II mediator complex; associates 
with core polymerase subunits to form the RNA polymerase II 
holoenzyme; general transcription factor involved in telomere 
maintenance 
YBL054W TOD6 Dn -3.85573 4 PAC motif binding protein involved in rRNA and ribosome 
biogenesis; subunit of the RPD3L histone deacetylase complex; 
Myb-like HTH transcription factor, similar to Dot6p; 
hypophosphorylated by rapamycin treatment in a Sch9p-
dependent manne 
YLR373C VID22 Dn -3.69627 6 Glycosylated integral membrane protein localized to the plasma 
membrane; plays a role in fructose-1,6-bisphosphatase (FBPase) 
degradation; involved in FBPase transport from the cytosol to Vid 
(vacuole import and degradation) vesicles 
YJL154C VPS35 Up -3.31256 1 Endosomal subunit of membrane-associated retromer complex 
required for retrograde transport; receptor that recognizes 
retrieval signals on cargo proteins, forms subcomplex with Vps26p 
and Vps29p that selects cargo proteins for retrieval 
YDR372C VPS74 Dn -3.23362 1 Protein required for Golgi localization of glycosyltransferases; 
binds the cytosolic domains of Golgi glycosyltransferases; binding 
to PtdIns4P required for Golgi targeting and function; tetramer 
formation required for function 
YNL246W VPS75 Dn -3.13105 6 NAP family histone chaperone; binds to histones and Rtt109p, 
stimulating histone acetyltransferase activity; possesses 
nucleosome assembly activity in vitro; proposed role in vacuolar 
protein sorting and in double-strand break repair 
YER123W YCK3 Dn -3.48264 6 Palmitoylated, vacuolar membrane-localized casein kinase I 
isoform; negatively regulates vacuole fusion during hypertonic 
stress via phosphorylation of Vps41p; shares essential functions 
with Hrr25p; regulates vesicle fusion in AP-3 pathway 
YDL118W - Up -3.21129 6 Non-essential protein of unconfirmed function; mutants are 
defective in telomere maintenance, and are synthetically sick or 
lethal with alpha-synuclein 
YMR010W - Up -3.82676 6 Putative protein of unknown function; green fluorescent protein 
(GFP)-fusion protein localizes to the cytoplasm; YMR010W is not 
an essential gene; YMR010W mRNA is transcribed with ADI1 
YNL170W - Dn -4.52595 6 Dubious open reading frame unlikely to encode a functional 
protein, based on available experimental and comparative 
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Table 3.1 List of hypersensitive mutants derived from HOP screen of FC-592 treated cells. 48 tags were identified that 
exceeded the threshold of three standard deviations from the mean. These tags represent 41 unique genes 
with seven represented by both Up and Dn tags. Genes were grouped according to cellular 
component/process: Group 1: ER/Golgi; 2: Nutrient/amino acid biosynthesis; 3: Cell wall; 4: Transcription ; 5: 
Mitochondria; 6: Miscellaneous components. Genes highlighted in red are linked with glycoprotein 
biosynthesis and/or the secretory pathway.  
 
FC-888 Chemigenetic profile ‘Hits’ 
sequence data 
YOL087C - Dn -3.0278 6 Putative protein of unknown function; green fluorescent protein 
(GFP)-fusion protein localizes to the cytoplasm; deletion mutant is 
sensitive to various chemicals including phenanthroline, 
sanguinarine, and nordihydroguaiaretic acid 
YHR155W YSP1 Dn -4.44032 5 Mitochondrial protein with a potential role in promoting 
mitochondrial fragmentation during programmed cell death in 
response to high levels of alpha-factor mating pheromone or the 
drug amiodarone 
ORF Gene Tag 
type 
Z-score Component Biological function 
YNR074C AIF1 Dn -3.19792 2 Mitochondrial cell death effector that translocates to the nucleus in response to 
apoptotic stimuli, homolog of mammalian Apoptosis-Inducing Factor, putative 
reductase 
YDR530C APA2 Up -3.17042 7 Diadenosine 5',5''-P1,P4-tetraphosphate phosphorylase II (AP4A phosphorylase), 
involved in catabolism of bis(5'-nucleosidyl) tetraphosphates; has similarity to 
Apa1p 
YDR530C APA2 Dn -3.1421 " " 
YJL095W BCK1 Dn -3.31904 3 Mitogen-activated protein (MAP) kinase kinase kinase acting in the protein kinase 
C signaling pathway, which controls cell integrity; upon activation by Pkc1p 
phosphorylates downstream kinases Mkk1p and Mkk2p 
YJL095W BCK1 Up -3.15677 " " 
YBL085W BOI1 Up -3.3999 5 Protein implicated in polar growth, functionally redundant with Boi2p; interacts 
with bud-emergence protein Bem1p; contains an SH3 (src homology 3) domain and 
a PH (pleckstrin homology) domain 
YNR051C BRE5 Dn -3.85368 6 Ubiquitin protease cofactor, forms deubiquitination complex with Ubp3p that 
coregulates anterograde and retrograde transport between the endoplasmic 
reticulum and Golgi compartments; null is sensitive to brefeldin A 
YOR061W CKA2 Dn -3.11888 3 Alpha' catalytic subunit of casein kinase 2 (CK2), a Ser/Thr protein kinase with roles 
in cell growth and proliferation; CK2, comprised of CKA1, CKA2, CKB1 and CKB2, 
has many substrates including transcription factors and all RNA polymerase 
YPL256C CLN2 Up -3.51291 5 G1 cyclin involved in regulation of the cell cycle; activates Cdc28p kinase to 
promote the G1 to S phase transition; late G1 specific expression depends on 
transcription factor complexes, MBF (Swi6p-Mbp1p) and SBF (Swi6p-Swi4p) 
YIR023W DAL81 Dn -3.40635 7 Positive regulator of genes in multiple nitrogen degradation pathways; contains 
DNA binding domain but does not appear to bind the dodecanucleotide sequence 
present in the promoter region of many genes involved in allantoin catabolism 
YIR023W DAL81 Up -3.3413 " " 
YDR385W EFT2 Dn -3.27818 8 Elongation factor 2 (EF-2), also encoded by EFT1; catalyzes ribosomal translocation 
during protein synthesis; contains diphthamide, the unique posttranslationally 
modified histidine residue specifically ADP-ribosylated by diphtheria toxin 
YKL160W ELF1 Dn -3.75475 9 Transcription elongation factor that contains a conserved zinc finger domain; 
implicated in the maintenance of proper chromatin structure in actively 
transcribed regions; deletion inhibits Brome mosaic virus (BMV) gene expression 
YKL160W ELF1 Up -3.70621 " " 
YMR222C FSH2 Dn -3.92239 10 Putative serine hydrolase that localizes to the cytoplasm; sequence is similar to S. 
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cerevisiae Fsh1p and Fsh3p and the human candidate tumor suppressor OVCA2 
YMR222C FSH2 Up -3.6408 " " 
YGL020C GET1 Dn -3.0561 11 Subunit of the GET complex; involved in insertion of proteins into the ER 
membrane; required for the retrieval of HDEL proteins from the Golgi to the ER in 
an ERD2 dependent fashion and for normal mitochondrial morphology and 
inheritance 
YDR508C GNP1 Up -6.3278 6 High-affinity glutamine permease, also transports Leu, Ser, Thr, Cys, Met and Asn; 
expression is fully dependent on Grr1p and modulated by the Ssy1p-Ptr3p-Ssy5p 
(SPS) sensor of extracellular amino acids 
YPL223C GRE1 Up -4.02055 12 Hydrophilin of unknown function; stress induced (osmotic, ionic, oxidative, heat 
shock and heavy metals); regulated by the HOG pathway 
YPL223C GRE1 Dn -3.50265 " " 
YOL089C HAL9 Up -3.30429 9 Putative transcription factor containing a zinc finger; overexpression increases salt 
tolerance through increased expression of the ENA1 (Na+/Li+ extrusion pump) 
gene while gene disruption decreases both salt tolerance and ENA1 expression 
YNL021W HDA1 Dn -4.20945 9 Putative catalytic subunit of a class II histone deacetylase complex that also 
contains Hda2p and Hda3p; Hda1p interacts with the Hda2p-Hda3p subcomplex to 
form an active tetramer; deletion increases histone H2B, H3 and H4 acetylation 
YDR295C HDA2 Dn -3.19602 9 Subunit of a possibly tetrameric trichostatin A-sensitive class II histone deacetylase 
complex containing an Hda1p homodimer and an Hda2p-Hda3p heterodimer; 
involved in telomere maintenance 
YOL013C HRD1 Up -4.15564 11 Ubiquitin-protein ligase required for endoplasmic reticulum-associated 
degradation (ERAD) of misfolded proteins; genetically linked to the unfolded 
protein response (UPR); regulated through association with Hrd3p; contains an H2 
ring finger 
YPL244C HUT1 Up -3.00916 11 Protein with a role in UDP-galactose transport to the Golgi lumen, has similarity to 
human UDP-galactose transporter UGTrel1, exhibits a genetic interaction with S. 
cerevisiae ERO1 
YPR006C ICL2 Up -5.66125 1 2-methylisocitrate lyase of the mitochondrial matrix, functions in the methylcitrate 
cycle to catalyze the conversion of 2-methylisocitrate to succinate and pyruvate; 
ICL2 transcription is repressed by glucose and induced by ethanol 
YPR006C ICL2 Dn -4.38872 " " 
YIR005W IST3 Up -3.02225 12 Component of the U2 snRNP, required for the first catalytic step of splicing and for 
spliceosomal assembly; interacts with Rds3p and is required for Mer1p-activated 
splicing 
YKL110C KTI12 Up -3.0078 5 Protein that plays a role, with Elongator complex, in modification of wobble 
nucleosides in tRNA; involved in sensitivity to G1 arrest induced by zymocin; 
interacts with chromatin throughout the genome; also interacts with Cdc19p 
YKL183W LOT5 Dn -3.52908 12 Protein of unknown function; gene expression increases in cultures shifted to a 
lower temperature 
YKL183W LOT5 Up -3.44937 " " 
YKL176C LST4 Dn -4.02574 6 Protein possibly involved in a post-Golgi secretory pathway; required for the 
transport of nitrogen-regulated amino acid permease Gap1p from the Golgi to the 
cell surface 
YKL176C LST4 Up -3.75203 " " 
YMR036C MIH1 Up -3.65194 5 Protein tyrosine phosphatase involved in cell cycle control; regulates the 
phosphorylation state of Cdc28p; homolog of S. pombe cdc25 
YKR095W MLP1 Dn -3.06369 4 Myosin-like protein associated with the nuclear envelope, connects the nuclear 
pore complex with the nuclear interior; involved with Tel1p in telomere length 
control; involved with Pml1p and Pml39p in nuclear retention of unspliced mRNAs 
YBL049W MOH1 Up -3.38468 12 Protein of unknown function, has homology to kinase Snf7p; not required for 
growth on nonfermentable carbon sources; essential for survival in stationary 
phase 
YMR070W MOT3 Up -4.81804 12 Nuclear transcription factor with two Cys2-His2 zinc fingers; involved in repression 
of a subset of hypoxic genes by Rox1p, repression of several DAN/TIR genes during 
aerobic growth, and repression of ergosterol biosynthetic genes 
YMR070W MOT3 Dn -3.97435 " " 
YML103C NUP188 Up -3.94728 4 Subunit of the nuclear pore complex (NPC), involved in the structural organization 
of the complex and of the nuclear envelope, also involved in nuclear envelope 
permeability, interacts with Pom152p and Nic96p 
YMR153W NUP53 Up -3.2464 4 Subunit of the nuclear pore complex (NPC), interacts with karyopherin Kap121p or 
with Nup170p via overlapping regions of Nup53p, involved in activation of the 
spindle checkpoint mediated by the Mad1p-Mad2p complex 
YGR178C PBP1 Dn -3.96506 12 Component of glucose deprivation induced stress granules, involved in P-body-
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dependent granule assembly; similar to human ataxin-2; interacts with Pab1p to 
regulate mRNA polyadenylation; interacts with Mkt1p to regulate HO translation 
YGR178C PBP1 Up -3.89031 " " 
YDR079W PET100 Dn -3.41509 1 Chaperone that specifically facilitates the assembly of cytochrome c oxidase, 
integral to the mitochondrial inner membrane; interacts with a subcomplex of 
subunits VII, VIIa, and VIII (Cox7p, Cox9p, and Cox8p) but not with the holoenzyme 
YGL153W PEX14 Dn -3.49637 6 Peroxisomal membrane peroxin that is a central component of the peroxisomal 
protein import machinery; interacts with both PTS1 (Pex5p) and PTS2 (Pex7p), 
peroxisomal matrix protein signal recognition factors and membrane receptor 
Pex13p 
YGL153W PEX14 Up -3.42615 " " 
YGR077C PEX8 Dn -3.75389 6 Intraperoxisomal organizer of the peroxisomal import machinery, tightly associated 
with the lumenal face of the peroxisomal membrane, essential for peroxisome 
biogenesis, binds PTS1-signal receptor Pex5p 
YIL107C PFK26 Up -3.50845 3 6-phosphofructo-2-kinase, inhibited by phosphoenolpyruvate and sn-glycerol 3-
phosphate; has negligible fructose-2,6-bisphosphatase activity; transcriptional 
regulation involves protein kinase A 
YBR092C PHO3 Dn -4.44967 12 Constitutively expressed acid phosphatase similar to Pho5p; brought to the cell 
surface by transport vesicles; hydrolyzes thiamin phosphates in the periplasmic 
space, increasing cellular thiamin uptake; expression is repressed by thiamin 
YBR092C PHO3 Up -3.25713 " " 
YOR104W PIN2 Dn -4.25829 12 Protein that induces appearance of [PIN+] prion when overproduced; predicted to 
be palmitoylated 
YBL051C PIN4 Up -4.63939 5 Protein involved in G2/M phase progression and response to DNA damage, 
interacts with Rad53p; contains an RNA recognition motif, a nuclear localization 
signal, and several SQ/TQ cluster domains; hyperphosphorylated in response to 
DNA damage 
YML017W PSP2 Up -3.16927 12 Asn rich cytoplasmic protein that contains RGG motifs; high-copy suppressor of 
group II intron-splicing defects of a mutation in MRS2 and of a conditional 
mutation in POL1 (DNA polymerase alpha); possible role in mitochondrial mRNA 
splicing 
YBL046W PSY4 Up -3.79219 3 Regulatory subunit of protein phosphatase PP4; presence of Psy4p in the PP4 
complex (along with catalytic subunit Pph3p and Psy2p) is required for 
dephosphorylation of the histone variant H2AX, but not for dephosphorylation of 
Rad53p, during recovery from the DNA damage checkpoint; localization is cell-cycle 
dependent and regulated by Cdc28p phosphorylation; required for cisplatin 
resistance; homolog of mammalian R2 
YJL204C RCY1 Dn -4.00186 12 F-box protein involved in recycling plasma membrane proteins internalized by 
endocytosis; localized to sites of polarized growth 
YJL204C RCY1 Up -3.1302 " " 
YBR030W RKM3 Up -3.53898 8 Ribosomal lysine methyltransferase specific for monomethylation of Rpl42ap and 
Rpl42bp (lysine 40); nuclear SET domain containing protein 
YMR242C RPL20A Up -3.28416 8 Protein component of the large (60S) ribosomal subunit, nearly identical to 
Rpl20Bp and has similarity to rat L18a ribosomal protein 
YGL147C RPL9A Up -3.01469 8 Protein component of the large (60S) ribosomal subunit, nearly identical to Rpl9Bp 
and has similarity to E. coli L6 and rat L9 ribosomal proteins 
YDL061C RPS29B Dn -3.54772 8 Protein component of the small (40S) ribosomal subunit; nearly identical to 
Rps29Ap and has similarity to rat S29 and E. coli S14 ribosomal proteins 
YFR040W SAP155 Dn -3.72949 3 Protein that forms a complex with the Sit4p protein phosphatase and is required 
for its function; member of a family of similar proteins including Sap4p, Sap185p, 
and Sap190p 
YBL102W SFT2 Up -3.82416 6 Non-essential tetra-spanning membrane protein found mostly in the late Golgi, can 
suppress some sed5 alleles; may be part of the transport machinery, but precise 
function is unknown; similar to mammalian syntaxin 5 
YBL102W SFT2 Dn -3.33554 " " 
YOR137C SIA1 Up -3.12923 12 Protein of unassigned function involved in activation of the Pma1p plasma 
membrane H+-ATPase by glucose 
YOR137C SIA1 Dn -3.03827 " " 
YDL033C SLM3 Dn -3.17629 1 tRNA-specific 2-thiouridylase, responsible for 2-thiolation of the wobble base of 
mitochondrial tRNAs; human ortholog is implicated in myoclonus epilepsy 
associated with ragged red fibers (MERRF) 
YHR030C SLT2 Dn -3.64054 3 Serine/threonine MAP kinase; involved in regulating maintenance of cell wall 
integrity, progression through the cell cycle, and nuclear mRNA retention in heat 
shock; required for mitophagy and pexophagy; affects recruitment of mitochondria 
to the phagophore assembly site (PAS); regulated by the PKC1-mediated signaling 
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pathway 
YBR172C SMY2 Dn -3.55944 12 Protein of unknown function involved in COPII vesicle formation; interacts with the 
Sec23p/Sec24p subcomplex; overexpression suppresses the temperature 
sensitivity of a myo2 mutant; has similarity to S. pombe Mpd2 
YBR172C SMY2 Up -3.22684 " " 
YLR025W SNF7 Dn -3.44354 6 One of four subunits of the endosomal sorting complex required for transport III 
(ESCRT-III); involved in the sorting of transmembrane proteins into the 
multivesicular body (MVB) pathway; recruited from the cytoplasm to endosomal 
membranes 
YLR025W SNF7 Up -3.12536 " " 
YHR163W SOL3 Dn -4.0004 12 6-phosphogluconolactonase, catalyzes the second step of the pentose phosphate 
pathway; weak multicopy suppressor of los1-1 mutation; homologous to Sol2p and 
Sol1p 
YBR169C SSE2 Dn -4.28149 12 Member of the heat shock protein 70 (HSP70) family; may be involved in protein 
folding; localized to the cytoplasm; highly homologous to the heat shock protein 
Sse1p 
YDR395W SXM1 Dn -4.20958 6 Nuclear transport factor (karyopherin) involved in protein transport between the 
cytoplasm and nucleoplasm; similar to Nmd5p, Cse1p, Lph2p, and the human 
cellular apoptosis susceptibility protein, CAS1 
YDR395W SXM1 Up -4.11698 " " 
YML072C TCB3 Up -3.30324 1 Lipid-binding protein, localized to the bud via specific mRNA transport; non-tagged 
protein detected in a phosphorylated state in mitochondria; GFP-fusion protein 
localizes to the cell periphery; C-termini of Tcb1p, Tcb2p and Tcb3p interact 
YJL138C TIF2 Up -3.35019 12 Translation initiation factor eIF4A, identical to Tif1p; DEA(D/H)-box RNA helicase 
that couples ATPase activity to RNA binding and unwinding; forms a dumbbell 
structure of two compact domains connected by a linker; interacts with eIF4G 
YPR074C TKL1 Dn -3.36535 12 Transketolase, similar to Tkl2p; catalyzes conversion of xylulose-5-phosphate and 
ribose-5-phosphate to sedoheptulose-7-phosphate and glyceraldehyde-3-
phosphate in the pentose phosphate pathway; needed for synthesis of aromatic 
amino acids 
YNL070W TOM7 Dn -3.22655 1 Component of the TOM (translocase of outer membrane) complex responsible for 
recognition and initial import steps for all mitochondrially directed proteins; 
promotes assembly and stability of the TOM complex 
YML028W TSA1 Up -3.40694 12 Thioredoxin peroxidase, acts as both a ribosome-associated and free cytoplasmic 
antioxidant; self-associates to form a high-molecular weight chaperone complex 
under oxidative stress; deletion results in mutator phenotype 
YER151C UBP3 Dn -3.05987 6 Ubiquitin-specific protease that interacts with Bre5p to co-regulate anterograde 
and retrograde transport between the ER and Golgi; inhibitor of gene silencing; 
cleaves ubiquitin fusions but not polyubiquitin; also has mRNA binding activity 
YDR049W VMS1 Up -3.01592 12 Component of a Cdc48p-complex involved in protein quality control; exhibits 
cytosolic and ER-membrane localization, with Cdc48p, during normal growth, and 
contributes to ER-associated degradation (ERAD) of specific substrates at a step 
after their ubiquitination; forms a mitochondrially-associated complex with Cdc48p 
and Npl4p under oxidative stress that is required for ubiquitin-mediated 
mitochondria-associated protein degradation (MAD); conserved in C. elegans and 
humans 
YDR049W VMS1 Dn -3.00464 " " 
YDR431W - Dn -5.47989 12 Dubious ORF unlikely to encode a functional protein, based on available 
experimental and comparative sequence data 
YDR521W - Dn -3.85005 12 Dubious ORF that overlaps YDR520C; mutant increases expression of PIS1 and RPL3 
in glycerol 
YDR521W - Up -3.22263 " " 
YEL007W - Dn -3.43104 12 Putative protein with sequence similarity to S. pombe gti1+ (gluconate transport 
inducer 1) 
YER187W - Up -3.61922 12 Putative protein of unknown function; induced in respiratory-deficient cells 
YER187W - Dn -3.47411 " " 
YGL042C - Dn -4.36732 12 Dubious open reading frame, not conserved in closely related Saccharomyces 
species; deletion mutation blocks replication of Brome mosaic virus in S. cerevisiae, 
but this is likely due to effects on the overlapping gene DST1 
YGL072C - Dn -3.72356 12 Dubious open reading frame unlikely to encode a protein; partially overlaps the 
verified gene HSF1; null mutant displays increased resistance to antifungal agents 
gliotoxin, cycloheximide and H2O2 
YIL100W - Dn -3.34288 12 Dubious open reading frame unlikely to encode a protein, based on available 
experimental and comparative sequence data; completely overlaps the dubious 
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Table 3.2 List of hypersensitive mutants derived from HOP screen of FC-888 treated cells. 94 tags were 
identified that exceeded the threshold of three standard deviations from the mean. These tags represent 74 
unique genes with 20 represented by both Up and Dn tags. Genes were grouped according to cellular 
component/process: Group 1: Mitochondria; 2: Apoptosis; 3: Phosphorylation; 4: Nucleus; 5: Cell cycle; 6: 
Transport; 7: Catabolism; 8: Ribosome; 9: Transcription; 10: Protein Synthesis; 11: ER/Golgi; 12: Miscellaneous 
or putative. 
After processing and removal of genes implicated in multidrug resistance, 41 genes were identified 
as hypersensitive in the FC-592 treated HOP screen. Of these 12 genes (29.3%) were identified as 
involved in protein production through the ER/Golgi/Glycosylation. These data could indicate a link 
between FC-592’s mode of action and protein synthesis disruption. 10 genes (24.4%) were identified 
as being involved in transcription although this is a very large class of genes, and not necessarily 
representative of enrichment. 
The HOP screen of FC-888 treated cells revealed 74 hypersensitive deletion mutants. The largest 
class represented was transport associated proteins (9 genes, 12.2%). Again, this is a very large class 
of genes, and does not necessarily represent significant enrichment. Genes representing hits in this 
screen were distributed over a large range of cellular components and processes, including many for 
which there was but a single representative. 29 genes from this set were designated as being of 
putative or unknown function, or having a function unrelated to any others within the set. These 
genes are regarded as unlikely as having a functional role in FC-888 sensitivity or representing 
functional enrichment. 
For both screens, statistical analysis was used to determine the relevance of Gene Ontology 
enrichment within these data sets. 
ORF YIL100C-A 
YLL044W - Up -3.43439 12 Dubious open reading frame unlikely to encode a protein, based on available 
experimental and comparative sequence data; transcription of both YLL044W and 
the overlapping gene RPL8B is reduced in the gcr1 null mutant 
YLR241W - Dn -3.03164 12 Putative protein of unknown function, may be involved in detoxification 
YDR057W YOS9 Up -3.03355 11 ER quality-control lectin; integral subunit of the HRD ligase; binds to glycans with 
terminal alpha-1,6 linked mannose on misfolded N-glycosylated proteins and 
participates in targeting proteins to ERAD; member of the OS-9 protein family 
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3.4.3 Gene Ontology (GO) Term analysis 
The Biological Networks Gene Ontology tool (BiNGO; http://www.psb.ugent.be/cbd/papers/BiNGO/) 
was used to determine which Gene Ontology (GO) terms are significantly overrepresented in the set 
of genes represented by the hits in the FC-592 and FC-888 HOP screens. For this analysis, genes 
within the HOP screen sets were compared with genes from the yeast genome as a whole. Because 
essential genes and genes implicated in multi-drug resistance by Hillenmeyer et al. (2008) were 
removed from the HOP screens, these genes were also disregarded from the BiNGO analysis.  
No significant enrichment was found at the 1% confidence level for genes in the FC-888 HOP screen. 
This means that the hits from this screen were distributed among the components and processes of 
the genome in a largely random fashion. This means there is no evidence that FC-888 affects any 
single pathway or function within the cell in a specific way that would make mutants deficient in that 
pathway hypersensitive to 
the compound. It is more 
likely that FC-888 displays a 
broad mechanism that 
affects mutants deficient in 
various pathways and 
functions relatively equally. 
On the other hand, the FC-
592 HOP screen showed 
significant enrichment in 
glycoprotein biosynthetic 
processes and glycoprotein metabolic processes at the 1% confidence level. These processes are 
based on the genes ALG6, ALG8, GDA1, HOC1 and OST6 which appear in the HOP screen set. ALG6, 
P(corr): 3.75×10
-2 
P(corr): 3.75×10
-2 
Figure 3.4 Genetic networks enriched for genes linked to FC-592 sensitivity. 
Glycoprotein Biosynthetic processes and metabolism are linked to further networks, 
including the secretory pathway. 
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ALG8 and GDA1 occur within the set as both Up and Dn tags, providing extra evidence for their 
relevance. 
3.4.4 Hit confirmation for FC-592 HOP screen 
23 strains recording hits in the FC-592 HOP assay were screened to confirm sensitivity to the 
compound in comparison to a wild type train (Y7092). This limited selection included all hits 
recorded that were grouped into ER/Golgi/glycoylation genes related to protein synthesis and 
transport; as well as transcription related genes; the G2/M phase progression protein PIN4; the fatty 
acid elongase FEN1; and the NAP family histone chaperone gene VPS75. These selections were made 
because of the limited quantity of compound available at this stage in the experimental process and 
their relevance to predicting a specific mechanism. In short, these genes were the only ones related 
enough to provide evidence for FC-592 action on a specific process. PIN4 and FEN1 were included 
because both Up and Dn tags showed up as hits in the HOP screen, increasing their relevance. For a 
similar reason, confirmation screens of FC-888 hits were deemed unnecessary at this point: no 
collection of genes from within that set offer evidence for a specific mechanism. 
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Figure 3.6 Confirmation screen for FC-592 HOP assay hits. All of the tested strains confirmed some level of additional 
sensitivity to FC-592 relative to a WT control strain (<90% residual growth), apart from the RNA polymerase II mediator 
complex subunit protein GAL11 and the mRNA-decapping factor PAT1. 
3.4.5 Unfolded protein response assay 
In order to investigate whether the unfolded protein response (UPR) was activated by FC-592 
treatment, YCG266-4×UPRE-GFP yeast cells were treated with the compound and examined for UPR 
expression via confocal microscopy. In this reporter strain, induction of the UPR causes increased 
GFP expression, which is measured as a stronger signal at 520 nm. FC-592 treated cells were 
compared to cells treated with the known UPR inducer Dithiothreitol (DTT). 
DTT 
(mM) 
Whole Cell GFP 
intensity 
FC-592 
(μM) 
Whole Cell GFP 
intensity 
0 353.428 0 340.081 
0.125 462.809 1.75 337.232 
0.25 683.612 3.5 353.869 
0.5 1013.08 7 334.125 
1 1112.16 14 349.495 
2 1396.02 28 385.384 
4 1442.35 56 365.244 
8 1524.05 112 388.802 
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Strain 
Confirmation of FC-592 HOP screen hits 
Table 3.3 Induction of UPR is not 
observed in FC-592 treated cells. 
Whole cell GFP intensity, measured at 
520 nm, increases with concentration 
in DTT treated cells, indicating a dose 
dependant response. GFP intensity 
remains relatively constant in FC-592 
treated cells, indicating an extremely 
weak or non-existent response. 
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DTT treated YCG326 cells 
 
 
 
 
 
 
 
 
 
FC-592 Treated YCG326 cells 
 
 
 
 
 
 
No evidence was seen for induction of the UPR by treatment with FC-592 in this assay. This means 
that the glycosylation biosynthetic processes suggested by the HOP assay (and which may have 
caused misfolded proteins upon disruption) cannot be confirmed as a target for FC-592. However, 
this result does not disprove any effect on this process, at least as a partial target of the compound. 
Absence of UPR does not mean that glycosylation processing genes, as distinct from glycosylation 
synthetic genes or genes affected by glycosylation post-ER are not involved. Glycoprotein synthesis is 
Figure 3.7 YCG326 cells treated for 4 h with 8 mM DTT. 
Cells were examined using confocal microscopy to 
determine induction of the UPR. The increased GFP 
signal intensity measured at 520 nm indicates a strong 
response to treatment with this compound. 
Figure 3.8 YCG326 cells treated for 4 h with 112 μM 
FC-592. No evidence is seen for induction of the UPR. 
The GFP signal intensity measured at 520 nm is much 
lower than that seen for DTT treated cells.  
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a common process (Murray et al. 2006) throughout the cell, and disruption may have more subtle 
effects, not triggering the UPR. 
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3.5 Discussion 
3.5.1 Chemigenomic HOP screen of FC-592 
A chemigenomic screen using yeast tag microarray technology was conducted using cells treated 
with FC-592 and FC-888 in an attempt to determine a likely target process or pathway for each of 
these inhibitory compounds. The homozygous profiling (HOP) screen takes advantage of modern 
advances in yeast genomics to identify single gene deletion strains which are hypersensitive to a 
certain compound (Nislow & Giaever, 2007). This is possible through the use of libraries of viable 
single gene deletion mutants encompassing some ~80% of the genome, in this case consisting of 
homozygous diploid cells. The deletion strains, whilst viable, are generally sensitive to attack in the 
pathways and processes for which they possess a null mutation. Identifying sensitive strains 
therefore gives insight into the likely mechanism of the screened compounds. 
The two screens were treated with a sub-inhibitory dose of the compounds and compared via tag 
microarray to a DMSO treated control. Tests conducted to identify an appropriate dose for these 
experiments revealed that the diploid cells used in these experiments were slightly less sensitive to 
FC-592 and FC-888 than haploid cells used in earlier inhibition screens. This is likely because diploid 
cells are larger than their haploid counterparts (Herskowitz, 1988) and thus have a lower surface 
area to volume ratio. For any compound dispersing across the membrane as a means of entry to the 
cell, this means that cytosolic concentration is likely to be marginally lower in larger cell types such 
as diploid cells. Additionally, diploid cells possess two copies of every gene and with a higher gene 
copy number (Gruber et al. 2012) may be slightly more tolerant where gene dosage plays a factor. 
Deletion mutants (and the genes they represent) were counted as ‘hits’ if their z-score (standard 
deviations below the mean) was at least -3.0 in the treated cell populations, compared to the 
untreated controls. The three standard deviation cut-off for significance was an arbitrary threshold 
that represents just a 0.13% chance of a gene appearing as a hit by chance alone, assuming 
underlying normality. The HOP screens identified 41 genes as ‘hits’ in the FC-592 treated cell 
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population, and 74 genes as ‘hits’ in the FC-888 treated cells. Of these, 7 genes in FC-592 and 20 
genes in FC-888 were identified by both Up and Dn tags, making them especially relevant as 
hypersensitive mutants. 
Whilst many genes were identified as mediating sensitivity to FC-592 and FC-888, the evidence is 
less clear cut supporting a particular target pathway or process. Gene enrichment was examined 
using the Biological Network Gene Ontology (BiNGO) tool (Maere, 2005). No significant enrichment 
was found for FC-888, whilst glycosylation biosynthetic and metabolic processes were identified as 
enriched in the FC-592 sensitive strains. Statistical evaluation therefore gave only limited insight into 
possible mode-of-action for these compounds. Chemigenomic analysis studies typically show 
enrichment in several components or processes, pointing to a larger pathway (Blackman et al. 2012). 
Examining the implications of glycosylation biosynthetic and metabolic processes as a sensitizer for 
FC-592, several determinations can be made. Biological glycosylation reactions involve the 
attachment of glycan carbohydrates to proteins and lipids to serve a variety of functions (Varki, 
2009). This process is important for correct folding of certain proteins, and in the secretory pathway 
where polysaccharides linked at the amide nitrogen of asparagine in the protein confer stability on 
some secreted glycoproteins. Glycosylation also helps mediate cell-cell adhesion through sugar-
binding lectin proteins. These mediate specific cell-cell interactions through recognition of certain 
carbohydrate moieties. In addition, experiments have shown that glycosylation is not a strict 
requirement for proper folding, but incorrectly glycosylated or non-glycosylated proteins are 
recognised as such by cellular mechanisms and quickly degraded (Parodi, 2000). 
FC-592 is implicated in affecting glycosylation biosynthetic and metabolic processes because of the 
genes ALG6, ALG8, OST6, GDA1 and HOC1, which are associated with the gene ontology (GO) 
functional terms N-directed glycosylation/deglycosylation; peptidoglycan anabolism; and 
modification with sugar residues (Mewes et al. 2002). In addition VPS74, VPS35, MON2 and GUP1 
were associated with functional terms linked with vacuolar/lysosomal transport and carbohydrate 
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transport. These all have links to the ER and secretory pathway, suggesting some activity in this 
functional area. The gene hits recorded do not represent a comprehensive interaction with genes of 
the secretory pathway. The lack of secretory pathway genes such as CPR8 (Dolinski et al. 1997); KEX2 
(Fuller et al. 1989); SPC2 (Fang et al. 1997) and LST4 (Roburg et al. 1997), amongst the sensitive 
mutant set means that the case for a direct mode-of-action on the sectretory pathway is not 
definitive. However it is a good indication of probable activity in this area. 
 
Figure 3.9 Cluster analysis of FC-592 hits.  Genes involved with glycosylation and located to the Endoplasmic Reticulum 
and Golgi make up the largest group. These genes are linked to the secretory pathway. Transcription related genes also 
feature strongly, although this is a large group and no statistical enrichment was seen in this group. A number of 
miscellaneous genes unrelated to others in this group were labelled as other; this group includes one of the most intriguing 
hits on this list: PIN4. 
Whilst statistical analysis of hits did not give conclusive evidence of a mode-of-action for FC-592, 
some insight can still be gained from examining the individual genes implicated in FC-592 resistance. 
Many Secretory pathway linked genes were not observed in the screen. However, the secretory 
pathway in yeast has at least 173 associated genes (Hartman et al. 2001). This means that there are 
probably redundant networks as distinct from redundant pathways within networks. Thus lack of a 
Synthetic Lethal (SL) mutant-drug pair in the HOP screen might only mean another network has 
taken over the function. This possibility allows assessment of a hit but not the discounting of a 
process by lack of a hit.   
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Of the 41 sensitive strains identified in the HOP assay, seven were represented by both Up and Dn 
tags. These were ALG6, ALG8, FEN1, GDA1, MON2, PIN4 and SNF2. ALG6, ALG8, GDA1 and MON2 
are associated with the above mentioned glycosylation and ER linked transport. The fact that these 
genes presented with both tag types reinforces their relevance. There are numerous reasons why a 
tag might be filtered out from the yeast tag microarray dataset, such as poor signal quality. 
However, the presence of both tags inspires confidence that these results were not due to random 
variance or some microarray based statistical artefact: the mutants represented by these genes 
were certainly sensitive in the experimental sample. Each of these hits was confirmed as sensitive on 
a follow up dose response assay. 
ALG6 and ALG8 are glucosyltransferases, directly involved in glycosylation (Reiss et al. 1996; Runge & 
Robbins, 1986). They appear to be involved in mediating resistance to a number of compounds, 
including hygromycin B and neothyonidiocide (Dudley et al. 2005; Yibmantasiri et al. 2012). 
Therefore whilst these genes likely have relevance to the general mechanism of FC-592 activity, they 
are unlikely to point to a direct target. The guanosine diphosphatase GDA1 is located in the Golgi 
and mediates transport of GDP-mannose into the Golgi lumen (Beninsone et al. 1994). It too is 
implicated in mediation of resistance to a number of compounds. These tend to be protein synthesis 
inhibitors such as cycloheximide, tunicamycin and maramomycin however (Alamgir et al. 2010; 
Kapitzky et al. 2010). A common mechanism of action, the presence of this gene in the FC-592 
dataset is potentially an excellent indicator of the compound’s mode-of-action. It is however by no 
means definitive: there are many pathways linked with protein synthesis that could have 
downstream effects on a gda1Δ mutant. 
MON2, a membrane protein encoding gene associated with endocytosis and vacuole integrity, is 
involved with the Sec7p family of proteins (Jochum et al. 2002). This is closely linked with the 
secretory pathway, but again is involved with mediating resistance to a range of drugs such as the 
TORC1 pathway inhibitor rapamycin (Xie et al. 2005) and the ergosterol biosynthesis inhibitor 
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fenpropimorph (Kapitzky et al. 2010). The varied nature of the compounds to which MON2 mediates 
resistance suggests a general fitness response rather than any specific pathway which might 
illuminate a target for FC-592. However it is illustrative that the compound is associated so closely 
with the sectretory pathway: a mechanism linked with other FC-592 sensitive mutants. In this way a 
group of genes provides evidence in a certain direction, where any single gene on its own could be 
ignored as frivolous. 
In a similar manner, the fatty acid elongase FEN1 is involved in sphingolipid biosynthesis and has 
regulatory effects on 1,3-beta-glucan synthase, vacuolar ATPase, and the secretory pathway (David 
et al. 1998). Like MON2, it seems to implicated in general toxicity resistance, mediating both 
resistance (rapamycin, bleomycin, amioderone, etc.) and sensitivity (fluconazole, hydroxyurea, etc.) 
(Alamgir et al. 2010; Kapitzky et al. 2010; Xie et al. 2005; Yadav et al. 2007). Some compounds, such 
as cycloheximide, register sensitivity or resistance mediated by FEN1 depending on the screen 
(Alamgir et al. 2010; Kapitzky et al. 2010)! It is therefore clear that FEN1 cannot prove a target 
pathway for FC-592, but the proximity to the secretory pathway is again intriguing. 
The SWI/SNF chromatin remodelling complex associated gene SNF2 (Peterson et al. 1995) is not 
associated with the mechanisms mentioned above. It mediates resistance to a very large array of 
anti-proliferatives (Alamgir et al. 2010; Lawrence et al. 2004). In addition, snf2Δ mutants are 
defective in sporulation, growth on nonfermentable carbon sources, mating-type switching and 
display increased sensitivity to mutagenising agents (Dror & Winston, 2004; Stern et al. 1984; 
Carlson et al. 1981; Backer & Foury, 1985). This data suggests that SNF2 mediates general cell fitness 
rather than resistance to attack on a certain pathway and is unlikely to offer insight into targets for 
FC-592. 
Of greater interest is the G2/M phase progression protein-encoding gene PIN4 (Pike et al. 2004). The 
second checkpoint in the cell cycle, this checkpoint triggers the start of the mitotic phase. If all the 
conditions required to ensure the cell is ready for mitosis are met, the cell initiates the signalling 
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cascade that signals the beginning of mitosis (Cooper, 2000). This is of interest because some of the 
most important anti-cancer drugs such as paclitaxel cause cell cycle arrest at the G2/M checkpoint 
(Bharadwaj & Yu, 2004). In addition, further testing revealed that FC-592 causes a block at the G2/M 
checkpoint, and thus this gene has probable relevance to the mode-of-action. This is discussed in 
further detail in chapter 4. 
Other significant hits from the set linked to glycoprotein synthesis or the secretory pathway include 
the ER membrane mannosylation mediating protein Csg2p (Tanida et al. 1996); the chorismate 
mutase ARO7 (Ball et al. 1986); and the chorismate synthase ARO2 (Jones et al. 1991). Taken 
together with the previously described glycoprotein synthesis/secretory pathway linked genes 
GDA1, ALG6, MON2, FEN1 and HOC1 these represent 8 of the top 12 hits from the HOP screen, in 
terms of z-score.  
This is of course a very wide ranging pathway encompassing a lot of genes within the genome. It is 
also true that FC-592 is likely to be a non-specific binder of hydrophobic pockets (see Chapter 2), a 
target that appears all over the cell. However it is still a good indication that these processes are 
affected by the compound. It is probable that FC592 has weak activity against a lot of process, but 
perhaps a bit more strongly against glycoprotein biosynthesis and the secretory pathway. 
3.5.2 Chemigenomic HOP screen of FC-888 
74 genes were identified as mediating sensitivity to FC-888 in the HOP screen for this compound. 
Unlike FC-592, the hits in this dataset represented no statistical enrichment for any GO term 
component, function or process. Therefore, it is difficult to build a case for the activity of FC-888 
against any single target process or pathway from this evidence. Considering the analysis of FC-888’s 
chemistry in chapter 2 as likely being a non-specific alkylating agent, this result is unsurprising: A 
range of targets all across the cell were affected and null mutants representing genes linked to many 
of those targets mediated sensitivity to the compound.  
90 
 
 
 
 
 
 
 
 
 
20 genes from the HOP screen were represented by both Up and Dn tags. For reasons discussed 
above, these are likely to be particularly relevant hits; there is less chance of them appearing in the 
dataset as a result of some statistical artefact or experimental variation. Genes represented by these 
hits include APA2, BCK1, DAL81, ELF1, FSH2, GRE1, ICL2, LOT5, LST4, MOT3, PBP1, PEX14, PHO3, 
RCY1, SFT2, SIA1, SMY2, SNF7, SXM1 and VMS1. These range in function from the methylisocitrate 
lyase protein of the mitochondrial matrix ICL2, which functions in glycolysis (Luttik et al. 2000), to 
the nuclear transcription factor MOT3, to the ER-associted degradation protein VMS1, which forms 
complexes with Cdc48p and functions at both the ER and mitochondria (Tran et al. 2011). There is no 
pattern to these genes which points to or suggests a cellular target process, component or function. 
Conspicuous by their absence are any genes associated with DNA repair, such as RAD1, RAD10, 
MGT1, SRS2 and DIN7 (Xaio et al. 1991; Prakash et al. 1993). With the strong likelihood that FC-888 
is an alkylating agent, it would be expected to find some of these genes amongst the HOP screen 
dataset. Apart from pointing to the fact that FC-888 likely targets a host of cellular nucleophiles 
independent of DNA, this screen doesn’t reveal a great deal about the compound or its targets. 
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Figure 3.10 Cluster analysis of FC-888 hits. A very wide range of genes are represented by hits in the FC-888 HOP screen. No single category is 
overrepresented to such an extent as to imply a potential target process or pathway for the compound. When considering the likely function of FC-
888 as a non-specific alkylating agent, this makes sense. 
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There is a good chance that much of the data from this experiment is clouded by background ‘noise’ 
and experimental variation. A single run of the experiment may not be reliable enough to make solid 
conclusions. 
3.5.3 Assessment of yeast tag microarray HOP screen as an experimental method 
Yeast tag microarrays are a proven technology with an established track record in identifying the 
targets of small molecule bioactives (Singh-Babak et al. 2012; Blackman et al. 2012; Skrtic et al. 2011; 
Minear et al. 2011; Nislow & Giaever, 2007). The cellular targets of FC-592 and FC-888 were not 
definitively identified by this technique in the current project however. In assessing the performance 
of this assay in this case there are several factors to consider. 
The purpose of the assay is to identify hypersensitive deletion mutants which cluster around the 
target site. There are several issues that have been identified in relation to the microarray method 
and the assay type in particular in general that may have contributed towards the ambiguous results 
seen in this experiment. Firstly, the likelihood is that neither FC-592 nor FC-888 is large or 
structurally complex enough to provide a specific binding site in a cellular context.  
This means that their mode-of-action is likely to be similarly non-specific, attacking targets and 
interfering with cellular processes in a very wide ranging manner. This non-specific mechanism 
therefore targets general cell fitness more than any individual process, function, or component, 
meaning hits within the dataset are not statistically enriched for any particular GO term. Many of the 
hits seen in the HOP screens conducted, especially for FC-888, mediate resistance to a wide range of 
small molecule inhibitors with diverse mechanisms. This is consistent with the theory that these 
genes mediate general fitness: the weakened cells are susceptible to attack against a broad range of 
targets. 
If this is the case, then the yeast tag microarray HOP assay is doing exactly what it was designed to 
do, even if the answers are discouraging. However, it is difficult to prove a negative (that FC-592 and 
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FC-888 do not target a specific process) in this way, especially considering the imprecise nature of 
the technique. Microarray data sets are commonly very large, and analytical precision is influenced 
by a number of variables (Groen, 2001), of both an experimental and analytical nature.  
Arrays may contain errors because of cross contamination in the clones used for the spotting 
procedure (Knight, 2001). This is obviously a problem because the algorithm for reading the chip is 
based on the assumption that each oligonucleotide-spot is correctly labelled and hybridises in 
exactly the same ways as others of its kind. Standard deviation in z-scores amongst identical 
oligonucleotide-spots was found to be 0.19. This result is not an unmanageable variance, however it 
still equates to a 7.53% average difference in percentile ranking between two spots which are in 
theory identical.  
High sensitivity is an issue that is endemic to microarray experiments (Van Berkum & Holstege, 
2001). Tiny variations as a result experimental error are magnified because of the extremely 
sensitive nature of the signal produced in microarray experiments and of the instruments used in 
measuring them. This issue is magnified at very low signal levels where the low signal to noise ratios 
can make it difficult to assess whether or not a certain result is valid (Newton et al. 2001). 
Microarrays are vulnerable to statistical variation caused by maximum and minimum signal strength 
(Smith et al. 2010). This is a result of hybridisation saturation, whereby oligonucleotide-spots 
become maximally saturated; and the threshold applied to low signal intensities, whereby 
oligonucleotide-spots displaying very low signal intensities are discarded. These artefacts are an 
unavoidable fact of life for most microarray methodologies, but may risk discarding good data in an 
effort to reduce noise. 
This is not to say that microarrays are a flawed technology. As previously mentioned they have a 
long track record of success. Several methods exist for analysing data in an effort to resolve several 
of the above issues (Little & Jones, 2011), which include various normalisation algorithms, increasing 
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replicates, new methods for correcting basal hybridisation levels (Lee et al. 2000), and removal of 
dubious and poor quality signals from the data set (Colantuoni et al. 2002). The fact remains 
however that microarray experiments are inherently ‘noisy’, with a great deal of unexplained 
variation.  
In a yeast tag microarray context, this means that it is impossible to ‘guarantee’ the appearance of a 
particular hit in a given dataset, even when that hit theoretically should appear. For this reason, it 
has proven impossible to detect linkage disequilibrium patterns in microarray datasets (Quek, 2011), 
even when those patterns of growth have been confirmed in a macro-scale, agar array based assay. 
This is of course the reason that these datasets are analysed for statistical enrichment of certain GO 
terms, the theory being that any single gene hit is unimportant for identifying a target process, 
function or component: the totality of hits will point in the correct direction. With non-specific 
mechanisms however, such as have been supposed for FC-592 and FC-888, this statistical method 
breaks down. There is not enough enrichment in any one GO term to indicate a mechanism. 
Therefore other assays may have been more appropriate for the identification of a mode-of-action 
for these compounds. These could have included computational based methods that predict a target 
type based on structure and chemistry (McInnes & Sykes, 1997). Basically this is a more detailed 
approach to the chemistry analysis conducted in predicting the activities of FC-592 and FC-888 in 
Chapter 2. In addition, suspected pathways could be assayed using biochemical methods such as the 
secretory pathway Gaussia luciferase assay (Badr et al. 2007). 
A further issue with the yeast tag microarray has been identified with the oligonucleotide tags 
themselves (Smith et al. 2009). These researchers found that ~20% of the barcodes and common 
priming sequences varied from expectation and thus were unable to achieve hybridisation in the 
required manner. This obviously has serious implications for the accuracy and relevance of the 
microarray. Although Smith et al. found that all 20 bp weren’t necessary to achieve hybridisation, 
and thus it is not as simple as saying ~20% of oligonucleotide-spots do not work, this result calls into 
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question the efficacy of the yeast barcode microarray when using uncorrected data (Smith et al. 
produced corrected sequences and data based on their research; however this was not available to 
use in the current microarray experiment). 
An alternative method that has been suggested takes advantage of next-generation sequencing 
technology to identify barcodes, known as Barcode analysis by Sequencing or Bar-Seq (Smith et al. 
2009). This method was found to be superior to microarray based methods in relation to sensitivity, 
dynamic range and detection limits. In addition, bioinformatic resources can be used to apply these 
techniques to any genome which has been sequenced, obviating the need to design and produce 
microarray chips, an expensive process.  
These advances were associated with reducing noise in relation to a previously identified drug target 
(Smith et al. 2009; Hoon et al. 2008). Therefore, such an approach may be useful in increasing 
resolution of the dataset and improving the chances of identifying relevant pathways and processes 
in experiments involving broad acting bioactive compounds. 
3.5.4 Unfolded protein response experiment 
Due to the range of hits indicating processes linked with glycoprotein biosynthesis and the 
sectretory pathway in the FC-592 HOP screen, an assay was conducted in an attempt to confirm 
activity of this compound on these processes. The thinking behind this is that disruption of certain 
enzymatic processes involved in these pathways, as indicated by certain hits from the assay, could 
lead to an accumulation of mis-folded proteins in the ER, triggering a series of cellular responses 
known as the Unfolded Protein Response (UPR). The UPR is mediated by the transcription factor 
Hac1p, whose translocation to the nucleus activates a promoter driving green fluorescent protein 
(GFP) expression. GFP expression in the reporter strain therefore acts as a proxy indicator of the UPR 
(Jonikas et al. 2009; Bernales et al. 2006; Okamuraa et al. 2000). 
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In this experiment however, FC-592 did not produce a strong response, with GFP expression only 
increasing slightly above basal levels. The primary causes of UPR induction in a cellular context are 
perturbation in calcium homeostasis or redox status, elevated secretory protein synthesis, 
expression of misfolded proteins through mutation, sugar/glucose deprivation, or altered 
glycosylation (Kaufman, 2002).  
If FC-592 is considered as a non-specific hydrophobic pocket binder, it could disrupt enzymatic 
activity in glycosylation proteins such as Alg6p and Alg8p by congregating in the active binding sites 
of such enzymes, thus preventing their native activity. This could cause altered glycosylation 
sufficient to trigger the UFP as described above. However, experimental results have shown that this 
is not the case.  
It is certainly possible that inhibition of certain enzymes in this fashion, even a broad range of 
enzymes, would not result in an accumulation of mis-folded proteins into the ER lumen. Whilst 
disruption of N-linked glycosylation has been shown to initiate the UPR (Li et al. 2011), this 
repression was at a high level. A lower level of glycosylation disruption from a compound with a 
more general mechanism may not produce enough mis-folded protein to accumulate to the ER, 
whilst still causing sufficient disruption (perhaps at a downstream target or targets) to cause arrest 
of cellular growth.  
The secretory pathway is an important cellular process. At each step along the process there are 
critical factors that determine how and if the protein will be processed, including regulation of 
transport, selection of particular proteins, and correct protein modification (Lodish & Berk, 2003). 
Whilst strong inhibition at any single step may trigger the UPR, it is possible that minor insult against 
a range of processes along the secretory pathway could be sufficient for inhibition of cellular growth 
whilst remaining below the threshold of mis-folded proteins that would initiate the response.  
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This is of course highly speculative. The likelihood is that FC-592 acts in a relatively non-specific 
fashion where there is only minimal enrichment of action amongst any specific pathway. With its 
large range of proteins and enzymatic processes, glycoprotein biosynthesis and the secretory 
pathway may be slightly more vulnerable to the compound than other processes. Lacking direct 
specificity to pathway single target however, it is unclear how FC-592 could be used as a therapeutic 
or genetic probe, although there is possible utility as a more general secretory pathway stressor. 
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4. Synthetic Genetic Array Mapping        
4.1 Introduction 
4.1.1 Resistance mutation as a target identification strategy 
The identification of the biological target of novel inhibitory compounds is a significant challenge (Ho 
et al. 2011). In recent times, identification of new drugs has become increasingly target based 
(Terstappen et al. 2007). However, these drug targets are often incompatible with conventional 
biochemical schemes of ligand identification (Chanda & Caldwell, 2003), and this strategy has failed 
to accelerate drug discovery (Sams-Dodd, 2005). The new paradigm incorporates functional 
genomics approaches in a holistic strategy; often incorporating in vivo models (Terstappen et al. 
2007; Lindsay, 2003) as well as genomic tools such as expression microarrays (Schena et al. 1998).  
One in vivo strategy that has stood the test of time is resistance analysis (Justice et al. 1998; Fried & 
Warner 1981; Fried & Warner 1982; Liu et al. 1994). This involves the generation and 
characterisation of mutants resistant to the compound being studied, and has been used to identify 
the targets of many small molecule inhibitors over the years. These include nystatin (Ahmed and 
Woods, 1967) and reveromycin (Miyamoto et al. 2002) in S. cerevisiae, as well as neumocandin and 
echinocandin anti-biotics in C. albicans (Douglas et al. 1997).  
The tractability and robustness of the genome in yeasts such as S. cerevisiae and C. albicans makes 
them uniquely suited for this type of experiment (Forsburg, 2001).  The utility of this technique is 
served by the ease of manipulation of yeast strains, generating mutant populations easily and cost 
effectively in both a random (e.g. EMS) and site directed (e.g. PCR mediated gene disruption) 
manner. The nature of yeast cells mean that large numbers can be assayed for resistance on 
selective media in a way that is not possible with other model organisms. In addition, the 
haploid/diploid lifecycle of the likes of S. cerevisiae means that mutations can be recovered easily 
and complementation tests can be readily performed. 
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Whilst resistant mutant generation is relatively easy, characterisation of the mutations responsible 
and linking those mutations to a precise mechanism of action remains a challenge. In the future, 
‘next generation DNA sequencing’ (Shendure and Handlee, 2008), combined with bioinformatic 
analysis offers perhaps the most promising route for the rapid and efficient characterisation of SNP 
mutations. However, for some researchers high sequencing costs and low throughputs have limited 
the depth of analysis of genomic elements (Fullwood et al. 2009), especially relative to requirements 
for a high throughput strategy often required in drug discovery. 
Several alternative approaches can be taken with S. cerevisiae that take advantage of the superlative 
range of genomics based tools available to the yeast researcher. Cloning by complementation, 
introducing a wild type copy of the gene to complement a drug hypersensitive phenotype is a 
commonly employed strategy (Douglas et al. 1994). In this strategy, a vector such as a plasmid 
library containing DNA fragments encompassing the entire genome rescues the wild type phenotype 
of transformed mutants, with each of the resulting transformants screened for drug sensitivity. This 
technique, although widely used (Douglas et al. 1994; Parsons et al. 2006; Justice et al. 1998; 
Heitman et al. 1991), requires large amounts of effort to assay a vast number of transformants. 
In more modern times a complementation strategy has been used that takes advantage of 
microarray barcode technology to identify recessive resistant mutations (Ho et al. 2009).  Molecular 
barcoded yeast open reading frames (MoBY-ORFs), each barcode unique to a genomic location, are 
constructed as a plasmid library. This allows population analysis of transformants based on barcode 
expression in a manner analogous to chemigenomic microarray profiling described in the previous 
chapter. Cells containing a recessive resistance mutation are transformed and grown in the presence 
of the compound of interest. The rescued phenotype (those cells containing the complementary 
barcode tagged wild type ORFs) does not grow in the presence of the drug, whilst all others do. This 
absence is determined on a barcode microarray, revealing the site of resistance. This advance is 
particularly important when limited quantities of the compound of interest are available.   
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Similar approaches utilising more classical techniques have been utilised in the past. Fried and 
Warner (1981) identified RPL3, a protein component of the large (60S) ribosomal subunit, as the 
molecular basis of resistance for a range of eukaryotic protein synthesis inhibitors such as 
trichodermin and verrucarin A as well as to the unrelated drug anisomycin. This was achieved 
through transforming trichodermin sensitive HF-T1 mutants with a cloned recombinant plasmid 
library carrying wild type genomic DNA fragments. These transformed mutants were grown on 
trichodermin resistance selective media and the surviving cells (containing the relevant trichodrmin 
resistance allele) sequenced using a plasmid based primer. In this way, sequencing efficiency is 
achieved because the entire genome does not have to be sequenced: only the relevant allele 
contained within the plasmid. 
These techniques allow an assessment of the mechanism of resistance in vivo, as opposed to 
traditional biochemical methods which directly focus on target affinity (Lindsay, 2003). This is 
important because resistance to a compound can be caused in a variety of ways, not limited to the 
direct binding of the target. For example, a loss-of-function mutation in an enzyme required for 
activation of some part of a compound’s toxicity could lead to a resistant phenotype, and reveals 
much about the mechanism of the compound in question (Heitman et al. 1991). This whole cell 
approach is a key advantage of resistance based target analysis. 
4.1.2 Synthetic genetic array mapping 
As mentioned previously, researchers have constructed a library of deletion mutants in S. cerevisiae 
that consists of all non essential genes disrupted by a kanamycin resistant marker (Winzeler et al. 
1999), known as the deletion mutant array (DMA). This genomic reagent’s utility has been discussed 
in regards to chemigenomic analysis, examining strains within the DMA that are hypersensitive to a 
compound of interest and the implications of such hypersensitivity for indentifying that compound’s 
mechanism of action. 
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The DMA possesses another utility as well. By mass mating the DMA against a query strain 
containing a single gene knockout, it is possible to 
readily create libraries of double mutants that contain 
two gene knockouts with selectable markers (Tong et 
al. 2001). When such double mutations appear in 
differing pathways, they are generally buffered 
against deleterious effect by redundant genes and 
pathways within their networks. However, when they 
are closely related, for example acting within parallel 
pathways, the cell is unable to overcome this dual insult 
to an essential process and an enhanced phenotype is 
seen. This typically takes the form of a synthetic sick 
(SS) or synthetic lethal (SL) phenotype that displays reduced or null vegetative growth. Such 
phenotypic enhancements indicate genetic interactions between gene pairs, and in this way it is 
possible to build a picture of large scale genetic networks of overlapping pairs of SL interactions. This 
methodology is known as the Synthetic Genetic Array, or 
SGA. 
SGA methodology has been used frequently and successfully 
for a range genetic research: from leveraging synthetic 
lethality as a means for selective killing of tumour cells 
(McClellan et al. 2012), to exploring the heredity of gene 
networks (Yang & Sankoff 2011), as well as matching gene 
function to gene and vice versa (Short et al. 2012; Ball et al. 
2009). The genome-wide selection markers present within 
the DMA allow an elegant alternative use, identifying the 
Figure 4.1 Examples of SGA methodology. (A) Isolation of 
whi5 in a systematic genetic screen for inhibitors of SCB-
dependent transcription. A cln3 strain containing an SCB-
HIS3 reporter (BY2054) was mated to 4812 haploid strains. 
This identifies deletion strains that rescue a phenotype. 
Source: Costanzo et al. 2004. (B) Enhanced synthetic lethal 
(SL) phenotype shows genetic interaction in an SGA. 
Source: Victoria University of Wellington Chemical Genetics 
Laboratory. 
Figure 4.2 Synthetic genetic array mapping. Only 
strains carrying both the resistance allele and a 
KanR cassette from the DMA are able to grow 
under double selection. Adapted with permission 
from AAAS: Science, Tong et al. 2001. 
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genomic location of a selectable trait, known as Synthetic Genetic Array Mapping or SGAM 
(Jorgensen et al. 2002). 
When the selectable trait is a resistance mutation, SGA methodology can be used to trace the source 
of resistance. The resistant strain is mass mated against the DMA and grown on selective media such 
that only progeny strains containing both the resistant 
allele and the kanamycin (G418) resistance cassette 
will grow in the presence of both drugs. In an SGAM 
strategy, this only occurs when the drug resistance 
gene and the G418 resistance gene are not the same or 
located in closely linked loci. When the G418 resistance 
allele and the drug resistance alleles are on the same 
or a nearby locus then strains will not grow in presence 
of both drugs, since haploid alleles cannot occupy the same locus.  Owing to linkage disequilibrium, 
strains with the G418 resistance 
allele immediately neighbouring the 
drug resistance allele will also be 
unable to grow under the double 
selective conditions, leaving a 
distinctive linkage pattern of non-
growth within the final array. The 
centre of this pattern serves to 
identify the region of the genome in 
which the resistance mutation is located (Yibmantasiri et al. 2012). 
Because the DMA is arranged in a specific genomic order, the linkage pattern is correlated to 
identifiable genes. These may not directly correspond to the resistance mutation, which may be 
Figure 4.3 Homologous recombination in SGAM. Where 
the KanR cassette and the unknown resistance mutation 
(xR) are in separate regions of the genome, cross over 
events allow double mutants which survive under double 
selection (bottom). When the resistance loci are closely 
linked or identical, these cross over events are rare or non-
existant (if allelic) and the double mutants do not occur, 
causing cells to die from sensitivity to one or other of the 
drugs. 
Figure 4.4 A linkage pattern is seen around the site of resistance in a SGAM 
experiment. Growth defect is maximal around the center of this region, where the 
fewest cross over events occur during meiosis relative to the KanR cassette. Source: 
Ploi Yibmantasiri. 
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located on an essential gene which does not occur in the DMA. However, the linkage pattern 
nonetheless forms from neighbouring genes because of reduced homologous recombination relative 
to the KanR cassette. Therefore genes represented by strains within the linkage pattern implicate 
neighbouring gene deletions bearing the replacement G418-reistance cassette as probable sites of 
the resistance mutation. 
It should be noted that a key weakness of the SGAM technique is the quantity of drug required to 
treat the ~14 plates typically present in an SGA assay, a relatively large total volume of growth 
medium. This is limiting and may prove prohibitive for novel compounds which are frequently in 
short supply.  It has been suggested that conducting such experiments in barcode-tagged microarray 
format, with a pooled DMA mass mated against a resistant strain, may be effective in reducing the 
amount of drug required. However the resolution achieved in microarrays has proven insufficient to 
identify linkage within a pooled array in this manner (Quek, 2011). Simply put, there is too much 
noise implicated in microarray experiments to make them viable in a SGAM strategy. 
4.1.3 Flow cytometry 
Flow cytometry is a laser based, biophysical technique used to count and sort cells based upon a 
measurable biomarker. This high-throughput technique is achieved by suspending cells in a stream 
of fluid and passing them by an electronic detection device. In this way, multiparametric analysis is 
possible on a scale that allows statistical interpretation of biological phenomena (Loken, 1990). One 
common utility of flow cytometry is for the analysis of cell proliferation in the study of the cell cycle 
(Gray et al. 1986). 
In this application, cells are fixed at a certain point during or after treatment with the studied 
condition. Cells are stained with a DNA binding dye such as SYTOX Green (Haase & Reed, 2002), 
which enables DNA content to be quantified via fluorescence activated cell sorter (FACS), 
determining cell cycle progression of each cell. Effects of the studied condition (which might be a 
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particular mutation or a small molecule drug) on the cell cycle can be determined by examining the 
proportion of cells in G1, G2 etc. (Sohn et al. 2000). 
4.2 Aims and objectives 
The aim of this chapter is to provide evidence for the identification of the mechanism of action of 
FC-592 by performing a Synthetic Genetic Array Mapping experiment. The key objectives are: 
1. Generate several S. cerevisiae mutants resistant to FC-592.  
2. Perform a proof of concept SGAM experiment using the cycloheximide resistant strain 
YCG191. 
3. Perform complementation analysis of resistant mutants to establish nature of mutations. 
4. Run SGAM procedure using at least one resistant mutant 
5. Identify site of resistance by determining linkage pattern in SGAM results 
4.3 Methods and materials 
4.3.1 Yeast strains 
Strain Genotype 
BY4742 MATα; his3Δ1; leu2Δ0; ura3Δ0;  
BY4741 MATa; his3Δ1; leu2Δ0; ura3Δ0;  
Y7092 MATα; can1Δ::STEpr-Sp_his5; lyp1Δ; his3Δ1; 
leu2Δ0; ura3Δ0; met15Δ0; LYS2+ 
YCG326 MATα; pdr1Δ::NAT; pdr3Δ::URA3; can1Δ::STEpr-
Sp_his5; lyp1Δ; his3Δ1; leu2Δ0; ura3Δ0; 
met15Δ0; LYS2+ 
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PdrΔ; His3Δ  MATa; his3Δ::KanR; pdr1Δ::NAT; pdr3Δ::URA3; 
can1Δ::STEpr-Sp_his5; lyp1Δ; his3Δ1; leu2Δ0; 
ura3Δ0; met15Δ0; LYS2+ 
YCG191 MATα; RPL28-ChxR; can1Δ::STEpr-Sp_his5; 
lyp1Δ; his3Δ1; leu2Δ0; ura3Δ0; met15Δ0; LYS2+ 
YCG432 MATα; pdr1Δ::NAT; pdr3Δ::URA3; can1Δ::STEpr-
Sp_his5; lyp1Δ; his3Δ1; leu2Δ0; ura3Δ0; 
met15Δ0; LYS2+; FC-592R+ 
YCG433 MATα; pdr1Δ::NAT; pdr3Δ::URA3; can1Δ::STEpr-
Sp_his5; lyp1Δ; his3Δ1; leu2Δ0; ura3Δ0; 
met15Δ0; LYS2+; FC-592R+ 
YCG434 MATα; pdr1Δ::NAT; pdr3Δ::URA3; can1Δ::STEpr-
Sp_his5; lyp1Δ; his3Δ1; leu2Δ0; ura3Δ0; 
met15Δ0; LYS2+; FC-592R+ 
YCG435 MATα; pdr1Δ::NAT; pdr3Δ::URA3; can1Δ::STEpr-
Sp_his5; lyp1Δ; his3Δ1; leu2Δ0; ura3Δ0; 
met15Δ0; LYS2+; FC-592R+ 
YCG436 MATα; pdr1Δ::NAT; pdr3Δ::URA3; can1Δ::STEpr-
Sp_his5; lyp1Δ; his3Δ1; leu2Δ0; ura3Δ0; 
met15Δ0; LYS2+; FC-592R+ 
Boone Deletion Mutant Array (DMA; Winzeler et 
al. 1999) 
MATa; xxxΔ::KanR; can1Δ::STEpr-Sp_his5; lyp1Δ; 
his3Δ1; leu2Δ0; ura3Δ0; met15Δ0; LYS2+ 
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4.3.2 Growth media 
Yeast growth assays were performed in the following media formulations. All media was made up 
with distilled deionised H2O (ddH2O) and autoclaved at 120˚C for 20 min. Sterile glucose was added 
to media post autoclave: 
Yeast peptone dextrose (YPD): As in Chapter 2. 
Synthetic complete (SC): As in Chapter 2. 
Synthetic deficient (SD) – Ura: As in Chapter 2. 
Synthetic deficient (SD) – His: As SC except without histidine in the amino acid mix 
Synthetic deficient (SD) – Arg: As SC except without arginine in the amino acid mix 
Synthetic deficient (SD) – Lys: As SC except without lysine in the amino acid mix 
Synthetic deficient (SD) – Leu: As SC except without leucine in the amino acid mix 
GNA: 3% (w/v) nutrient broth (Acumedia), 1% yeast extract (Bacto), 2% select agar (Invitrogen), 5% 
glucose, 0.012% adenine hemisulfate. 
Sporulation (SPO): 1% potassium acetate, 0.005% zinc acetate, 0.1% yeast extract (Bacto), 0.01% 
sporulation supplement (2 g histidine, 2 g uracil, 10 g leucine; 2g lysine; all SigmaAldrich), 0.05% D-
glucose. 
Agar: As in Chapter 2. 
NAT: As in Chapter 2. 
G418: As in Chapter 2. 
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Can: Where noted, 50 mg/mL (final concentration) canavanine (SigmaAldrich) was added to media 
after sterilization. 
Thia: Where noted, 50 mg/mL (final concentration) thialysine (SigmaAldrich) was added to media 
after sterilization. 
4.3.3 Compounds and chemicals 
Ethyl methanesulfonate (EMS, SigmaAldrich), sodium thiosulfate, sodium phosphate (19.5% 200 mM 
NaH2PO4, 30.5% 200 mM NaHPO4, 50% ddH2O) and sodium hydroxide were used in a mutagenesis 
experiment to introduce genetic variation in yeast populations.  
A Geneaid High-Speed Plasmid MiniPrep kit was used to purify plasmids for transformation. Lithium 
acetate (SigmaAldrich), polyethylene glycol (SigmaAldrich), salmon sperm single stranded DNA 
(SigmaAldrich), Tris-EDTA (Fischer Scientific), sodium hydroxide and absolute ethanol were used in 
plasmid transformations. Zymolase (Invitrogen) and sorbitol (SigmaAldrich) were used during tetrad 
analysis. Pepsin (SigmaAldrich), RNase A (Qiagen), absolute ethanol, Tris-HCl (SigmaAldrich) and 
SYTOX Green (Invitrogen) were used during cell fixing and staining for the cell cycle flow cytometry 
experiment. 
Cycloheximide (SigmaAldrich), rapamycin (LC Laboratories), hygromycin B (SigmaAldrich), 
fluconazole (SigmaAldrich) and nystatin (SigmaAldrich) were dissolved in DMSO at a range of 
concentrations for comparative analysis. Benomyl (SigmaAldrich) was dissolved in ddH2O for the 
same purpose. All compounds were stored at -20˚C. 
4.3.4 Resistant mutant generation 
Ethyl methanesulfonate (EMS) mutagenesis was performed on a parent population of YCG326 pdrΔ 
cells. Safety note: EMS is a powerful mutagen. Perform all EMS work in a fume hood. Discard any 
EMS containing liquids into a beaker containing 50% sodium thiosulfate solution. Wash all EMS 
containing material with 10% sodium thiosulfate solution. All glassware coming into contact with 
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EMS must be immersed in a large beaker of 1 M NaOH before washing and reuse. Ensure EMS never 
touches the outside of tubes, gloves etc. 
A single colony of YCG326 was grown overnight in 3 mL SC at 30˚C on a rotating drum. Cell titre was 
determined via haemocytometer and diluted to 2×108 cells mL-1 with fresh SC. 1 mL samples were 
transferred to sterile 1.5 mL microcentrifuge tubes, centrifuged for 30 s at 13000 rpm, supernatant 
discarded and cells resuspended in 1 mL ddH2O. This wash step was repeated, with supernatant 
being discarded leaving a cell pellet which was resuspended in 1 mL of 100 mM sodium phosphate. 
30 μL EMS was added to one tube for a final concentration of ~3% (with the other tube serving as 
the unmutagenised control). Tubes were vortexed vigorously to mix and incubated at 30˚C for 1 h on 
a rotating drum. The tubes were then centrifuged at 13000 rpm for 30 s, supernatant discarded (into 
breaker containing 50% sodium thiosulfate), and cells resuspended in 20 μL 5% sodium thiosulfate. 
These suspensions were transferred into fresh sterile 15 mL microcentrifuge tubes and centrifuged 
at 13000 rpm for 30 s, supernatant discarded and resuspended in 5% sodium thiosulfate. This wash 
step was repeated once more, before supernatant was discarded and cells resuspended in 1 mL 
ddH2O. These suspensions were transferred into 15 mL falcon tubes, centrifuged for 2 min at 4000 
rpm, supernatant discarded and cells resuspended in 3 mL YPD.  
After mutagenesis, a viability assay was conducted to ensure adequate mutation level. Cell titre of 
mutagenised and unmutagenised populations were determined via haemocytometer and diluted to 
5×105 cells mL-1 in ddH2O. 20 μL aliquots of these cell suspensions were pipetted into 200 μL pools of 
ddH2O which had been dispensed onto the surface of SC Agar plates to aid spread. These pools were 
spread over the surface with the aid of a sterile glass rod, and grown for ~48 h at 30˚C. Plates were 
visually examined to ensure desired attrition rate had been achieved (10-30%).  
Simultaneously, the cultures were grown at 30˚C for ~4 h on a rotating drum to allow mutant 
proteins to replace wild type proteins in the population.  
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4.3.5 Screening for FC-592 resistance 
The mutant populations generated in the EMS mutagenesis experiment were screened for 
resistance to FC-592. 50 μL samples of mutagenised and unmutagenised cells were harvested after 
outgrowth and transferred into 1.5 mL microcentrifuge tubes. Cells were washed with 1 mL ddH2O, 
centrifuged at 13000 rpm for 30 s and supernatant discarded, and resuspended in 1 mL dd H2O. Cell 
titre of these suspensions was determined via haemocytometer and diluted to 1×106 cells mL-1 with 
ddH2O. 200 μL aliquots (for a total of ~200,000 cells) of mutagenised and unmutagenised cells were 
spread on five (each) SC Agar plates containing FC-592 (50 μM, 70 μM, 90 μM and 110 μM). These 
plates were grown at 30˚C for ~48 h. Plates were visually inspected for growing colonies, with 
resistant mutants selected from those plates containing an FC-592 that completely inhibited growth 
on the unmutagenised plates. 
Resistant characteristics of these mutants (designated YCG432, YCG433, YCG434, YCG435 and 
YCG436) were determined via solid state dose response. A half-log dilution series was created in 
DMSO for FC-592 with final concentrations of 354.6 μM, 112.1 μM, 35.5 μM, 11.2μM, 3.55 μM, 1.12 
μM & 355 nM. A solid state dose response plate was created in a clear flat-bottom 48-well plate 
(Interlab), according to the protocol set out in Chapter 2. Single colony cultures of each resistant 
mutant, as well as a YCG326 control, were grown overnight in YPD, cell titre determined via 
haemocytometer and diluted to 5×105 with fresh YPD and cell suspension vortexed to ensure 
homogenization. 2×2 μL of each suspension was spotted into separate wells (such that each strain 
would be challenged against each concentration), allowed to diffuse for 5 min then incubated for 
~40 h at 30˚C. Photographs (Canon Powershot S3-IS) were then taken using ZoomBrowser EX remote 
shooting software (Canon Inc, NY, USA) and visually inspected to determine cell growth.  
4.3.6 Tetrad analysis 
Resistant mutants were characterised by tetrad analysis. Single colonies of YCG432, YCG433, and 
YCG434 were transformed with cenLeu plasmid extracted from the pRS315 E. coli strain (Geneaid 
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High-Speed Plasmid MiniKit) according to the protocol outlined in Geitz and Schiestl (2008). 
Transformants were confirmed by growth on SD-Leu Agar, and single colonies mated to PdrΔ:His3Δ 
according to the protocol outlined in Burke et al. (2005). Mated cells were replica plated on to SD-
Leu G418 Agar diploid selection media and grown at 30˚C for ~24 h. Diploid selection plates were 
then replica plated onto GNA pre-sporulation media and grown at 30˚C for ~12 h. ~500 mg of diploid 
cells from GNA plates were transferred via sterile rod into 3 mL SPO media, briefly vortexed, and 
incubated for ~5 days at 24˚C on a rotating drum. Cells were visually inspected via microscopy to 
ensure adequate spore formation.  
150 μL aliquots of each sporultated strain were dispensed into sterile 1.5 mL microcentrifuge tubes, 
centrifuged at 13000 rpm for 30 s and supernatant discarded. 50 μL 0.25 mg ml-1 zymolase in 1 M 
sorbitol was added to each tube and incubated at 30˚C for 30 min before being quenched with 150 
μL ddH20 and cooled on ice. Tetrads were then spread on thin YPD Agar plates and dissected 
according to the protocol outlined in Burke et al. (2005) using a dissection microscope (Singer 
Instruments MSM System). 
Dissected tetrads were allowed to grow at 30˚C for ~48 h before being replica plated onto the 
following media types: SD-Leu Agar, SC G418 Agar. Cells from selected tetrads were manually 
transferred onto SC FC-592 (150 μM) Agar media by picking colonies with a sterile rod, transferring 
into 1.5 mL microcentrifuge tube containing 1 mL sterile dd H2O, vortexing to mix, and dispensing 1 
μL aliquots. This was done because SC FC-592 (150 μM) Agar media was made up in smaller 8 mL 
Petri plates, in an effort to minimise the amount of compound used. 
4.3.7 Dominance/recessive testing 
Separately, diploid cells resulting from mating during tetrad analysis were assayed for resistance to 
FC-592 to establish whether each mutant displayed dominant or recessive resistance. A single colony 
of YCG432×PdrΔ;His3Δ, YCG433×PdrΔ;His3Δ and YCG434×PdrΔ;His3Δ diploids were transferred via 
sterile rod into 1.5 mL microcentrifuge tubes containing 1 mL ddH20 and vortexed. A 10x serial 
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dilution series was constructed from these cells to produce a range of cell suspensions in descending 
cellular concentrations. 1 μL aliquots of these cell suspensions were dispensed onto SC FC-592 (150 
μM) Agar, along with YCG 326 & YCG434 controls, and grown for ~48 h at 30˚C. Photographs (Canon 
Powershot S3-IS) were then taken using ZoomBrowser EX remote shooting software (Canon Inc, NY, 
USA) and visually inspected to determine cell growth. 
4.3.8 Complementation testing 
A complementation test was conducted for YCG433 and YCG434 to determine whether the two 
recessive mutations were in the same functional unit or gene. Two recessive mutant strains crossed 
together complement each other if the resulting diploid has a wild type phenotype. A Mat A KanR+ 
cenLeu- YCG434 mutant progeny was selected from tetrad analysis and crossed according to the 
protocol in Burke et al. (2005) with a YCG433 cenLeu+ transformant. Diploid selection was carried 
out on SD-Leu G418 Agar media and a single colony transferred via sterile rod into 1.5 mL 
microcentrifuge tubes containing 1 mL ddH20 and vortexed. 1 μL aliquots of this suspension, along 
with YCG326 and YCG434 controls, were dispensed onto a SC FC-592 Agar dose response (150 μM, 
135 μM, 120 μM, 105 μM, 90 μM, 75 μM and 1% DMSO) and grown for ~48 h at 30˚C. Photographs 
(Canon Powershot S3-IS) were then taken using ZoomBrowser EX remote shooting software (Canon 
Inc, NY, USA) and visually inspected to determine cell growth. 
4.3.9 Multidrug resistance analysis 
In order to establish the specificity of resistance mutations in YCG433 and YCG434 to FC-592, dose 
responses were carried out in liquid media against a range of other known inhibitory compounds. 
Dilutions (all final concentrations) of rapamycin (1000 nM, 316 nM, 100 nM, 31.6 nM, 10 nM, 3.16 
nM, 1 nM); cycloheximide (1000 nM, 316 nM, 100 nM, 31.6 nM, 10 nM, 3.16 nM, 1 nM); hygromycin 
B (317.1 μM, 117.4 μM, 31.7 μM, 11.7 μM, 3.17 μM, 1.17 μM, 317.1 nM); benomyl (100 μM, 31.6 
μM, 10 μM, 3.16 μM, 1.0 μM, 316 nM, 100 nM); fluconazole (32.6 μM, 10.32 μM, 3.26 μM, 1.03 μM, 
326 nM, 103 nM, 32.6 nM); nystatin (10.75 μM, 3.4 μM, 1.075 μM, 340 nM, 107.5 nM, 34 nM, 10.75 
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nM) and FC-592 (150 μM, 47.43 μM, 15 μM, 4.74 μM, 1.5 μM, 474.3 nM, 150 nM, 47.4 nM) were 
prepared in a 96-well V-bottomed plate (Interlab). 
Single colonies of YCG326, YCG433 and YCG434 were inoculated into 3 mL of SC broth and incubated 
at 30˚C on a 40 rpm rotary drum overnight. Cell titre was determined via haemocytometer, diluted 
with fresh SC to a final concentration of 5×105 cells mL-1. 100 μL aliquots of these suspensions were 
dispensed (Eppendorf Xplorer Plus 8 Channel Electronic Pipette) into each well of a clear 96 well flat-
bottom polystyrene cell culture plate (Interlab) and 1 μL aliquots of each dilution of test compound 
were dispensed in triplicate using a multi-channel pipettor (Eppendorf Research Plus 8 Channel) into 
these wells, along with 1% DMSO controls. Plates were grown and assayed for growth as per the 
dose response protocol (Chapter 2). 
4.3.10 Growth rate comparison of resistant mutants 
In order to ensure that YCG433 and YCG434 displayed an appropriate growth rate relative to wild 
type cells, a growth rate comparison assay was performed. Single colonies of YCG326, YCG433 and 
YCG434 were inoculated into 3 mL of SC broth and incubated at 30˚C on a 40 rpm rotary drum 
overnight. Cell titre was determined via haemocytometer, diluted with fresh SC to a final 
concentration of 5×105 cells mL-1. 100 μL aliquots of these suspensions was dispensed (Eppendorf 
Xplorer Plus 8 Channel Electronic Pipette) into each well of a clear 96 well flat-bottom polystyrene 
cell culture plate. Cells were incubated at 30˚C and assayed for growth as per the dose response 
protocol (Chapter 2) at 1 h timepoints from 12-24 h. 
4.3.11 Synthetic genetic array mapping – proof of concept 
A pilot synthetic genetic array mapping (SGAM) experiment was carried out to confirm the utility of 
the technique. In order to minimise the amount of compound used up in this experiment, the DMA 
was condensed down to seven plates from 14, utilising duplicate rather than quadruplicate repeats 
of each strain. A synthetic array was constructed using the cycloheximide resistant strain YCG191 
(which contains a mutation on the ribosomal protein encoding gene RPL28) and the Boone DMA 
112 
 
according to the protocol set out in Baryshnikova et al. (2010), using a Singer Instruments RoToR 
HDA pinning robot. The final selection of haploid double mutants was pinned onto SD –His –Arg –Ura 
–Lys  Can Thia G418 (10 μM cycloheximide) Agar media, and allowed to grow at 30˚C for ~18 h. 
Photographs (Canon Powershot S3-IS) were recorded using ZoomBrowser EX remote shooting 
software (Canon Inc, NY, USA) and visually inspected to determine cell growth. 
4.3.12 Synthetic genetic array mapping – FC-592 resistant mutant 
The SGAM technique was utilised in an attempt to determine the site of the resistant allele in 
YCG434. A synthetic array was constructed using YCG434 and the Boone DMA as for the SGAM pilot 
experiment set out above. The final selection of haploid double mutants was pinned onto SD–His –
Arg –Ura –Lys  Can Thia G418 (150μM FC-592) Agar media, and allowed to grow at 30˚C for ~18 h. In 
an attempt to ameliorate patchy growth observed in earlier selection stages, the final selection step 
onto FC-592 media was pinned twice, in order to seed more yeast cells onto the plate. Plate images 
(Canon Powershot S3-IS) were recorded using ZoomBrowser EX remote shooting software (Canon 
Inc, NY, USA) and visually inspected to determine cell growth. 
4.3.13 Cell cycle analysis by flow cytometetry 
Cell cycle effects of FC-592 were analysed by SYTOX visualisation of chromosome content by flow 
cytometry. A mid log-phase cell population was prepared by inoculating a single colony of YCG326 
into ~50 mL SC in a conical flask and grown for 12 h at 30˚C in a shaking incubator. Cell titre was 
determined via haemocytometer and diluted to 2×107 cell mL-1 with fresh SC. Two sets of triplicate 5 
mL cultures were transferred to 15 mL Falcon tubes and treated with 100 μM FC-592 or 1% DMSO. 
Cultures were grown at 30˚C on a rotating drum for 6 h. 
After treatment, cultures were centrifuged at 4000 rpm for 1 min and supernatant discarded. Cells 
were washed with 5 mL ddH2O, centrifuged at 4000 rpm for 1 min and supernatant discarded. This 
wash step was repeated once more. Supernatant was discarded a final time and cells resuspended in 
70% ethanol (from absolute) to fix. These cells were then incubated overnight at 4˚C.  
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Tubes were centrifuged at 4000 rpm for 1 min and EtOH supernatant discarded. Cells were 
transferred to sterile 1.5 mL microcentrifuge tubes and resuspended in 1×RNase A solution and 
incubated at 37˚C for 1 h. Cells were then washed with ddH2O, centrifuged, supernatant discarded 
and treated with 1000 μL freshly prepared Pepsin solution (0.005 g mL-1 Pepsin, 50 mM HCl) for 5 
min at room temperature. Cells were centrifuged, supernatant discarded and the pellet resuspended 
in 500 μL 50 mM Tris-HCl (pH 7.5). 100 μL aliquots of these cell suspensions were stained with 500 
μL SYTOX Green (1 μM SYTOX Green stain in Tris-HCl (pH 7.5)), along with an unstained control. 
Stained cells were assayed using a BD FACSCanto II florescence activated cell sorter controlled with 
BD FACS Diva software (both BD Bioscoences, San Jose, CA). Results were analysed using FlowJo 
TreeStar data analysis software (http://www.flowjo.com/). 
4.4 Results 
4.4.1 Resistant mutant generation 
A mutant population was generated using EMS mutagenesis. In order to determine adequate 
mutagenesis, a viability assay was conducted. Mutagenised cells were compared to an 
unmutagenised control on SC Agar plates. The mutant population generated showed a sufficient 
attrition rate to demonstrate a good level of mutagenesis had been achieved, and was suitable for 
carrying forward to the screening stage. 
 
 
  
Figure 4.5 Mutagenised cells treated with 3% EMS for 1 
h. Note the number of petite cells in this population. This 
phenotype is likely caused by a deleterious mutation 
causing cells to grow slower or smaller, or the loss of 
mitochodria. There are a sufficient number of healthy 
colonies at this level of mutagenesis to proceed with 
screening. 
Figure 4.6 Unmutagenised control population. Large 
healthy colonies show no sign a petite phenotype. There 
is about a 30% attrition rate in the mutagenised 
population compared to this control sample. 
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4.4.2 FC-592 resistance screening 
The resistant mutant population was washed, grown for 4 h to express mutant proteins, and 
screened for resistance to FC-592 on SC FC-592 Agar at a range of concentrations. After growth, 5 
mutants were identified growing on FC-592 concentrations which proved inhibitory to 
unmutagenised control cells. These resistant colonies were harvested and designated as YCG432, 
YCG433, YCG434, YCG435 and YCG436.  
 
 
 
 
 
 
 
 
 
These five mutants were obtained on FC-592 concentrations of 90 μM and 110 μM. Larger numbers 
of viable cells were observed on concentrations lower than this. However, at these lower 
concentrations several viable cells were also observed on unmutagenised control plates. This calls 
into question the resistance of cells on these plates – because quantities of unmutagenised cells 
were able to survive, they clearly do not require a strong level of increased resistance to thrive. 
In order to characterise the resistant characteristics of each mutant, a solid state dose response was 
carried out. Cells were spotted into wells of a 48-well plate containing different concentrations of 
FC-592. 
YCG434 
YCG435 
YCG436 
YCG432 
YCG433 
Figure 4.8 Mutagenised cells screened on 110 μM FC-
592 (r). Two viable colonies were obtained, one 
considerably larger than the other.  This could be 
because of a deleterious mutation on the part of YCG433, 
or a mutation conferring only partial resistance, whose 
phenotype is significantly ablated by FC-592. 
Figure 4.7 Mutagenised cells screened on 90 μM FC-592 
(r). Three viable colonies were obtained. YCG436 shows a 
petite phenotype, whilst YCG434 and YCG435 colonies 
are larger. No cells grew from the unmutagenised 
population (l) screened at the same concentration. 
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Figure 4.9 Solid state dose response assay of resistant mutants. YCG432, YCG433 and 
YCG434 proved highly resistant against the compound, whilst YCG435 and YCG436 actually 
showed decreased resistance. Note that two wells in the top row (YCG432) were desiccated 
during the incubation process due to uneven quantities of media, and showed no growth. 
For this reason, the 354.6 μM well for YCG432 was repeated (inset). 
YCG433 and YCG434 demonstrated strong growth on 354.6 μM, the highest concentration of FC-592 
available. YCG432 demonstrated growth at 112.1 μM. The well containing 354.6 μM FC-592 became 
desiccated during the first run of this experiment and was repeated. YCG432 grew at this 
concentration in the repeat experiment. The highest concentration that the background strain 
YCG326 was able to grow on was 11.2 μM. Despite growing previously at 90 μM FC-592 
concentrations in a resistance screen, YCG435 and YCG436 were sensitive to the compound relative 
to YCG326, being unable to grow at the 11.2 μM concentration. YCG436 growth was severely 
attenuated at the 3.55 μM level as well. For this reason, these mutants were discarded from further 
study. 
4.4.3 Dominance/recessive testing 
Dominant/recessive characteristics of the three remaining mutants (YCG432, YCG433, YCG434) were 
tested by crossing with a PdrΔ; His3Δ strain and growing resultant diploid strains on 150 μM FC-592. 
If mutations were dominant, the resultant heterozygous diploids would be resistant and grow on the 
YCG432 
YCG433 
YCG434 
YCG435 
YCG436 
YCG326 
112.1 
μM 
354.6 
μM 
35.5 
μM 
11.2 
μM 
3.55 
μM 
1.12 
μM 
354.6 
nM 
1% 
DMSO 
354.6 
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test plate. If they were recessive the mutation would be masked by the wild type copy of the gene 
and the cells would fail to grow. 
 
 
 
 
 
 
Results from this assay indicated that the FC-592 resistance mutation for YCG432 was dominant, 
whilst those for YCG433 and YCG434 were co-dominant or recessive. As there are several mutant 
identification strategies that rely on a distinguishable heterozygotic phenotype (such as plasmid 
library phenotype rescue; Avrahami-Moyal et al. 2012), YCG433 and YCG434 were selected for 
further study. 
4.4.4 Tetrad analysis 
Diploid YCG433×PdrΔ;His3Δ and YCG434×PdrΔ;His3Δ diploid cells were sporulated and dissected 
under microscopy to determine whether FC-592 mutations within those strains were caused by a 
variation at single locus. A single locus genotype would give 2:2 segregation of progeny possessing 
FC-592 resistance. 16 tetrads were 
dissected and progeny cells transferred to 
SC media containing 150 μM FC-592. 
 
YCG432 diploid 
YCG433 diploid 
YCG434 diploid 
YCG326 
Figure 4.10 Spot assays on 150 μM FC-592 of resistant 
mutants crossed with WT stains to create heterozygous 
diploids. YCG432 grows strongly, showing a dominant 
mutation, whereas YCG433 and YCG434 failed to grow, 
showing a recessive or haplo-insufficiency effect. No 
growth is seen from an YCG326 control. Note cells did not 
grow in a visible fashion for any mutant except at the 
highest density of cells in this spot dilution assay.  
Figure 4.11 Tetrad analysis of resistant mutants. Tetrads 
1-8 (YCG434×PdrΔ;His3Δ) and 9-16 (YCG433×PdrΔ;His3Δ) 
display 2:2 segregation of alleles mediating FC-592 
resistance. Of 16 tetrad sets, only #7 and #14 do not 
show a 2:2 pattern of growth on FC-592 media. This 
could be due to an error in cell transfer to the assay 
plate. YCG434 haploid and YCG326 cells serve as positive 
and negative controls respectively. 
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Results of tetrad analysis suggest that resistant mutations in YCG433 and YCG434 are due to single 
locus effects. This is because resistance alleles segregated 2:2 in 87.5% of tetrads tested for each 
strain, accepting experimental error for the outliers. This result is important for proceeding to 
synthetic genetic array mapping, as a double locus mutation results in a low proportion of viable 
progeny. This would result in patchy colonies due to selecting for essentially three mutations: G418 
resistance and the two alleles that mediate resistance to the compound of interest. 
4.4.5 Complementation testing 
A complementation test between YCG434 and YCG433 was conducted to determine whether the 
resistance allele was located in the same functional unit or gene. A Mat A KanR+ cenLeu- YCG433 
mutant progeny was crossed with a YCG434 cenLeu+ transformant and tested on a solid state dose 
response to establish the resultant diploid’s resistant properties. If the mutant alleles were located 
on the same gene, the diploids would possess no wild type copy and the cells would display a 
resistant phenotype. If the alleles were on differing genes, the wild type copy of each would mask 
the resistant allele and the cells would display a sensitive phenotype. 
 
 
 
 
The results of this assay revealed a partially resistant phenotype for the YCG433×YCG434 diploids. 
These data are indicative of a quantitative trait with multiple genes contributing to a phenotype. It is 
possible but unlikely that both resistant mutants represent differing mutant alleles on the same 
gene (reduction in function mutations), in which case the two differentially defective genes in the 
diploid may restore some functionality and thus sensitivity. 
150 μM 135 μM 120 μM 105 μM 90 μM 75 μM 1% DMSO 
YCG434 
YCG326 
YCG434×YCG433 
Diploids 
Figure 4.12 Dose 
response assay showing 
complementation. 
YCG434×YCG433 show 
partial resistance to FC-
592 relative to YCG434. 
This likely indicates 
mutations in different 
complementation 
groups, displaying a co-
dominant allele type for a 
quantitative trait. 
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More likely is two loss-of-function mutations on different genes which both contribute to FC-592 
sensitivity. In this case, haplo-insufficiency means the single functional copy of each gene does not 
produce enough of a gene product to bring about the wild-type level of sensitivity. In this way, the 
genes in question would be quantitative trait loci (QTLs), contributing to a quantitative characteristic 
– namely FC-592 resistance. 
4.4.6 Multidrug resistance analysis 
In order to determine whether the resistance mutations in YCG43433 and YCG434 conferred general 
resistance or specific resistance to FC-592 compared to the background strain YCG326, dose 
response experiments were conducted utilising cycloheximide, rapamycin, hygromycin B, 
fluconazole and nystatin, as well as FC-592. If resistance to these known inhibitory compounds were 
observed in the resistant mutants, it would suggest a general mechanism of resistance not giving 
insight into the mode of action for FC-592. 
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Figure 4.13 Multidrug resistance analysis of the FC-592 resistant strains YCG433 and YCG434. The resistance strains show 
specific resistance to FC-592, being able to grow in a higher concentration than a control strain, YCG326. However, these 
strains show comparative sensitivity, relative to YCG326, to rapamycin, cycloheximide, hygromycin B, benomyl and 
nystatin. YCG433 shows some limited resistance to fluconazole relative to YCG326, whilst YCG434 is comparatively 
sensitive to this compound as well.  
The FC-592 resistant mutants were shown to be specifically sensitive to that compound in a multi-
drug resistance assay. Apart from fluconazole, neither strain exhibited increased viability at higher 
doses of the tested compounds compared to the background strain YCG326. In addition, YCG434 
showed no increased resistance to fluconazole, and YCG433 showed only marginally increased 
resistance. These data provide strong evidence that resistant mutations observed in YCG433 and 
YCG434 do not cause general resistance to a wide range of inhibitory compounds, although the 
sample size in this case is limited.  
4.4.7 Growth rate of resistant mutants 
Growth rate of resistant mutants was determined to ensure they were close enough to wild type 
growth rate to proceed on with. This assay revealed that YCG434 grew at very close to the same rate 
as the background strain control. However, YCG433 displayed a significant growth defect in 
comparison to that strain. It is important for the SGAM experiment that the query strain grows at a 
WT rate, as otherwise the resistant mutants will be outcompeted during the initial selection phases 
of the experiment, resulting in an underrepresentation of resistant alleles in the final selection 
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sample, and thus an underestimation of resistance. For this reason, YCG434 alone was selected to 
carry on to the SGAM phase of the experiment. 
 
Figure 4.14 Time series growth assay. The growth rate of resistant mutants YCG433 and YCG434 was assayed in non-drug 
conditions against a background strain control, which grows at a WT rate. Grown from a similar starting titre, YCG433 
displayed a severely attenuated growth rate, making it inappropriate for use in future experiments. YCG434 displayed little 
or no growth defect compared to the WT and was selected for use in SGAM experiment. YCG434 and YCG326 were only 
just reaching saturation after 24 h, longer time than expected. This may have been due to a low starting titre. 
 
4.4.7 Synthetic genetic array mapping (SGAM) – proof of concept 
In order to prove the utility of the SGAM technique, a pilot experiment was conducted using the 
cycloheximide resistant strain YCG191 and a cycloheximide/G418 double mutant selection. Only 
strains which possess copies of the mutant RPL28 gene and a KanR resistance cassette from the 
Boone DMA would be viable under this selection. 
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Figure 4.15 A linkage disequilibrium pattern is observed on plate three of the SGAM. These ‘holes’ in growth on the plate 
represent deletion strains from the Boone DMA, which when crossed with the cycloheximide (CHX) resistant mutant 
YCG191, are inviable under the double mutant selection of 200 μg mL-1 G418 and 10 μM CHX. Homologous recombination 
means that DMA strains carrying a KanR cassette on genes close to the site of CHX resistance (the ribosome protein 
encoding gene RPL28) cannot carry both resistance mutations, and are therefore inviable under double selection 
conditions. Note that RPL28 is an essential gene and does not appear as a deletion mutant in the DMA. Therefore the holes 
observed in the above SGAM plate represent genes that surround the RPL28 locus on chromosome VII within the yeast 
genome. These genes all occur within 7000 bp of RPL28. 
The results from the pilot SGAM experiment confirmed this as a viable technique. The DMA strains 
Δrmd9, Δarc1, Δvps73, ΔYGL101W, Δseh1 and Δlsg1 were identified in a linkage disequilibrium 
pattern illustrating the genomic location of the cycloheximide resistance mutation RPL28-ChxR. 
RPL28 is surrounded by these genes on chromosome VII in the S. cerevisiae genome. It is especially 
noteworthy that this technique is able to identify a mutation on an essential gene, which are usually 
invisible to assays incorporating the haploid DMA. 
Δrmd9 
Δarc1 
Δvps73 
ΔYGL101W 
Δseh1 
Δlsg1 
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Figure 4.16 The genomic location of RPL28. RMD9, ARC1, VPS9, YGL101W, SEH1 and LSG1 are the nearest non-essential 
neighbours on chromosome VII. The improbability of recombination events during meiosis amongst neighbours this close 
means that progeny are unable to carry copies of both KanR and  RPL28-ChxR mutations. Source: yeastgenome.org. 
 
4.4.8 YCG434 FC-592 resistant mutant – Synthetic genetic array mapping 
YCG434 was selected as a query strain for the SGAM experiment. A synthetic genetic array was 
created using this stain and the Boone DMA. During construction of double mutants for the array, 
patchy growth was noticed on several steps. For this reason, a high copy strategy was used whereby 
each plate was pinned twice to maximise the amount of cells that were transferred to each new 
selection. However, this proved insufficient to create sufficient growth in the final selection step. 
 
 
 
 
 
 
Figure 4.17 Plate 7, YCG434 SGAM. Very 
patchy growth is seen under the final 
selection for this assay. This is due to the 
lack of viable double mutants at this stage 
in the selection process. Insufficient cells 
capable of surviving in the presence of FC-
592 and G418 were pinned. 
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Growth was too patchy after the final selection of this experiment to make any conclusions about 
the genomic location of the FC-592 resistance mediating locus in YCG434. Colonies displaying a 
growth phenotype provided inconsistent coverage of the array and made identification of any 
linkage pattern impossible. 
4.4.9 Cell cycle analysis by flow cytometry 
The effects on the cell cycle of FC-592 were analysed using flow cytometry. Treated cells were fixed 
and stained with SYTOX Green before analysis with a fluorescence activated cell sorter. This assay 
determines the proportion of the cell population at each phase of the cell cycle by measuring SYTOX 
stained DNA content of each cell. 
 
 
 
 
 
 
 
 
 
Figure 4.18 Resistance phenotypes. This image shows a resistant (growth) phenotype (red), and a 
sensitive (non-growth phenotype (blue). Substantial amounts of cells are seen even in the non-growth 
phenotype because a large amount were pinned from the previous selection in an attempt to overcome 
patchy growth problems, an effort that proved in vain. A true growth ‘hole’, established at an earlier 
selection, is shown in yellow. This hole represents the array position of PDR3, which is unable to survive 
under selective conditions due to the URA3 auxotrophic marker. 
#1 
#2 
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Results from this experiment indicated a likely G2/M phase block upon treatment with FC-592. 
Proportion of cells in this phase increased an average 22.67% (STDEV=3.28%). This suggests that the 
mode of action of FC-592 prevents the cell proceeding through cytokenesis, at some step in late 
interphase or early mitosis. There is also a notable decline in S phase cells in two of three replicates. 
Whilst possibly an artefact or experimental error, this decline could indicate an effect of FC-592 on 
the G1 checkpoint control mechanism. 
  
Figure 4.19 Three replicates of FC-592 treated cells compared to untreated cells in a flow cytometry cell 
cycle experiment. Replicates were run on separate days using different cultures of YCG326, explaining the 
differences seen between each replicate. Within each replicate however, the proportion of cells in G1 phase 
fell whilst the proportion of cells in G2/M phase increased substantially. In replicate #1, S phase cells 
increased slightly as a proportion, whilst in the other two replicates the proportion of S phase cell declined 
sharply. This difference is likely caused by differences in the starting cultures. These data indicate a G2/M 
phase block caused by FC-592. 
#3 
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Chapter 4 Discussion 
4.5.1 Resistant mutant generation 
Mechanisms of resistance frequently give insight into mode-of-action studies for novel compounds 
(Kahan et al. 1974; Davidse, 1986). This strategy was used in an attempt to identify a gene or genes 
mediating sensitivity to FC-592 in a manner which would provide insight into its mode-of-action 
and/or target. Resistant mutants were successfully generated for this compound. This involved 
recruiting a mutant population from EMS mutagenised cells, screening them for resistance on FC-
592 containing media, and defining some of the characteristics of these mutations through tetrad 
analysis. 
 A mutagenised population was produced via the EMS protocol, displaying a high-quality range of 
diversity in growth phenotypes when grown on SC media. For example, many small colonies were 
seen, indicating a deleterious mutation that slowed growth rate, whilst many normal sized colonies 
were also seen. In addition, kill rate of ~30% was achieved in the mutegenised population relative to 
the unmutageised control. These factors are a good indication that a level of mutagenesis was 
introduced to the population that struck a balance between introducing sufficient variation into the 
population and survivability of cells (Winston, 2008). 
Screening revealed five resistant mutants in an initial screen, three of which proved to have 
sustainable resistance on follow up dose response assays. It is unknown why the remaining two 
mutants grew in the initial screen, but showed reduced resistance relative to the wild type in the 
dose response, but could be due to some revertant mechanism. 
A dominance/recessiveness test revealed that one was dominant, whilst two mutants were 
recessive, when the tested trait was grown at 150 μM FC-592. Further testing revealed a likely semi-
dominant mechanism in the latter two, where mutations in YCG433 and YCG434 both contributed to 
FC-592 resistance. This makes sense in view of resistance as a quantitative trait: this is commonly the 
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case with respect to resistance to antiproliferatives (Sen & Ferdig, 2004). The semi-dominant 
(functionally recessive when tested at 150 μM) mutants were selected, due to their possible utility in 
future experiments such as genomic library plasmid rescue assays. 
The recessive/semi-dominant nature of these alleles makes it likely that they are a result of loss-of-
function or partial loss-of-function mutations (Lodish et al. 2000). This has implications for the 
mechanism of resistance, which will be discussed later in this chapter. 
Tetrad analysis revealed that resistance traits for both YCG433 and YCG434 were mediated by single 
locus mutations. This is because they segregated 2:2 in meiotic progeny produced by mating with a 
(mating type switched) background strain query. This is important for the success of SGAM and 
makes it easier to identify the mechanism of resistance involved in each of these cases, as it 
presumably doesn’t involve complex interactions between multiple resistant loci.  
On the other hand, complementation analysis revealed that the resistance mediating alleles in the 
two strains were likely located on different genes. This obviously means that there are multiple 
mechanisms of resistance involved, although they could affect the same process or pathway. The 
upshot of this is that it will be harder to specify a specific mode of action from these resistance 
strains: it is apparent that resistance is not mediated by a single target. Of course, based on previous 
results from this project, it seems unlikely that FC-592 affected a specific target in any case. As 
discussed in Chapters 2 & 3, a broad based mode-of-action is far more likely. It is likely therefore 
that there are more genes mediating resistance, which if discovered could allow a greater 
understanding of the compound’s multiple targets. 
Finally, a multidrug resistance assay was conducted to ensure that the mutations withinYCG433 and 
YCG434 did not mediate general resistance to antiproliferatives, for example by up-regulating efflux 
pumps. This is critical because such a mutation would give no insight into the mechanism of the 
compound. The only indication of cross resistance in any of these assays was slightly increased 
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resistance for YCG433 to the triazole antifungal fluconazole. Fluconazole bears little structural 
similarity to FC-592, so it is unknown how this cross resistance is caused, especially considering 
YCG433 did not display any such resistance to any of the other compounds assayed. It is possible 
that this result was due to experimental error or some artefact of the testing procedure, as the extra 
resistance relative to the background strain in this case was minimal. 
4.5.2 Synthetic genetic array mapping 
The two components for mode-of-action studies utilising resistant mutants include the generation 
and screening of the mutants themselves, and the identification and characterisation of the 
mechanism of resistance. It is this second component which gives insight into the possible mode-of-
action of the compound, and is frequently the more difficult part of the process. Although mutants 
resistant to FC-592 were successfully generated for this experiment, the synthetic genetic array 
mapping (SGAM) strategy used to identify the resistance-causing 
locus proved ineffective. Since a pilot experiment using a 
previously identified cycloheximide resistant mutant proved 
successful, the protocol itself is clearly not at fault. Instead, the 
failure of this experiment is likely mediated by the resistance 
mutation itself. 
A growth phenotype was seen on selective media containing 150 μM FC-592. However, rather than 
the even growth phenotype that is normally seen in SGA experiments (Baryshnikova et al. 2010), the 
growth phenotype was seen in only a few colonies. This obviously did not allow a linkage 
disequilibrium pattern to be detected in a way which would reveal the resistance mediating locus in 
the genome: most regions were too sparsely covered by growing colonies to detect the distinctive 
inhibition zones in neighbouring colonies. 
Figure 4.20 Growth phenotype 
colonies were few and far between. 
This proved insufficient to identify a 
linkage pattern on any of the plates in 
this assay. 
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Significant growth was seen outside of the ‘growth’ phenotype colonies. These are identified as 
smaller colonies on the SGA final selection plates. The two phenotypes are however quite 
distinctive: there is a clear difference between the larger, growing colonies and the smaller, non-
growth phenotypes. Partial growth in the ‘non-growth’ phenotype colonies is likely due to several 
factors.  
In an effort to alleviate patchy growth seen at earlier selection stages, and to achieve a higher ratio 
of ‘growth’ colonies, larger amounts of yeast were pinned to the plate during the SGA protocol. This 
meant that a sizeable amount of cells in each colony were transferred to the plate before the growth 
assay was even started. It is feasible that cells in these larger starting colonies were able to achieve a 
small level of growth even if they did possess the requisite alleles to thrive on the selective media on 
which they were being grown. Since some of these cells would have been situated away from direct 
contact with the surface of the drug-containing media, it is possible that they were in essence 
shielded from the compound and received a lesser dose. These cells could still have obtained the 
nutrients required for limited growth from the breakdown of dead yeast cells within their own 
colony, or through development of filamentous growth (Zaman et al. 2008; Jin et al. 2008). 
Therefore, these cells were able to grow but at a much slower rate than those colonies which 
displayed a ‘growth’ phenotype. 
These ‘growth’ cells are proposed to be those cells which were the object of the SGAM all along: 
meiotic progeny of the original cross containing both the FC-592 resistance mutation from the 
resistant strain YCG434 and the KanR cassette from the Boone DMA. As already noted, these cells 
were not common enough amongst the colonies in toto to produce a viable array experiment. There 
are several possible reasons for this stemming from one basic cause. 
There were not enough double mutant cells at the penultimate stage of selection to provide good 
growth characteristics in all colonies. This means that the FC-592 resistance mutation was far rarer in 
the combined array population than would be expected for a single locus mutation, wherein we 
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would expect fully half the cells to exhibit this trait. A multi locus mutation could explain this 
discrepancy. In this case, rather than segregating 2:2, the resistance trait would segregate 1:3 (for a 
two locus mediated trait), or 1:7 (for a three locus mediated trait). In these circumstances there 
would be fewer resistant cells in the population, and therefore fewer viable cells transferred onto 
the selective media. This can result in patchy growth (Tong & Boone, 2007), as many colonies do not 
possess enough viable cells to produce a visible growth phenotype relative to other colonies. 
However, tetrad analysis showed that FC-592 resistance segregated 2:2 amongst the meiotic 
progeny of YCG434 (and YCG433 for that matter). Therefore it is possible to rule out a multi-locus 
mediated trait as a cause of SGAM failure. The resistance trait should have been present in 50% of 
meiotic progeny, meaning they should have been just as abundant in relative terms as KanR 
resistant cells, or any of the other selectable traits which worked as predicted in earlier selection 
steps. 
An alternative theory for why FC-592 resistant cells were present in insufficient numbers is that the 
mutation causes sensitivity to other compounds, which were used as selectable markers during the 
SGA process, such as nourseothricin, geneticin, canavanine, thialysine. Indeed there is some 
evidence that YCG434 is generally sensitive to a range of other compounds: in a multidrug sensitivity 
assay, YCG434 was significantly more sensitive than a background strain control in response to 
cycloheximide, fluconazole, hygromycin B and rapamycin. For this reason, the resistance mutation 
may have been selected against long before the final selection step in the SGAM experiment. 
This is a plausible explanation. However, nourseothricin (inactivates NAT by monoacetylation of ß-
amino group of the ß-lysine residue) and geneticin (through action of aminoglycoside 3'-
phosphotransferase) are protected against by resistance cassettes which provide a very high level of 
resistance to these compounds (Van Driessche et al. 2005; Goldstein & McCusker, 1999; Davies & 
Jimenez, 1980; Sohn et al, 1999). Therefore, a general sensitivity caused by the FC-592 resistance 
mutation seems unlikely to cause growth defect amongst the resistant mutants in this manner. 
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In the case of canavanine and thialysine, resistance is mediated by mating type (Broach et al, 1979; 
Tong & Boone, 2006).  Mat α cells activate the arginine permease CAN1, which allows cellular uptake 
of the L-arginine analogue canavanine, which is incorporated into biosynthesis thereby producing 
structurally aberrant proteins which cannot perform their native functions (Rosenthal, 1986). This 
function is absent in can1Δ::STEpr-Sp_his5 Mat a cells, such as the SGA strains used in ths 
experiment.  
Similarly, the toxic lysine analogue thialysine is excluded from Mat a lyp1Δ cells, for which the lysine 
permease LYP1 is deleted. Barring breakdown of the cellular mechanisms which exclude these drugs 
in the absence of CAN1 and LYP1, it is highly unlikely that weakening the cells against a general 
chemical attack, as is supposed with YCG434, would explain sensitivity to canavanine and thialysine 
in Mat a cells. 
A third plausible reason for the lack of resistance mutation carrying cells at the penultimate selection 
stage is general slow growth in these mutants. If this were the case, the mutant progeny would be 
out-competed by their wild type peers at every stage of selection. In this circumstance, even a mild 
growth defect could add up over the course of the experiment so that the population of resistant 
mutants by final selection would be drastically reduced. In order to try to circumvent this, a growth 
rate assay was conducted with YCG434 and YCG433. YCG434 displayed WT levels of growth and at 
the time was judged to be sufficient for continuation into the SGAM protocol. However, 
reconsideration was necessary after the failure in growth at the final selection stage. 
 The growth rate assay which determined the near WT fitness of YCG434 was conducted in liquid 
media, whilst the SGAM was entirely grown on agar based plates. Cellular metabolism is known in 
many cases to be different in solid or liquid based media (ZoBell, 1943). This is especially so relating 
to nutrient gathering, where solid media can trigger filamentous growth and a change in gene 
expression profiles (Prinz et al. 2004).  For this reason, wild type and FC-592 resistant segregants 
were examined for growth defects via tetrad analysis. 
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Small colony phenotypes observed in tetrads grown on non-selective media were congruent with FC-
592 resistance in tetrads grown on selective media. This evidence very strongly suggests that despite 
the fact that YCG434 grew at or near WT rates in liquid media, it was a slow grower in agar based 
assays. The possibility is that the FC-592 resistance mediating mutation affects a gene that is 
important for growth on solid media, for example an invasive growth associated protein such as the 
MEK kinase Ste11p. This would account for the difference in growth on differing media types, but it 
is unclear how it would mediate resistance to FC-592. Xu et al. (2002), and Anastasia et al. (2012) 
suggest a link between G2/M arrest, cell size and secretory genes. The regulation of cell cycle 
mediating secretion is mediated by the exocyst complex, which consists of eight subunits, SEC3, 
SEC5, SEC8, SEC10, SEC15, EXO70 and EXO84. Assuming FC-592 activity against this pathway, a 
reduction-of-function mutation here may mediate resistance to FC-592 activity against the complex, 
whilst also causing a small cell or slow growth phenotype. 
YCG434 possessing a slow growth phenotype on agar neatly explains the failure of the SGAM 
experiment as performed: progeny from the original cross that carried the resistance mutation were 
Figure 4.21 Tetrads growing on SC media. Tetrads seem to 
segregate into large and small colony sizes, in a 2:2 fashion. 
This seems to indicate a growth mediating single locus 
mutation. 
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Figure 4.22 Tetrad phenotyping on 150 μM FC-592. 
Marked colonies match up to tetrads from left. Each 
resistant mutant displaying a growth phenotype in 
the FC-592 containing media also displayed a small 
colony phenotype in the tetrad plate. This is 
compelling evidence that the resistance allele also 
mediates a small growth phenotype in non-selective 
media. 
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strongly outcompeted by WT cells, meaning they were present in insufficient quantities to achieve 
coverage of the genome. Only a few rare examples possessed a significant number of these double 
mutant cells and displayed a growth phenotype in the final selection. 
An alternate strategy that would counter this problem would be to grow each of the stages of the 
SGAM experiment on FC-592 containing media. This would counter any advantage WT cells hold 
over the resistant mutants by selecting for the resistance mutation at each step. In this scenario, the 
final selection would be performed with G418, selecting for KanR containing double mutants in a 
way that would reveal the sought after linkage disequilibrium pattern. However, a phenomenal 
quantity of the compound would be necessary to achieve this, far more than has ever been 
synthesised. This would clearly only be feasible if an effective and efficient synthesis were devised 
for the compound, enabling large quantities to be produced. 
A less compound hungry strategy might be to adapt the SGAM protocol for use entirely in liquid 
based assays. This would use a plate handling robot to transfer cells between wells in 384-well cell 
culture plates. Each selection would be performed as for the Agar based assay, except in liquid 
media, allowing the resistant mutants to compete on an equal footing. An additional advantage of 
this approach would be the fact that cells are more sensitive to FC-592 in liquid media, meaning less 
of the compound would be required for a given number of assays. A literature search reveals that 
this strategy has not been tried before, and therefore is speculative. However it would seem that it is 
an approach worth trying. Proving the feasibility of such an assay could have utility for future 
applications. 
4.5.3 Common mechanisms of resistance 
There are several common mechanisms of resistance in resistant mutants which could give insight 
into the possible causes of FC-592 resistance in YCG433 and YCG434. These include loss-of-
function/gain-of-function in a gene required to activate/deactivate the bioactive compound; 
disruption of the binding site in the compound’s target protein, or a gene that affects the target 
135 
 
protein; up-regulation of defensive cellular responses such as the PDR drug efflux network; and 
modification of uptake mechanisms such as permeases that mediate the ability of the compound to 
penetrate the cell. 
Mechanisms of resistance mediated by alteration of activators/deactivators, rely on disrupting a 
mode of bioactive chemical activity which requires modification to an active form. The inhibitory 
compound is inactive in its original form, but is metabolised into a toxic metabolite by cellular 
processes. This type of compound is commonly known as a prodrug, and has no effect on the cell if 
the bioactivation mechanisms are disrupted (Blanchard, 1996). Relatedly, organisms can develop 
defences that will degrade the bioactive compound into an inactive form, rendering it harmless 
(Morrissey & Osbourn, 1999), either through direct action of the mutant protein on the compound, 
or through upstream effects that lead to an up-regulation of the degratory enzymes. FC-592 is a 
structurally simple compound with no chemical moieties which immediately suggest a mechanism 
for activation to a more functional form, nor breakdown to a less active form. However, these 
remain distinct possibilities and are some of the more plausible mechanisms of resistance to this 
compound in YCG433 and YCG434. 
In circumstances where the binding site of the target protein or complex is modified, affinity of the 
inhibitory agent for that binding site is reduced (Weisblum, 1995), lowering the potential for 
inhibition of the function of that protein or complex. When the native activity of that target remains, 
it may be able to carry out its biological function without being disrupted. This is most commonly 
seen when the compound has high affinity for a very specific binding site (Pryor et al. 2002). In cases 
where a more general mechanism is responsible for the activity of the compound, modification of 
just one target is unlikely to seriously ablate that activity. Since FC-592 is predicted to have a multi-
target mechanism, it seems unlikely that direct modification of a specific target is responsible for the 
resistant phenotypes seen in YCG433 and YCG434. 
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A common mechanism of drug resistance in yeast is the system of drug efflux pumps mediated by 
the PDR network, which has been previously described in this thesis. Mutations causing up-
regulation of genes within this network have been frequently implicated in inhibitory compound 
resistance (Tsai et al. 2010; Vandeputte et al. 2011). However, this mechanism is less likely as a 
mediator of resistance to FC-592 in these resistant mutants for a pair of reasons. Firstly, the PDR 
network in these cells has been severely attenuated by deletion of the PDR1 and PDR3 transcription 
factors. Therefore, there is little PDR response left to up-regulate in this particular circumstance. In 
addition, evidence from the multidrug dose response assay suggests that YCG433 and YCG434 are 
specifically resistant to FC-592, whereas the PDR network mediates resistance to a broad range of 
compounds.  
Modification of compound uptake is frequently implicated as a mediator for resistance across a 
range of bioactives and in numerous species (Maser et al. 1999; Schnappinger & Hillen, 1996; Hall, 
2002; Bray et al, 2003). Numerous transmembrane proteins are involved in regulating transport of 
extracellular molecules into the cytosol. A loss-of-function or partial loss-of-function in the 
transmembrane transporter or permease responsible for uptake of FC-592 would explain the 
resistance to this compound seen in YCG433 and YCG434. Since many of these proteins are relatively 
specific for the type of substrate whose uptake they mediate (Abumrad et al. 1999; Wartlick et al. 
2004), chances are good that a mutation in this process could specifically cause resistance to FC-592. 
Slow growth witnessed in liquid and solid media for YCG433 and on agar for YCG434, could be 
explained by reduced nutrient uptake caused by the loss-of-function in the uptake protein. Taking all 
evidence into consideration, this seems like the most plausible mechanism for resistance mediation 
to the compound by the two resistant mutants studied in this project. However, due to the failure of 
the SGAM assay, this possibility was not confirmed and remains speculative. 
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4.3.5 Cell cycle analysis by flow cytometry 
Taxane diterpenes have a history of clinical use related to cell cycle arrest (Hagiwara & Sunada, 
2004). As a diterpene natural product, FC-592 was therefore analysed for its effect on the cell cycle 
utilising flow cytometry techniques in a fluorescence activated cell sorter. 
The cell cycle encompasses the distinct series of processes and events which lead to cell 
reproduction (Cooper, 2000). In eukaryotes, these processes are divided into discrete phases in 
which certain functions must take place before the cell can move on to the next phase of the cycle. 
At the highest level, the cell division process is divided into the stages of interphase and mitosis. 
During interphase, the first stage, the cells increase in size, producing the chemicals required for cell 
division and replicate their genome. In mitosis (M phase), the chromosomes separate to produce 
two sets of the genome (anaphase), at which point the cell divides into two daughter cells, a process 
known as cytokinesis. In the budding yeast S. cerevisiae, this takes the form of a slowly growing bud 
rather than binary fission.   
The key factors that make this process useful to researchers are a series of checkpoints, during 
which genetic processes assess the cell against a range of criteria to ensure it is competent to 
proceed to the next stage. The biological purpose of checkpoints is to ensure that damaged or 
incomplete DNA is not passed on to daughter cells; preserving larger organisms from deleterious 
tumours and single cell organisms from deficient, evolutionary dead ends. Clinically, this process can 
be targeted to achieve a desirable effect: most notably the arrest of tumours in rapidly dividing 
cancer cells (Bharadwaj & Yu, 2004). Drugs such as paclitaxel (Jordan & Wilson, 2004) and 
demecolcine (Yang et al. 2010) stabilise and destabilise microtubule formation respectively, during 
early mitosis, preventing chromosome separation. This leads to arrest of the cell cycle, and eventual 
apoptosis.  
Cell cycle targeting drugs are tumour non-specific, but take advantage of the fact that cancer cells 
tend to divide much more rapidly than healthy somatic cells. Since only dividing cells are affected by 
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these agents, the effect on tumour cells is much greater than on healthy cells, leading to a 
therapeutic window.  
The flow cytometry cell cycle assay revealed that FC-592 causes a cell cycle block at the G2/M 
checkpoint. This means that like Paclitaxel, demecolcine and laulimalide, FC-592 causes cell cycle 
arrest in dividing cells. In a flow cytometry experiment such as the one conducted for this research 
project, this is apparent as an increase in the proportion of cells with a higher fluorescent index – 
this is analogous to those cells with a higher DNA content, i.e. those cells which have replicated their 
genome but have not divided yet. This pattern is seen in cells treated with microtubule 
stabilisingagents peloruside (Hood et al. 2002) and laulimalide (Mooberry et al. 1999). 
  
 
 
 
 
 
 
Results obtained from cell cycle analysis demonstrated a G2/M cell cycle checkpoint block, producing 
a similar or better looking G2/M block profile to two known cell-cycle arresting agents, paclitaxel and 
peloruside, one of which has a long and storied history as an anti tumour chemotherapeutic.  
However, it should be noted that FC-592 treatment was conducted at 100 μM, whilst the peloruside 
and paclitaxel assays were conducted at 1 μM. In addition, the peloruside and paclitaxel assays were 
conducted against mammalian tumour cells rather than yeast. There is considerable homology 
Figure 4.23 Comparison of FC-592 treated cells with previously published assay of paclitaxel and 
peloruside treated cells. A similar looking increase in G2/M phase cells is seen compared to these 
established microtubule stabilising drugs. It should be noted that the paclitaxel and peloruside treated 
populations were mammalian tumour cell lines, whilst the FC-592 treated cells were yeast. These 
model systems have similar cell cycle mechanisms however. Images on right reprinted with permission 
from AACR: Cancer Research, Hood et al. 2002. 
100 μM FC-592 
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between these model systems, especially in regards to cell division mechanisms (Cooper, 2000), and 
thus the relevance of comparisons is likely. However, this comparison shouldn’t be treated as 
quanitative as it is unknown how different levels of cell cycle arrest would affect the profile of the 
respective cell types seen in the assays. Simply put, it is probably safe to say that FC-592 produces a 
cell cycle blockage as seen in the other two figures, but these numbers shouldn’t be treated as 
quantitative until further work can be done, comparing like with like. 
This result has intriguing implications for FC-592. Although previous work has suggested that the 
compound is likely to be a non-specific binder, and therefore unlikely to provide the specificity 
required in a chemotherapeutic, it would be of considerable interest to explore the mechanism of 
cell cycle arrest. This is especially so considering the rarity of cytoskeletal targeting drugs like 
paclitaxel (Jordan & Leslie, 2004).  
It is unlikely that FC-592 has similar activity to the likes of paclitaxel through binding to the taxol 
binding site. The reason for this is that the taxol binding site is highly specific (Buey et al. 2004) to its 
ligands, with relatively few known 
compounds with affinity for the 
domain. The chances of FC-592 acting 
in this way therefore seem low. 
However there are other mechanisms 
by which FC-592 could be causing cell 
cycle arrest.  
An emerging strategy in drug discovery 
is targeting of the signalling 
mechanisms in the cell phase 
checkpoints (DiPaola, 2002). The 
Figure 4.24 Mammalian component of the Cdk pathway regulating 
entry to mitosis. Inhibition at several binding sites in this pathway could 
lead to deactivation of the Cdc2-B1 complex which is required for mitosis 
to proceed. This would result in a G2/M phase cell cycle block such as 
that observed experimentally in FC-592 treated cells. A conserved 
pathway analogous to this exists in yeast. Reprinted with permission 
from AACR: Clinical Cancer Research, DiPaola, 2002. 
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checkpoint control system is regulated by a family of protein kinases, the cyclin-dependant kinases 
(known as cell division cycle or CDC genes in yeast), which are in turn controlled by a complex array 
of proteins, primarily the cyclins. These regulate prgression of the cell cycle through the G1 and G2 
checkpoints. For example, in response to DNA damage Chk1p is activated and phosphorylates Pds1p, 
which in turn inhibits anaphase by binding the separin Esp1p (Jackson et al. 2000; Liu et al. 2000). An 
analogous mammalian pathway sees Chk1 inactivating Cdc25 in response to DNA damage. This 
mechanism prevents Cdc25 from activating the Cdc2-B1 complex which is required for progression 
from G2 to M phase (DiPaola, 2002; Jackson et al. 2000). A compound that inhibits certain stages in 
these processes, such as by competing for binding sites in activating enzymes, could cause a cell 
cycle arrest. For example flavopiridol, a semi-synthetic derivative of the plant alkaloid rohitukine, is 
believed to act on the CDC pathway through inhibition of the Cdk-activating enzyme KIN28, docking 
on Cdk ATP-binding sites and decreasing cyclin D1 levels (Bible & Kaufmann, 1997; Carlson et al. 
1999). In this way it prevents cell cycle progression through selectively inhibiting a key component of 
the pathway, which in turn leads to the inactivation of other CDC pathway proteins, including the 
critical Cdc28p, catalytic subunit of the main cyclin-dependent kinase complex (Mendenhall & 
Hodge, 1998). 
In a similar way, inhibition of targets such as these by FC-592 could cause G2/M cell cycle arrest as 
observed experimentally in the flow cytometry experiment. This would occur even if the compound 
bound to other cellular targets as a non-specific binder of hydrophobic pockets: it would cause cell 
cycle arrest in this manner, but it would also cause disruption in other parts of the cell. A more 
intriguing thought presents itself when it is considered that that the vast majority of CDC genes are 
essential, and thus not present in the HOP screen assayed in Chapter 3. This means that these strains 
were not present to show sensitivity in the assay, and thus were not part of the dataset that was 
analysed for GO term enrichment. It is not possible to say that FC-592 did not target the CDC 
pathway from the results of the HOP screen, simply because deletion mutants representing these 
genes were not present to be screened.  
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This pathway could be more readily assayed through use of the haploinsufficiency profiling (HIP) 
screen, a yeast tag microarray experiment that uses heterozygous diploid DMA strains, which 
contain one functional copy of the query gene. This assay examines the sensitivity mediating 
properties of gene dosage effects and allows the interrogation of essential genes such as many of 
those found in the CDC pathway. 
The cell cycle associated deletion mutants pin4Δ, cdc10Δ and cdc50Δ were present in the screen. 
Pin4p directly participates in G2/M phase progression and becomes inactivated when DNA is 
damaged (Pike et al. 2004). Cdc10p is a septin ring protein that contributes to cytokinesis (Hanrahan 
& Snyder, 2003). The endosomal Cdc50p controls polar growth through modulation of the 
polarisation of the actin cytoskeleton and cell surface (Misu et al. 2003).  Pin4Δ represented one of 
the strongest hits overall by z-score, whilst cdc10Δ and cdc50Δ presented with z-scores of ~-2, which 
rank them in the top 2.5% of recorded z-scores in the HOP screen.  
Of slightly less relevance, the spindle-assembly checkpoint complex protein Mad2p presented with a 
z-score ~-1.3 in the FC592 treated HOP screen, which still qualifies it for the top 5% of z-scores. This 
protein delays the onset of anaphase in cells with defects in mitotic spindle assembly, and has been 
implicated in mediating resistance to microtubule binding agents such as benomyl (Tsuchiya et al. 
2011; Chen et al. 1999). Compounds registering sensitivity on the HOP screen for this mutant would 
be expected to affect the cell cycle pathway in some respect. Although FC-592 recorded only a very 
weak hit against this strain, it does not rule out some activity in this respect. 
Whilst this data is by no means definitive, with a very small sample size and a lot of unrelated genes 
presenting with similar or higher z-scores, it suggests the CDC pathway as a site of action. Most 
probably, given the likely non-specific nature of FC-592 binding, it would be one of several pathways 
affected. 
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5. Final discussion          
5.1.1 Mode of action for FC-592 and FC-888 
The synthetically modified diterpene natural product FC-592 and the synthetically derived halo-
alkyne ester FC-888 potently inhibit yeast growth. A series of experiments utilising the budding yeast 
S. cerevisiae provided some evidence towards the biological activity of these compounds. Initial 
assessment revealed that the inhibitory potency of neither compound is abrogated by changes in pH 
conditions in common media types. FC-592 proved to be a substrate for the PDR network of efflux 
pumps, whilst FC-888 did not. Further experiments were conducted using PDR attenuated strains to 
take advantage of this fact, in a strategy to reduce compound usage. FC-592 was shown to reversibly 
inhibit yeast growth, displaying cytostatic activity. On the other hand, FC-888 was shown to kill or 
irreversibly inhibit cells, in a cytotoxic manner. 
In the homozygous profiling (HOP) assay, FC-592 showed weak enrichment for genes associated with 
glycoprotein biosynthesis and the secretory pathway. A follow-up assay attempting to confirm FC-
592 activity against these pathways screened for initiation of the unfolded protein response. 
However, this response was not observed in reaction to FC-592 treatment. FC-888 showed no 
statistical enrichment in the HOP screen, instead inducing a sensitive reaction in a broad array of 
deletion mutants representing genes all across the genome.  
A synthetic genetic array mapping (SGAM) strategy was attempted to characterise mutants that 
were resistant to FC-592. Whilst a range of mutants were successfully generated for this experiment, 
the SGAM failed when the resistant mutation caused slow growth on agar. This led to resistant 
progeny being outcompeted at selection steps during the construction of the array, and thus not 
being present in sufficient quantities in the final selection. Therefore, they were unable to generate 
the distinctive linkage disequilibrium pattern which identifies the target locus in SGAM experiments 
(Jorgensen et al. 2002). Based on experimental results, it is proposed that the mechanism of 
resistance observed in the mutants generated in this study, YCG433 and YCG434, is modification of a 
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cellular uptake mediator. This explains the specific resistance to the compound, whilst allowing the 
possibility for a more general mode-of-action for the compound. 
A cell cycle analysis experiment using flow cytometry techniques successfully identified a G2/M 
phase block as a result of FC-592 treatment. It was proposed that this is likely a result of the 
compound acting on the cell-division cycle (CDC) pathway through interaction with regulatory 
mechanisms, rather than acting on cytoskeletal elements like actin or microtubules. Alternatively, a 
link with membrane transport associated cell-cycle control is possible. 
Chemistry analysis of the structure of FC-592 and FC-888 suggested that these compounds do not 
have the structural complexity to be capable of highly specific binding to particular cell targets. 
Therefore it is likely that each compound employs are more general mechanism, interacting with a 
wide array of targets. 
The evidence produced during this project is indefinite in determining a precise mode-of-action for 
either compound. Taken together however, some determinations can be suggested. Chemically, FC-
592 is likely to be a non-specific binder of hydrophobic pockets. It lacks the structural complexity to 
selectively bind specific targets however, and thus probably inhibits activity in a wide variety of 
enzymes by non-specifically binding to and blocking their catalytic sites. HOP screen evidence 
suggests that this particularly affects glycoprotein biosynthesis and the secretory pathway. There are 
a large range of enzymatic processes in these pathways with ubiquitous distribution throughout the 
cell, meaning there are a lot of targets to aim at.  
Cell-cycle arrest was demonstrated as the likely mechanism of cellular inhibition due to the observed 
G2/M block by FC-592. Like the glycoprotein biosynthesis and the secretory pathways, it is likely that 
the CDC pathway is one of several being hit by this compound due to its non-selective nature. 
However, the CDC pathway is obviously such a critical process in cell growth that activity upon it 
could well be the process by which cell division is shut down. Of course, this process is 
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interconnected with many others throughout the cell: effects on these other pathways and 
processes are likely to have a general weakening effect which impacts on growth as well. The fact 
that FC-592 proved to be cytostatic indicates that the compound did not irreversibly bind to its 
targets. Rather it is likely that the compound is able to be removed from its targets, either through 
enzymatic action or native dissociation, when the cell is removed to fresh, FC-592 free media. 
An interesting novel mechanism for control of mitotic entry is proposed by Anastasia et al. (2012). 
Their data suggest that Wee1-dependent inhibitory phosphorylation of Cdk1 (a mammalian gene 
that has a yeast homologue, SWE1; Nurse et al, 1976) causes mitotic checkpoint arrest via blocking 
membrane traffic. Signalling in this pathway is conducted by the protein kinase C (Pkc1), Rho1 
GTPase and PP2ACdc55, a specific form of protein phosphatase 2A, and increases during polar bud 
growth. The researchers therefore suggest that signalling is dependent on membrane traffic, 
increasing linearly with delivery of vesicles to the site of bud growth. 
This mechanism has relevance to FC-592 because it reconciles proposed activity against transport 
pathways with the observed mitotic arrest. If confirmed, FC-592 activity against vesicle transport 
would have downstream anti-mitotic effects due to blocking of this signalling pathway. An emerging 
area of understanding, further research would be required to develop a testing protocol to assay FC-
592 against this mechanism, but could involve examining membrane mutants for differential 
sensitivity to the compound, or an assay which directly assesses membrane integrity (e.g. the 
propidium iodide exclusion assay described by Macklis & Madison, 1990).  
This process offers an alternative explanation of FC-592 activity to the FC-592 as a non-specific 
inhibitor theory proposed above. Knowing whether it is simply promiscuous or has a multiple, but 
still limited, number of targets is important. A QTL type approach, crossing resistant with sensitive 
mutants and isolating F1 phenotypes may prove illuminating in this respect. It would give an 
indication about whether the targets of the compound segregate out in a few-loci or many-loci 
manner. 
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FC-888 is likely to be a potent alkylating agent based on its chemistry. It almost certainly irreversibly 
binds cellular nucleophiles, causing disruption to a host of processes and leading to cell death. It 
does not have sufficient structural complexity to suggest a selective target. Instead, a wide range of 
targets is likely. DNA repair mechanisms, associated with mediating resistance to DNA alkylating 
agents (Simon et al. 2000) were not seen as hits in the HOP assay, indicating that FC-888 most 
probably does not target DNA more than other cellular nucleophiles. 
5.1.2 Assessment of FC-592 and FC-888 utility 
The utility of FC-592 depends on its characterisation as a non-specific promiscuous inhibitor, or a 
compound with a multiple but limited range of targets. Evidence for both of these mechanisms was 
seen in this project and further study will be required to definitively elucidate the answer. 
The best use for FC-592 based on current evidence would be in the initiation of cell-cycle arrest, in 
circumstances when this would be useful experimentally. Cell cycle arrest drugs such as laulimalide 
tend to be expensive, and a less complex compound such as FC-592 could be easier and cheaper to 
synthesize. However, the probability is that the compound would affect a range of processes outside 
of the cell cycle pathways, so it would be inappropriate for experiments attempting to explore these 
other genetic pathways.  
Further study into the precise mechanism by which FC-592 causes arrest may elucidate a clearer 
utility for the compound as a reagent in this regard. In addition, synthetically modified derivatives of 
this compound may be able to mimic its mechanism of action on this pathway, whilst increasing 
specificity. This scenario would lead to promising cell-cycle targeting leads and is worth pursuing. 
Additional study into the specific mechanisms by which FC-592 affects glycoprotein biosynthesis and 
the secretory pathway could also bear fruit. There is potential for the compound to be used as a 
genetic probe in this sense in assays which require general secretory pathway stress. The mechanism 
by which the compound affects the pathway would need to be elucidated, perhaps in a genome-
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wide over-expression assay (Luesch et al. 2005). This may help further define any specificity for the 
pathway as well. 
The expected non-specific activity of FC-888 diminishes its potential utility in terms of application as 
a genetic probe or in some putative therapeutic context. This is because the compound will affect 
too many cellular processes to be useful in either of these respects: creating too much ‘noise’ to be 
relevant in a research setting, and likely causing significant off-target effects in a clinical setting. For 
this reason it is unlikely that significant applications will be found for this compound in its present 
form. 
Useful applications for FC-888 are therefore unclear. Since it seems to have a general mechanism of 
toxicity against eukaryotic cells, this compound would not be useful in any clinical context. It has 
potential as a general antifungal, and its activity against other classes of organisms could be explored 
to assess its potential as a general antimicrobial compound. There are of course numerous chemical 
engineering based uses for the compound utilising the cross-linking properties. Non-specifically 
dimerizing cellular macromolecules could also prove to have interesting biochemical applications, 
especially in in vitro experiments, although a specific use for this remains unclear. 
Perhaps the clearest use of the compound would be in assessing the genetic properties of general 
alkylating agent resistance. An assay exploring the genetic basis of resistance to a generic alkylating 
agent such as this could be conducted, again using a genome wide over-expression assay. Genes 
mediating resistance to cellular alkylation could be identified in such a screen. With little enrichment 
for DNA repair associated genes, HOP screen results seem to indicate that FC-888 does not act 
primarily on DNA. Therefore, it must affect other cellular nucleophiles to just as great an extent as 
nuclear ones. Since most alkylating agents used in a clinical context specifically target the DNA 
(Warwick, 1963), this offers a somewhat novel biochemical probe: an alkylator of cytosolic 
nucleophiles. 
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5.1.3 Assessment of experimental strategies and protocols 
The overall strategies and specific protocols used in this project allowed a good deal of evidence to 
be gathered in a coherent manner, rather than taking stabs in the dark on biochemical based assays. 
The halo assay allowed bioactive compounds to be identified from a decent sized library of novel 
synthetics. However, the utility of the halo assay over more traditional liquid media based assays 
was not proven. The liquid based assay was able to identify more bioactives from the same library, 
and furthermore, did not have the same issues with gas evolution and buffers causing bubbles in the 
media. The only advantage of the halo assay is that it is theoretically able to assay a much larger 
concentration range; i.e. relevant results will be seen at much higher concentrations, because they 
just cause a larger halo. The liquid assay is unable to distinguish between concentrations that are 
just inhibitory and those that are inhibitory by many orders of magnitude. In practice however, this 
was not found to be an issue. All noted bioactives from the halo assay were characterised via dose 
response for inhibitory potency. This would be just as easy to do with results from the liquid assay. 
Limitations observed in the HOP screen based approach were mainly due to the nature of the 
selected compounds themselves. Neither FC-592 nor FC-888 appeared to mediate a highly selective 
target or mechanism of action. The assay itself identifies overrepresentation in a sensitive sample of 
genes involved in a certain process or pathway. It loses resolution when multiple pathways are 
involved, and a single group of genes no longer presents statistical enrichment. Considering this fact, 
the assay performed well in providing the evidence it did in the case of FC-592. The HOP screen 
remains a proven technology; however it is probably more effective in compounds that have a 
mode-of-action targeted to a single specific pathway. 
The only aspect of this project which truly failed was the SGAM characterisation of the resistant 
mutant YCG434. The resistance mutation itself mediated slow growth on agar, which caused 
depletion of mutation carrying cells at the final selection step. The assay itself was proven in a 
cycloheximide resistance based pilot experiment and has been used to successfully identify a target 
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and mechanism with another compound (Yibmantasiri et al. 2012). The lesson to take away from 
this is to ensure WT fitness levels in selected mutants before proceeding with an SGAM program. It 
should also be remembered that mutants can behave very differently on agar than they do in liquid 
media, so should always be assayed on the relevant media type where possible. 
The UPRE assay was effective and efficient in providing answers about induction of the unfolded 
protein response. Unfortunately, in this project those answers turned out to be negative, and the 
assay did not provide positive evidence for the activity of FC-592. It remains an effective method for 
assaying this biological process however. 
The flow cytometry cell-cycle analysis experiment worked well in identifying a G2/M phase block in 
FC-592 treated cells. This quick and efficient assay is easily repeatable in varying conditions and 
could form the basis of future investigations into the mitosis arresting activity of the compound. The 
basis of this strategy could be attempting to rescue mitotic function in various over-expression 
mutants representing genes in the CDC pathway. 
5.1.1 Assessment of aims and objectives 
The overall aim of this project was to identify novel bioactives from a library of novel organic 
compounds and characterise their action. In this respect it was largely a success, as a number of 
inhibitory compounds were identified, and two chosen for further study. FC-592 and FC-888 were 
assayed with a number of strategies that provided a range of evidence as to their mode-of-action, as 
described above. Although the precise nature of each compound’s mechanism was not identified, 
general mechanisms were proposed that fit the evidence obtained. Given time and resource 
constraints, a good level of understanding was achieved.  
All aims and objectives presented in Chapter two were achieved. FC-592 and FC-888 were identified 
as bioactives through the halo assay and characterised with respect to their potency and PDR affinity 
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profiles. The halo assay was characterised however as generally inferior to the liquid based inhibition 
assay, a legacy technique. 
The objectives set out in Chapter three involve the successful implementation of the yeast tag 
microarray HOP screen, which was achieved. Selected hit strains were confirmed via growth assay 
and several determinations made about the activity of the assayed compounds. The results of this 
assay were better able to characterise the activity of FC-592 than FC-888. However analytical 
techniques provide little insight, with low levels of statistical enrichment seen in FC-592 and no 
statistical enrichment identified in FC-888. This was later assessed as being due the non-pathway 
specific activity of the compounds clouding the statistical sample with sensitive hits from multiple 
pathways. 
The first objective of chapter four was met, with FC-592 resistant mutants being successfully 
generated. These were then partially characterised by tetrad analysis, complementation testing, and 
testing for dominance/recessiveness. In addition, the SGAM strategy was proven to be viable by the 
successful completion of a pilot experiment utilising the cycloheximide resistant mutant YCG191. 
However, the identification of the resistant locus on the FC-592 resistant mutant YCG434 failed 
when cells carrying the resistance allele proved unable to compete with non-resistant cells under 
non-selective conditions. 
A cell-cycle analysis assay was performed in this section of the project. Successful completion of this 
assay and the identification of a G2/M black in FC-592 exceeded the original objectives of this 
chapter. On balance therefore, this component of the project was a success.  
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6. Future Directions          
There are several avenues of study that remain in the investigation of FC-592 and FC-888. Assays 
exploring the alkylating nature of FC-888 will confirm its activity in that respect, as well as assessing 
its viability as a genetic probe for exploration of alkylation resistance. In terms of FC-592 several 
genomic screens utilising different strategies than the HOP screen could prove efficacious in further 
defining the activity of this compound against the secretory pathway and cell-cycle pathway. 
Further, several additional strategies could be attempted to characterise the mechanism of 
resistance seen in the resistant yeast strains YCG433 and YCG434. 
6.1 Future directions in FC-592 
6.1.1 Haploinsufficiency profiling assay in FC-592 
The activity of FC-592 against the CDC pathway could be better understood through the use of a 
diploid haploinsufficiency profiling (HIP) screen (Giaever et al. 2003). This is because most of the 
genes involved in this pathway are essential to the growth of yeast and thus do not show up in a 
haploid deletion screen. The diploid screen, consisting of heterozygotic deletion mutants, could 
identify gene dosage effects in essential genes such as the CDC path, confirming FC-592 activity in 
this area in a manner that the haploid screen is not able to. 
6.1.2 Genomic over-expression assay in FC-592 
CDC and secretory pathway examination by genomic over-expression assay as with the HIP screen 
seeks to examine gene dosage effects on the bioactivity of the compound.  An array of yeast 
transformants containing a multi-copy yeast genomic library can be screened for resistance to 
growth inhibitors such as FC-592, determining genes which mediate resistance in a specific pathway 
(Luesch et al. 2005). This could provide a high degree of certainty about which processes within the 
affected pathways are abrogated by the activity of the compound. In addition, multi-copy over-
expression of mutant alleles can identify phenotype suppressing effects in either sensitive or 
resistant mutants (Puig et al. 2002). This allows a still greater characterisation of the genetic 
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mechanism of action, but relies on characterisation of a resistance- or sensitivity-mediating 
mutation.  
6.1.3 GFP-linked proteomics assay in FC-592 
One of the mechanisms by which FC-592 could be affecting activity in both the CDC and secretory 
pathways, is by blocking some enzymatic process which leads to gene expression of a protein 
involved in these pathways. This could be examined using the GFP-linked proteomics screen 
described above. Such a strategy could identify reduced protein expression, which could be 
bioinformatically linked to its promoters and transcription factors in an attempt to determine the 
mechanism by which such expression is blocked. This strategy has the additional advantage that 
possible alterations in sub-cellular location caused by the drug can be used as a phenotype to 
measure the effect of deletion mutations in other genes. 
6.1.4 Secretory pathway screen in FC-592 
Further dissecting the effects of FC-592 on glycoprotein biosynthesis and the secretory pathway is 
necessary in determining the usefulness of the compound as a genetic probe in this area. Several 
assays are available which would assist in this type of characterisation. Recombinant luciferase from 
Drosophila S2 cells can be used as a reporter for activity of the pathway (Wendler et al. 2010). This 
would allow efficient assessment of the function of the pathway in combination with a range of 
treatment conditions involving FC-592 and various yeast mutants. 
An alternate strategy utilises western blot techniques to identify conditional effects on glycosylation 
and the sectretory pathway (Hood-DeGrenier, 2008). This methodology takes advantage of the 
defined pathway roles of N-linked and O-linked glycosylation (Karp, 2005) to determine where in the 
pathway disruption occurs. Western blots using an antibody recognising a distinct secreted or cell-
surface protein can be used to determine which form of the protein accumulates under a given drug 
condition. By examining which glycosylated residues the secreted protein is deficient in, these data 
can reveal the intracellular compartment in which the protein is trapped and therefore the specific 
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secretory step that is compromised. A broad organelle specificity assay of glycosylation is available in 
yeast since the ER form of a glycosylated protein (e.g. secreted invertase) is readily distinguished by 
SDS PAGE from the Golgi form owing to the high-mannose oligosaccharides added in the latter.  This 
would be effective in confirming the specificity or otherwise of FC-592 for a certain target in the 
process. 
 6.1.5 Characterisation of FC-592 resistance mutations by sequencing 
Whilst resistant mutants were successfully generated in this project, characterisation of the nature 
of these mutations proved elusive for reasons that have been previously elucidated. Such 
characterisation remains a valuable source of information however, and could confirm the proposed 
nature of the mutation as a cellular uptake mediator. Next generation sequencing methods such as 
Massively Parallel Signature Sequencing (Brenner et al. 2000), and polony sequencing (Shendure et 
al. 2005) have reduced the cost and efficiency of genomic sequencing experiments (Schuster, 2008). 
This makes sequencing and subsequent bioinformatic analysis of mutational effects a viable strategy, 
although the cost still remains significant for a small lab. In addition, multiple SNP mutations are 
likely to be identified, most of them having no effect. This means a significant amount of ‘noise’ is 
likely to be encountered in such an experiment when trying to identify the locus of resistance. 
6.1.6 Characterisation of FC-592 resistance mutations by plasmid rescue 
A plasmid rescue strategy can also be used to identify a locus of interest that mediates restoration of 
a native phenotype (Epstein & Cross, 1992). In this methodology, a recessive mutant population is 
transformed with plasmids containing fragments of genomic DNA. A cell which restores WT activity 
must contain a gene which suppresses the mutant phenotype, very probably a WT copy of the 
mutant allele. This suppressor gene is identified through sequencing of PCR amplification of the 
plasmid. When a comprehensive library of plasmids is used in this fashion, the entire genome can be 
interrogated for suppressive function (Yan & Burgess, 2012). 
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This strategy requires a recessive mutation that is able to be suppressed by the WT allele. It also 
requires a deleterious phenotype, so that suppressed mutation can be recovered. Ordinarily a 
resistance mutation such as that observed in YCG433 and YCG434 would not make a good candidate 
for this strategy, as a rescued (sensitive) phenotype would fail to grow on a screening assay.  
The slow growth phenotype mediated by the resistance mutation seen in these strains (agar based 
screens only for YCG434) however, makes them viable candidates for a plasmid rescue screen. 
Treatment with FC-592 would not be required for this – the transformed population would be grown 
for many generations on ordinary media, with the rationale being that the rescued transformants 
would out-compete the other cells. These transformants could then be assayed against FC-592 to 
confirm restoration of WT sensitivity before using a colony PCR and sequencing strategy to identify 
the gene involved. 
6.1.7 Characterisation of FC-592 resistance mutations by liquid phase SGAM 
Another intriguing possibility for the identification of these resistance mutations would be to adapt 
the SGAM protocol for use entirely in liquid media, hopefully avoiding the slow-growing phenotype 
seen in agar based assays. This would be a novel strategy, as it hasn’t been attempted before in the 
published literature. All post sporulation steps in this assay would be transferred via pinning robot to 
384-well cell culture plates containing the appropriate liquid media. Plates would be grown as 
normal and cell growth measured via imaging plate reader. This concept would allow cells carrying 
the resistance mutation from YCG434 to compete with WT cells and maintain a viable presence in 
the final population. In theory, the SGAM premise would work just as well in liquid media as on agar. 
This would however have to be empirically verified. 
6.1.8 Further investigation in cell-cycle analysis 
The cell-cycle was identified as a likely target pathway of FC-592. This holds great interest because of 
the medical relevance of cell-cycle targeting drugs in tumour suppression (Shapiro & Harper, 1999). 
Although it is proposed that FC-592 has a relatively non-specific mode-of-action, this utility is worth 
154 
 
investigating. A cell-cycle screen against mammalian cells, as described in Mooberry et al. (1999) and 
Hood et al. (2002), would allow direct comparison of the G2/M phase blocking activity of FC-592 in 
comparison to more established drugs which act on this pathway. This screen would be an important 
first step in establishing the relevance of FC-592 activity in this field. 
In addition to the genomic screens described above (sections 6.1.1, 6.1.2 & 6.1.3), a method of 
defining FC-592’s interactions with this pathway would involve the screening for sensitivity of 
particular mutants. For example the β–tubulin subunit Tub2p is implicated in the mediation of 
resistance to microtubule stabilising agents such as benomyl (Thomas et al. 1985). TUB2 attenuated 
mutants (for example TUB2/tub2Δ heterozygotes) would give an indication of the site of action of 
FC-592 on the CDC pathway if they conferred sensitivity relative to a wild type. This assay would 
require investigation into candidate CDC associated genes to screen for sensitivity.  
Finally, activity against the CDC pathway generally could be confirmed by screening against a known 
model for G2/M phase blockage resistance. For example, a mammalian model overexpressing 
UBE2C, the G2/M phase associated gene known to be overexpressed in various chemotherapeutic 
resistant solid tumours (Wang et al. 2011), would give a strong indication in this direction. If this 
model were to prove resistant to the compound, it would confirm suspected activity against this 
pathway.  
6.2 Future directions in FC-888 
6.2.1 Alkylating agent assay 
An experimental strategy that has proven effective in characterising alkylation activity seeks to 
evaluate the candidate compounds in several assays in which alkylating agents would have 
predictable effects (Mertins et al. 2004). In this study chlorambucil-resistant Walker rat carcinoma 
cells were assayed for cross-resistance to the test compounds compared with known alkylating 
agents. In addition, proteomics assays were used to identify increased expression of proteins which 
155 
 
are associated with DNA repair. This proved effective at assaying the activity of compounds targeting 
different sites within the DNA molecule and other biologically relevant nucleophiles. Such a strategy 
could be used to confirm the alkylating properties of FC-888. 
6.2.2 GFP-linked proteomic screen in FC-888 
An alternative approach would be utilising a genomic library of GFP-linked proteins (Huh et al. 2003) 
in an attempt to identify DNA or alkylation repair associated proteins whose expression and 
localisation is altered under FC-888 treatment. The advantages to this assay include short time frame 
and low experimental error. However, there may be other genomic effects observed which are not 
specifically related to DNA or alkylation repair mechanisms: the ramifications are difficult to predict, 
but this could cloud results. 
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7. Appendices           
7.1.1 Appendix 1 – IRL compound library data 
Cat. # Mass 
(g) 
Mol. 
mass 
Vol. (μL) Conc. 
(mg/mL) 
Conc. 
(mM) 
Cat. # Mass (g) Mol. 
mass 
Vol. 
(μL) 
Conc. 
(mg/mL) 
Conc. 
(mM) 
FC-002 0.0095 230 950 10 43.48 FC-517 0.0103 565 1030 10 17.70 
FC-004 0.0098 161.5 980 10 61.92 FC-518 0.0083 515 830 10 19.42 
FC-006 0.0107 225.5 1070 10 44.35 FC-520 0.0179 565 895 20 35.40 
FC-007 0.0096 184.6 960 10 54.17 FC-521 0.0045 429 450 10 23.31 
FC-010 0.0093 163 930 10 61.35 FC-523 0.0107 565 1070 10 17.70 
FC-011 0.0088 199.5 880 10 50.13 FC-524 0.0063 ?? 630 10 ?? 
FC-017 0.0127 286 1270 10 34.97 FC-526 0.0069 ?? 690 10 ?? 
FC-018 0.0124 262 1240 10 38.17 FC-527 0.0185 ?? 925 20 ?? 
FC-019 0.0092 301 920 10 33.22 FC-531 0.0010 549 100 10 18.21 
FC-023 0.0123 163 1230 10 61.35 FC-532 0.0090 220 900 10 45.45 
FC-024 0.0051 133 510 10 75.19 FC-535 0.0103 534 1030 10 18.73 
FC-025 0.0093 414 930 10 24.15 FC-536 0.0060 630 600 10 15.87 
FC-026 0.0111 194 1110 10 51.55 FC-538 0.0311 ? 1555 20 ?? 
FC-027 0.0153 180 765 20 111.11 FC-539 0.0128 264 1280 10 37.88 
FC-028 0.0055 180 550 10 55.56 FC-540 0.0027 270 270 10 37.04 
FC-029 0.0104 194 1040 10 51.55 FC-541 0.0052 ?? 520 10 ?? 
FC-034 0.0097 232 970 10 43.10 FC-542 0.0018 277 180 10 36.10 
FC-035 0.0114 460 1140 10 21.74 FC-543 0.0103 350 1030 10 28.57 
FC-036 0.0116 221 1160 10 45.25 FC-544 0.0067 310 670 10 32.26 
FC-040 0.0104 194 1040 10 51.55 FC-545 0.0123 278 1230 10 35.97 
FC-041 0.0097 164 970 10 60.98 FC-546 0.0134 370 1340 10 27.03 
FC-042 0.0090 356 900 10 28.09 FC-547 0.0035 264 350 10 37.88 
FC-044 0.0084 215.5 840 10 46.40 FC-548 0.0090 268 900 10 37.31 
FC-045 0.0104 256.5 1040 10 38.99 FC-549 0.0022 ?? 220 10 ?? 
FC-046 0.0121 212 1210 10 47.17 FC-550 0.0130 304 1300 10 32.89 
FC-047 0.0119 194 1190 10 51.55 FC-551 0.0084 248 840 10 40.32 
FC-051 0.0096 370 960 10 27.03 FC-552 0.0085 290 850 10 34.48 
FC-054 0.0083 180 830 10 55.56 FC-553 0.0100 268 1000 10 37.31 
FC-056 0.0030 173 300 10 57.80 FC-554 0.0106 350 1060 10 28.57 
FC-057 0.0109 212 1090 10 47.17 FC-555 0.0130 250 1300 10 40.00 
FC-060 0.0070 203 700 10 49.26 FC-556 0.0127 290 1270 10 34.48 
FC-061 0.0137 161 1370 10 62.11 FC-557 0.0152 ?? 760 20 ?? 
FC-062 0.0120 308 1200 10 32.47 FC-558 0.0065 306 650 10 32.68 
FC-063 0.0104 323 1040 10 30.96 FC-559 0.0010 288 100 10 34.72 
FC-064 0.0115 473 1150 10 21.14 FC-560 0.0164 ?? 820 20 ?? 
FC-500 0.0165 357 825 20 56.02 FC-561 0.0124 268 1240 10 37.31 
FC-501 0.0095 ? 950 10 ?? FC-562 0.0164 292 820 20 68.49 
FC-504 0.0115 ? 1150 10 ?? FC-563 0.0170 354 850 20 56.50 
FC-506 0.0148 ? 1480 10 ?? FC-564 0.0173 278 865 20 71.94 
FC-507 0.0097 593 970 10 16.86 FC-565 0.0050 402 500 10 24.88 
FC-510 0.0140 ? 1400 10 ?? FC-566 0.0138 268 1380 10 37.31 
FC-512 0.0192 468 960 20 42.74 FC-567 0.0108 ?? 1080 10 ?? 
FC-513 0.0088 ? 880 10 ?? FC-568 0.0106 332 1060 10 30.12 
FC-515 0.0147 ? 1470 10 ?? FC-569 0.0013 266 130 10 37.59 
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Cat. # Mass 
(g) 
Mol. 
mass 
Vol. 
(μL) 
Conc. 
(mg/mL) 
Conc. 
(mM) 
Cat. # Mass (g) Mol. 
mass 
Vol. 
(μL) 
Conc. 
(mg/mL) 
Conc. 
(mM) 
FC-570 0.0054 326 540 10 30.67 FC-715 0.0317 190 1585 20 105.26 
FC-571 0.0114 382 1140 10 26.18 FC-717 0.0136 306 1360 10 32.68 
FC-572 0.0084 350 840 10 28.57 FC-732 0.0091 142 910 10 70.42 
FC-573 0.0200 278 1000 20 71.94 FC-733 0.0093 448.5 930 10 22.30 
FC-574 0.0171 308 855 20 64.94 FC-734 0.0028 415 280 10 24.10 
FC-575 0.0159 282 795 20 70.92 FC-735 0.0056 511 560 10 19.57 
FC-576 0.0079 292 790 10 34.25 FC-736 0.0038 486 380 10 20.58 
FC-577 0.0142 306 1420 10 32.68 FC-737 0.0076 413 760 10 24.21 
FC-578 0.0049 ?? 490 10 ?? FC-738 0.0069 342 690 10 29.24 
FC-579 0.0059 ?? 590 10 ?? FC-739 0.0094 550 940 10 18.18 
FC-580 0.0174 264 870 20 75.76 FC-740 0.0080 323 800 10 30.96 
FC-581 0.0130 278 1300 10 35.97 FC-741 0.0085 427 850 10 23.42 
FC-582 0.0062 330 620 10 30.30 FC-742 0.0107 387 1070 10 25.84 
FC-583 0.0077 291 770 10 34.36 FC-743 0.0136 429 1360 10 23.31 
FC-584 0.0077 288 770 10 34.72 FC-744 0.0136 443 1360 10 22.57 
FC-585 0.0124 306 1240 10 32.68 FC-745 0.0066 607 660 10 16.47 
FC-586 0.0041 278 410 10 35.97 FC-746 0.0099 698 990 10 14.33 
FC-587 0.0133 291 1330 10 34.36 FC-747 0.0102 661 1020 10 15.13 
FC-588 0.0081 248 810 10 40.32 FC-748 0.0046 557 460 10 17.95 
FC-589 0.0174 322 870 20 62.11 FC-749 0.0082 438 820 10 22.83 
FC-590 0.0084 308 840 10 32.47 FC-750 0.0157 502 785 20 39.84 
FC-591 0.0148 306 1480 10 32.68 FC-751 0.0107 376 1070 10 26.60 
FC-592 0.0079 282 790 10 35.46 FC-752 0.0072 562 720 10 17.79 
FC-594 0.0137 275 1370 10 36.36 FC-754 0.0050 550 500 10 18.18 
FC-596 0.0135 308 1350 10 32.47 FC-755 0.0144 376 1440 10 26.60 
FC-597 0.0146 302 1460 10 33.11 FC-756 0.0085 557 850 10 17.95 
FC-598 0.0138 240 1380 10 41.67 FC-776 0.0086 516 860 10 19.38 
FC-599 0.0102 280 1020 10 35.71 FC-777 0.0089 555 890 10 18.02 
FC-665 0.0101 231 1010 10 43.29 FC-779 0.0136 477 1360 10 20.96 
FC-674 0.0091 103 910 10 97.09 FC-785 0.0028 462 280 10 21.65 
FC-676 0.0053 159 530 10 62.89 FC-787 0.0069 ? 690 10 ?? 
FC-677 0.0071 219 710 10 45.66 FC-788 0.0090 279 900 10 35.84 
FC-678 0.0055 300 550 10 33.33 FC-792 0.0136 434 1360 10 23.04 
FC-679 0.0081 251 810 10 39.84 FC-797 0.0216 429 1080 20 46.62 
FC-680 0.0115 89 1150 10 112.36 FC-805 0.0066 322 660 10 31.06 
FC-682 0.0051 192 510 10 52.08 FC-808 0.0143 ? 1430 10 ?? 
FC-683 0.0143 295 1430 10 33.90 FC-810 0.0010 161 100 10 62.11 
FC-684 0.0010 ?? 100 10 ?? FC-811 0.0041 295 410 10 33.90 
FC-685 0.0026 ? 260 10 ?? FC-812 0.0020 325 200 10 30.77 
FC-694 0.0109 189 1090 10 52.91 FC-815 0.0224 190 1120 20 105.26 
FC-697 0.0134 363 1340 10 27.55 FC-816 0.0182 121 910 20 165.29 
FC-698 0.0124 226 1240 10 44.25 FC-817 0.0055 121 550 10 82.64 
FC-699 0.0079 ? 790 10 ?? FC-822 0.0027 147 270 10 68.03 
FC-700 0.0041 ? 410 10 ?? FC-823 0.0046 121 460 10 82.64 
FC-701 0.0213 ? 1065 20 ?? FC-825 0.0057 161 570 10 62.11 
FC-708 0.0173 554 865 20 36.10 FC-826 0.0171 187 855 20 106.95 
FC-709 0.0132 540 1320 10 18.52 FC-827 0.0063 147 630 10 68.03 
FC-710 0.0188 572 940 20 34.97 FC-828 0.0058 269 580 10 37.17 
FC-711 0.0193 572 965 20 34.97 FC-830 0.0037 265 370 10 37.74 
FC-714 0.0131 454 1310 10 22.03 FC-831 0.0215 283 1075 20 70.67 
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Cat. # Mass 
(g) 
Mol. 
mass 
Vol. 
(μL) 
Conc. 
(mg/mL) 
Conc. 
(mM) 
Cat. # Mass (g) Mol. 
mass 
Vol.(μL) Conc. 
(mg/mL) 
Conc. 
(mM) 
FC-832 0.0070 352 700 10 28.41 FC-910 0.0155 152 775 20 131.58 
FC-834 0.0115 151 1150 10 66.23 FC-911 0.0033   330 10 ?? 
FC-836 0.0093 254 930 10 39.37 FC-912 0.0113 437 1130 10 22.88 
FC-837 0.0025 282 250 10 35.46 FC-913 0.0145 152 1450 10 65.79 
FC-838 0.0039 147 390 10 68.03 FC-914 0.0125 290 1250 10 34.48 
FC-845 0.0253 337 1265 20 59.35 FC-915 0.0150 429 1500 10 23.31 
FC-853 0.0058 278 580 10 35.97 FC-916 0.0096 436 960 10 22.94 
FC-854 0.0177 194 885 20 103.09 FC-917 0.0094 152 940 10 65.79 
FC-856 0.0010 174.5 100 10 57.31 FC-918 0.0069 289 690 10 34.60 
FC-858 0.0010 202 100 10 49.50 FC-919 0.0066 330 660 10 30.30 
FC-859 0.0146 250.5 1460 10 39.92 FC-920 0.0117 374 1170 10 26.74 
FC-864 0.0272 344 1360 20 58.14 FC-921 0.0093 374 930 10 26.74 
FC-866 0.0010 288 100 10 34.72 FC-922 0.0134 152 1340 10 65.79 
FC-867 0.0234 266 1170 20 75.19 FC-923 0.0056 170.5 560 10 58.65 
FC-868 0.0047 288 470 10 34.72 FC-925 0.0099 169 990 10 59.17 
FC-869 0.0011 326 110 10 30.67 FC-926 0.0074 494 740 10 20.24 
FC-870 0.0014 238 140 10 42.02 FC-927 0.0023 517 230 10 19.34 
FC-871 0.0010 284 100 10 35.21 FC-928 0.0117 152 1170 10 65.79 
FC-873 0.0070 380 700 10 26.32 FC-929 0.0090 181 900 10 55.25 
FC-874 0.0020 250 200 10 40.00 FC-930 0.0208 315 1040 20 63.49 
FC-875 0.0075 106.5 750 10 93.90 FC-931 0.0080 315 800 10 31.75 
FC-876 0.0097 208 970 10 48.08 FC-932 0.0147 509 1470 10 19.65 
FC-878 0.0125 324.5 1250 10 30.82 FC-933 0.0089 300 890 10 33.33 
FC-879 0.0043 156.5 430 10 63.90 FC-935 0.0029 495 290 10 20.20 
FC-880 0.0075 300 750 10 33.33 FC-936 0.0100 300 1000 10 33.33 
FC-881 0.0083 312 830 10 32.05 FC-937 0.0022 517 220 10 19.34 
FC-882 0.0164 258 820 20 77.52 FC-938 0.0124 227 1240 10 44.05 
FC-883 0.0030 386.5 300 10 25.87 FC-939 0.0051 227 510 10 44.05 
FC-884 0.0137 374.5 1370 10 26.70 FC-940 0.0136 507 1360 10 19.72 
FC-885 0.0071 244.5 710 10 40.90 FC-941 0.0030 641 300 10 15.60 
FC-886 0.0077 244.5 770 10 40.90 FC-942 0.0100 626 1000 10 15.97 
FC-887 0.0148 404.5 1480 10 24.72 FC-944 0.0061 506 610 10 19.76 
FC-888 0.0223 177 1115 20 112.99 FC-945 0.0082 173 820 10 57.80 
 
Table 7.1 Molecular data on compound library from IRL. Library consists of synthetic compounds and synthetic derivatives 
of diterpine natural products. They are dissolved in DMSO, and stored at -20˚C at the Chemical Genetics Laboratory, 
Victoria University of Wellington. 
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7.1.2 Appendix 1 – Plate layout data for dose response screen 
Compound Row A Row B Row C Row D Row E Row F Row G Row H 
FC-018 381.68 120.78 38.22 12.10 3.83 1.21 0.38 0.12 
FC-526 ?? ?? ?? ?? ?? ?? ?? ?? 
FC-561 373.13 118.08 37.37 11.83 3.74 1.18 0.37 0.12 
FC-566 373.13 118.08 37.37 11.83 3.74 1.18 0.37 0.12 
FC-567 ?? ?? ?? ?? ?? ?? ?? ?? 
FC-570 306.75 97.07 30.72 9.72 3.08 0.97 0.31 0.10 
FC-571 261.78 82.84 26.22 8.30 2.63 0.83 0.26 0.08 
FC-574 649.35 205.49 65.03 20.58 6.51 2.06 0.65 0.21 
FC-575 354.61 112.22 35.51 11.24 3.56 1.13 0.36 0.11 
FC-578 ?? ?? ?? ?? ?? ?? ?? ?? 
FC-580 757.58 239.74 75.87 24.01 7.60 2.40 0.76 0.24 
FC-582 303.03 95.90 30.35 9.60 3.04 0.96 0.30 0.10 
FC-588 403.23 127.60 40.38 12.78 4.04 1.28 0.40 0.13 
FC-589 621.12 196.56 62.20 19.68 6.23 1.97 0.62 0.20 
FC-592 354.61 112.22 35.51 11.24 3.56 1.13 0.36 0.11 
FC-596 324.68 102.75 32.51 10.29 3.26 1.03 0.33 0.10 
FC-599 357.14 113.02 35.77 11.32 3.58 1.13 0.36 0.11 
FC-697 275.48 87.18 27.59 8.73 2.76 0.87 0.28 0.09 
FC-732 704.23 222.86 70.52 22.32 7.06 2.23 0.71 0.22 
FC-734 240.96 76.25 24.13 7.64 2.42 0.76 0.24 0.08 
FC-856 573.07 181.35 57.39 18.16 5.75 1.82 0.58 0.18 
FC-888 381.68 120.78 38.22 12.10 3.83 1.21 0.38 0.12 
CHX 10.00 3.16 1.00 0.32 0.10 0.03 0.01 0.00 
 
Table 7.2 Plate layout for original dose response experiment assessing potency of hits from the halo assay. All 
concentrations are given in μM. Molecular data was unknown for several compounds, and thus molar concentrations could 
not be calculated. Cycloheximide (CHX) served as a positive control, as an inhibitory compound of known potency.  
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7.2 Appendix 2 – HEPES buffer action on halo assay 
A multi condition experiment was conducted to identify the cause of the ‘bubbles’ seen in the early 
halo assays. 
  
  
A B 
C D 
F E 
Figure 7.1 Conditional test based on the halo assay. Tests were conducted to determine the cause of bubbling seen 
in the HEPES buffered halo assay. A: original assay SC Agar, ~2×10
5
 cells, 2% glucose, 25 mM HEPES buffer. B: as A 
with reduced glucose (0.5%) C: as A with reduced cell concentration (~2×104). D: as A with no HEPES buffer. E: as A 
with HEPES replaced with 100 mM NaHCO3. F: as A with HEPES replaced with 25 mM MOPS. B and C indicate that 
bubble formation is mediated by cellular metabolism: less cells or cells growing slower due to reduced nutrients 
produce fewer bubbles. Plate D suggests a buffer mediated effect. Of the three buffers, (A, E, F), MOPS produces 
plates with the fewest bubbles. 
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7.3 Appendix 3 – confirmation of PCR product for HOP screen 
 
 
 
 
 
 
 
 
 
7.4 Appendix 4 – tetrad analysis of FC-592 resistant mutants 
Mutants were selected for complementation testing based on tetrad analysis of cells. YCG434 was 
crossed with a Mat A his3Δ::KanR; pdr1Δ::NAT; pdr3Δ::URA3 mutant obtained from Namal Coorey. 
This diploid was sporulated and dissected as described in Chapter 4. Meiotic progeny were screened 
for mating type, FC-592 resistance, loss of CenLeu plasmid so that this selection could be reused, and 
G418 resistance. 
 
  
56 bp PCR product 
Unreacted primer 
A B C D E F G H 
Figure 7.2 Confirmation of PCR product for HOP screen. Cy labelled 56 bp PCR products 
were confirmed by 4% MetaPhor agarose gel electrophoresis, validating HOP screen data. 
FC-592 treated cells (and controls): A: Cy5 labelled UP tags. B: Cy5 labelled DN tags. C: Cy3 
labelled UP tags. D: Cy3 labelled DN tags. FC-888 treated cells (and controls): E: Cy5 
labelled UP tags. F: Cy5 labelled DN tags. G: Cy3 labelled UP tags. H: Cy3 labelled DN tags. 
A faint band representing unreacted primer was also seen. 
1 
2 3 
4 
5 
6 
7 
8 
9 
10 
Figure 7.3 Mat A selection of YCG434 meiotic progeny. Tetrad plates were 
replica plated onto Mat A selective media (SD -His, -Arg, -Lys, +Can, +Thia). 
Mat A segregants were labelled and transferred to additional selections. 
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Data from this analysis identified Tetrad #9 as Mat A, CenLeu-, FC-592R+, and KanR+. This made it 
suitable for mating with a CenLeu transformed YCG433 strain for complementation, as it enabled 
diploid selection. 
  
Figure 7.4 Selection on 150 µM FC-592 media. Only tetrad # 9 still 
carried the FC-592 resistance mutation.  The reason for this is 
unknown, the mutation had previously been characterised as single 
locus mediated via tetrad analysis (discussed in Chapter 4). 
Figure 7.5 Phenotyping of Tetrad #9. Tetrad #9 displayed no growth on SD-Leu +G418 media (l) and SD-Leu (m). It did 
however grow on SC +G418 media (r). This shows that this strain has lost its CenLeu plasmid, which mediates 
resistance to leucine auxotrophy. However, it grew in the presence of g418, showing that it retained the KanR 
resistance cassette. YCG434 (here labelled RM3), was used as a control. 
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